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Chapter I
1.1. The definition of pain
 In the 17th century, René Descartes, who is generally considered as the ‘father of 
modern philosophy’, was one of the first in history to inquire into the feeling of pain on a 
rational (scientific) basis. Some of his philosophical reasoning, like his theory on the du-
alistic nature of humans with a clear separation between the mind and the body, are still 
found in our culture today. Several of his other statements, e.g. that animals do not have 
a mind and therefore are not able to feel pain, are now generally considered as outdated. 
Nevertheless, his view on the transmission of pain [6], represented as the pulling of a 
thread (Fig. 1), and on the functional importance of pain are not completely at odds with 
current views on pain transmission.
Fig. 1:“For example, if the fire A is close to 
the foot B, the small particles of fire, which 
as you know move very swiftly, are able to 
move as well the part of the skin which they 
touch on the foot. In this way, by pulling at 
the little thread cc, which you see attached 
there, they at the same instant open e, 
which is the entry for the pore d, which is 
where this small thread terminates; just as, 
by pulling one end of a cord, you ring a bell 
which hangs at the other end.... Now when 
the entry of the pore, or the little tube, de, 
has thus been opened, the animal spirits 
flow into it from the cavity F, and through it 
they are carried partly into the muscles 
which serve to pull the foot back from the 
fire, partly into those which serve to turn 
the eyes and the head to look at it, and 
partly into those which serve to move the 
hands forward and to turn the whole body 
for its defense.”
 Painful stimuli are indeed detected by specialized fibers in the skin and transmit 
their information to the spinal cord [56], and from there to higher centers of the central 
nervous system [23]. Furthermore, pain serves as a warning system leading to retraction 
of our body from the source of physical danger. Since Descartes’ time and especially in 
the last century, there has been a tremendous increase in research on pain. The Interna-
tional Association for the study of Pain (IASP), founded in the 1973, describes pain as ‘An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’. This definition points out that pain, while 
serving as a warning system of our body, is in essence a feeling with a major emotional 
impact. This makes pain a prominent part of our daily live, especially for patients with 
chronic pain. 
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1.2. The pain system
 The feeling of pain is generally initiated by the activation of specialized primary 
afferents, termed nociceptors, which innervate the skin [56] but also the majority of the 
internal organs [8, 74], with clinically notable exceptions like the liver, the lungs, and the 
brain. Nociceptors are activated by actual or potential damaging stimuli directed to our 
body  and hence require our immediate attention. Activated nociceptors convey their in-
formation to the spinal cord, or, when our face is involved, to the brainstem [24, 80]. 
In the spinal cord and the brainstem, nociceptors establish the first synapse in the pain 
system by contacting second order nociceptive neurons [76]. There are two main types 
of nociceptive fibers, namely slow conducting unmyelinated C-fibers that are responsible 
for the dull aching pain, and fast conducting myelinated Aδ-fibers that are responsible for 
acute pin prick-like pain [22, 72]. C-fibers contact nociceptive neurons located in lamina I 
and especially lamina II, while Aδ-fibers project to secondary nociceptive neurons mainly 
in laminae I, IV and V [76]. Subsequently, via crossing axons of the second order neurons 
nociceptive information is conducted contralaterally to various nuclei in the brainstem, 
the midbrain and the thalamus by way of the antero-lateral system [23]. 
 The antero-lateral system contains several important ascending pathways includ-
ing projections to: 1) the thalamus, i.e. spinothalamic tract (STT) [23]; 2) the homeostatic 
control regions in the medulla and the brainstem, i.e. spinomedullary, spinopontine and 
spinomesencephalic pathways that project to the regions of catecholamine cell groups 
(A1-A7) [23, 68], the parabrachial nucleus (PB) [10, 14, 26], the periaqueductal grey (PAG) 
[82], and the reticular formation of the medulla and pons [9]; 3) the hypothalamus (the 
spinohypothalamic tract, SHT) and the ventral part of the forebrain [17]. In addition there 
are projections to the forebrain, originating in the brainstem, which include the anterior 
cingulate cortex (ACC), the insular cortex (IC) and the prefrontal cortex [23]. Further, there 
are also nociceptive projections to the SI and SII regions in the somato-sensory cortex, 
mainly through the thalamus [15]. While the projections to the somato-sensory cortex 
are primarily involved in identifying the location and intensity of the nociceptive stimulus 
[48, 49, 60], the projections to the limbic forebrain provide the basis for the emotional 
impact of the nociceptive stimulus [7, 31, 51, 79]. Collectively, these various supraspinal 
structures that are involved in pain processing are known as the pain matrix [11, 63]. The 
pain matrix, which includes sensory, motor, cognitive and emotional parts of the brain, 
emphasizes that the feeling of pain is a multidimensional percept, in line with the fact that 
pain is of essential importance in our daily lives. 
1.3. Hyperalgesia and allodynia: increased sensitivity to pain stimuli
 As experienced in daily life, an injury usually leads to a direct painful sensation. 
However, when the initial pain has subsided and the healing process has started, the area 
of injury often becomes more sensitive to both noxious and non-noxious stimuli. This con-
dition, in which a non-noxious stimulus is perceived as painful (referred to as allodynia) 
and a noxious stimulus causes more pain than normal (referred to as hyperalgesia) [12, 45, 
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85] is important, since both allodynia and hyperalgesia will make a subject to protect the 
injured area, thus aiding the healing process. The increased sensitivity of the injured area 
to non-noxious and noxious stimuli is the result of an increased sensitivity of nociceptors 
in the periphery (peripheral or primary sensitization) as well as neurons in the spinal cord 
(central or secondary sensitization) [83, 86]. In addition, descending pathways originating 
in the brainstem further facilitate this process by modulating the sensitivity of the spinal 
nociceptive neurons [66, 81]. 
1.4. Chronic pain
 The feeling of pain usually subsides with the disappearance of the nociceptive 
stimuli during the healing time. However, when an injury becomes chronic the associ-
ated pain, including allodynia and hyperalgesia, will persist. For example, during chronic 
arthritis the joints are affected by chronic inflammation [52], and the patients suffering 
from such a disease complain of a nagging pain in the affected joints, together with limi-
tations of their movements due to their painfulness. Treatment is directed at eliminating 
or decreasing the inflammation process and suppressing the pain, using analgesics [75]. 
Another major cause of chronic pain is the so-called neuropathic pain, which develops 
after nerve injury, e.g. after transection by trauma or surgery, or after ischemic events 
[21]. Post-injury, there is ectopic firing in the damaged nerve, increased sensitivity of spi-
nal nociceptive neurons, and altered descending control originating in the brainstem [5, 
37, 59]. All these changes lead to spontaneous pain without the presence of a noxious 
stimulus at the injured area, often accompanied by allodynia and hyperalgesia [16, 84]. 
More so than chronic inflammatory pain, neuropathic pain is notoriously difficult to treat 
with even the strongest analgesics [5]. Both chronic inflammatory and neuropathic pain 
are seriously debilitating conditions that affects millions of people worldwide [19]. Thus, 
research dedicated to the understanding of the processes underlying chronic inflamma-
tory and neuropathic pain is of essential importance for patients in need of pain relief. 
1.5. Pain inhibition at the spinal cord level
1.5.1. Spinal inhibitory interneurons
 Incoming nociceptive fibers not only contact projection neurons that relay the in-
formation to higher centers but also local excitatory and inhibitory interneurons [18, 27]. 
These interneurons are involved in controlling the spinal sensitivity to incoming nocicep-
tive stimuli [41, 78, 90], and are therefore believed to contribute to the maintenance of 
chronic pain states [90]. Recently, it has been shown that glial cells, especially microglia, 
are also involved in gating the sensitivity for nociceptive stimuli, especially during neuro-
pathic pain [13, 44, 69]. Thus, spinal projections neurons, local interneurons and glial cells 
form an intricate network that controls the nociceptive information that is conveyed to 
supraspinal sites, thereby strongly influencing the pain that is experienced. 
 Inhibitory neurons use the fast neurotransmitters glycine and/or GABA as their 
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inhibitory neurotransmitter(s) [2, 46]. The importance of GABA and glycine in pain trans-
mission was shown by blocking glycinergic and/or GABAergic neurotransmission in naïve 
animals, which induced many behavioral signs of hypersensitivity as observed in inflam-
matory and neuropathic pain conditions [70, 71, 87]. Accordingly, decreased inhibition 
was found in the spinal cord during chronic inflammatory pain [58, 64], as glycinergic inhi-
bition in the spinal cord was blocked by a pathway involving prostaglandin E2 (PGE2) [90]. 
During neuropathic pain there is loss of synaptic inhibition due to a shift in the neuronal 
chloride gradient, which reverses the inhibitory effect of GABA into a depolarizing one 
[13]. Further, it was recently shown that selective activation of GABA(A) receptors contain-
ing the α2 and/or α3 subunits leads to pronounced nociceptive inhibition in chronic pain 
states [50]. These findings underline the importance of glycine and GABA in modulating 
the spinal processing of nociceptive information, especially during chronic pain.
1.5.2. Rostral ventromedial medulla 
 Next to the influence exerted by spinal interneurons, the spinal nociceptive sys-
tem is also under control of descending projections originating in the brainstem, espe-
cially from the locus coeruleus and subcoeruleus, and the rostral ventromedial medulla 
(RVM) [29, 36, 81]. The RVM, which is largely located in the pons, is predominantly un-
der control of PAG that is located in the midbrain [36]. In turn, PAG receives projections 
from several cortical and subcortical structures such as the ACC, IC, hypothalamus and the 
amygdala (Amy) [3, 67, 89]. The first evidence that descending pathways are able to con-
trol pain transmission in the spinal cord was provided in 1976 [55] by producing analgesia 
with electrical stimulation of the PAG, without affecting the animal’s response to most 
other environmental stimuli. Since the PAG has no direct projections to the dorsal horn 
[53], its effects are produced through its connections with the RVM, which has extensive 
projection to the spinal dorsal horn [30, 36]. Therefore, the PAG-RVM circuitry is of critical 
importance for the descending control of pain transmission in the spinal cord. 
 It has been shown that microinjection of morphine into the Amy, IC, PAG or RVM 
produces analgesia, while the analgesic effect of systemic administered opioids is abol-
ished by microinjection of opioid antagonists into these sites [88]. With respect to the 
RVM, it has been shown that electrical stimulation of the RVM produces direct inhibition 
of spinal nociception [65], which is also produced by microinjection of excitatory amino 
acids into the RVM [29]. Further, there is enhancement of descending inhibition from the 
RVM in animals with chronic inflammatory pain induced by injection of complete Freund’s 
adjuvant (CFA) [65]. Next to descending inhibition, RVM also facilitates spinal nociception, 
i.e. enhancing of nociceptive transmission, in inflammatory and neuropathic pain models 
resulting in hyperalgesia and allodynia [81]. Thus, the PAG-RVM system is capable of inhib-
iting and facilitating spinal nociception in certain pain models through RVM projections to 
the spinal dorsal horn.  
 The existence of a parallel inhibitory and facilitatory output from the RVM suggest 
that there are distinct neurons in the RVM that are involved in inhibiting or facilitating spi-
         12
Chapter I
nal nociception. In the RVM there are indeed three different, physiologically characterized, 
neuronal cell types that project to the dorsal horn and have distinct noxious stimulus de-
pendent activity patterns. The ON-cells, which enter a period of activity before execution 
of a withdrawal reflex from a noxious heat, and have a net facilitatory effect on nocicep-
tion [29]. The OFF-cells, which enter a period of silence before execution of a withdrawal 
reflex and have a net inhibitory effect on nociception [35]. The third group, which was 
termed neutral cells, was classified by exclusion. These cells have no characteristic noxious 
stimulus dependent activity pattern and therefore are most likely not involved in the acute 
modulation of nociception [29, 54]. With respect to their neurochemical characteristics, 
there is still no convincing evidence which neurotransmitters the ON- and OFF-cells use to 
induce facilitation and inhibition, respectively [28, 57]. For a long time it was believed that 
serotonin was the neurotransmitter that induced pain inhibition at spinal level [33, 43]. 
However, later on other studies have shown the involvement of serotonin in facilitating 
spinal nociception [77], and that a subgroup of the neutral cells contain  serotonin rather 
than the OFF-cells [32, 61]. Anterograde tracing from the RVM area, combined with GABA 
and glycine immunohistochemistry (IHC) at the ultrastructural level [20, 38, 39, 40] has 
shown that the terminals of the RVM fibers in the spinal dorsal horn contain glycine and 
GABA [1]. Up to now it is not clear whether these transmitters are present exclusively in 
the OFF-cells and whether the ON-cells, which have a facilitatory effect on pain transmis-
sion in the dorsal horn  use glutamate as their neurotransmitter [28, 57]. 
1.6. Aim of this PhD project
 Spinal neurons that use GABA and/or glycine as their inhibitory neurotransmit-
ters (Gly/GABA neurons) play important roles in spinal nociception. Most likely, Gly/GABA 
neurons in the RVM that project to the spinal dorsal horn are also important in modulat-
ing spinal nociception, although up to now there is lack of evidence for their expression in 
OFF-cells and their involvement in spinal nociception. It has proven difficult to stain glycin-
ergic and GABAergic neurons since using IHC to identify glycine, GABA, or their transmem-
brane transporters results in weak soma labeling and intense terminal labeling [4, 34, 42]. 
Therefore, the method of choice for identifying these inhibitory neurons is in situ hybrid-
ization (ISH), which will identify the mRNA of proteins that are specific for neurons that 
use glycine or GABA as their transmitter. Since mRNA is present in the cell soma and not 
in the terminals, ISH well label exclusively the cell somata of these neurons. In our studies 
we have used the glycine transporter 2 (GlyT2) [62, 73] to specifically identify the somata 
of glycinergic neurons, and glutamic acid decarboxylase (GAD) 67 [25, 47] to identify the 
somata of GABAergic neurons
 In this PhD project, we have combined fluorescent ISH (FISH) for GlyT2 and GAD67 
mRNA with fluorescent IHC, and with fluorescent tracing. Using these techniques we have 
investigated the activity patterns of Gly/GABA neurons in the spinal cord as well as the 
descending projections from the RVM. In Chapter 2 we have described the distribution 
pattern of spinal glycinergic neuronal somata in the rat spinal cord. In Chapter 3 the activa-
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tion pattern of spinal inhibitory neurons in acute and chronic pain states was investigated. 
In Chapter 4 we have determined the activation pattern of spinal inhibitory neurons after 
stimulation with capsaicin in rats with chronic inflammatory or neuropathic pain, and in 
Chapter 5 the distribution pattern of RVM neurons that are inhibitory and project to the 
spinal cord was investigated. In addition, we have identified a new pathway that projects 
to the RVM that is inhibitory and originates in the spinal cord. In Chapter 6 we have de-
scribed the expression pattern of the immediate early gene Arc/Arg3.1 in the rat spinal 
cord in various acute and chronic pain models, with a focus on inhibitory Gly/GABA and 
enkephalinergic neurons, as well as the neurokinin-1 expressing nociceptive projection 
neurons. Further, we have determined the behavioral response of Arc/Arg3.1 knockout 
mice to acute and chronic pain stimuli. Finally, in the general discussion, Chapter 7, we 
discuss the various findings in a broader perspective.
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Glycine transporter 2 (GlyT2) mRNA is exclusively expressed in glycinergic neurons, and is
presently considered a reliable marker for glycinergic neuronal somata. In this study, we
have performed non-radioactive in situ hybridization to localize GlyT2 mRNA in fixed free-
floating sections of cervical (C2 and C6), thoracic (T5), lumbar (L2 and L5) and sacral (S1)
segments of the rat spinal cord. The results showed that in all segments the majority of the
GlyT2 mRNA labeled (glycinergic) neuronal somata was present in the deep dorsal horn and
the intermediate zone (laminae III–VIII), with around 50% (range 43.7–70.9%) in laminae
VII&VIII. In contrast, the superficial dorsal horn, the motoneuronal cell groups and the area
around the central canal contained only few glycinergic neuronal somata. The density
(number of glycinergic neuronal somata per mm2) was also low in these areas, while the
highest densities were found in laminae V to VIII. The lateral spinal nucleus and the lateral
cervical nucleus also contained a limited number of glycinergic neurons.
Our findings showed that the distribution pattern of the glycinergic neuronal somata is
similar in all the examined segments. The few differences that were found in the relative
laminar distribution between someof the segments, aremost likely due to technical reasons.
We therefore conclude that the observed distribution pattern of glycinergic neuronal somata
is present throughout the spinal cord. Our findings further showed that the non-radioactive
in situ hybridization technique for identifying GlyT2mRNA in fixed free-floating sections is a
highly efficient tool for identifying glycinergic neurons in the spinal cord.
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1. Introduction
Strong evidence that the amino acid glycine is acting as a
neurotransmitter in themammalian spinal cord was provided
for the first time in 1965 (Aprison and Werman, 1965). In
subsequent years glycine became established as the main
inhibitory neurotransmitter in the caudal region of the central
nervous system (CNS), next to the amino acid γ-aminobutyric
acid (GABA). Glycinergic neurons are abundantly present in
the spinal cord, brainstem and cerebellum (Borowsky et al.,
1993; Luque et al., 1995), but scarce in rostral parts of the CNS,
like the diencephalon and hippocampus (Rampon et al., 1996;
Song et al., 2006).
The main strategies for identifying neurons that use an
amino acid as neurotransmitter are based on the localization
of the transmitter, its biosynthetic enzyme, or its transporter.
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Antibodies against glycine have been used most frequently to
identify glycinergic neurons (Campistron et al., 1986; Rampon
et al., 1996; Todd and Sullivan, 1990). In general, glycine
antibodies preferentially stain glycinergic terminals because
they contain a high concentration of glycine, while soma
labeling is much weaker. However, in recent reports (Allain et
al., 2006; Song et al., 2006; Zeilhofer et al., 2005) a glycine
antibody was used that was directed against paraformalde-
hyde-fixed glycine (Pow et al., 1995), resulting in a much
improved staining of neuronal somata in addition to axons
and terminals. The use of antibodies against the biosynthetic
enzyme that produces glycine in the brain, serine hydroxy-
methyltransferase, has never been reported, probably because
the activity of this enzyme is correlated with the general pool
of glycine (Daly and Aprison, 1974), rather than with the
transmitter pool. Similarly the vesicle transporter that trans-
ports glycine also transports GABA, and therefore cannot be
used for identifying glycinergic neurons only (Chaudhry et al.,
1998). However, glycine transporter 2 (GlyT2), one of the GlyTs
(Zafra et al., 1995a,b), is present exclusively in the plasma
membrane of glycinergic neurons (Jursky and Nelson, 1995;
Luque et al., 1995), where it is primarily involved in the
reuptake of synaptically released glycine (Betz et al., 2006).
GlyT1, on the other hand, is exclusively present in glial cells
(Adams et al., 1995; Zafra et al., 1995a,b). Since GlyT2 is the
only marker that is present exclusively in glycinergic neurons
(Poyatos et al., 1997; Spike et al., 1997), and GlyT2 antibodies
preferentially label glycinergic terminals rather than somata
(Jursky and Nelson, 1995; Spike et al., 1997), GlyT2 in situ
hybridization is the method of choice for identifying glyciner-
gic neuronal somata. GlyT2 mRNA has been identified
previously in the spinal cord by means of radioactive in situ
hybridization (Zafra et al., 1995a). Since these studies
described GlyT2 mRNA distribution throughout the CNS, the
descriptions of the spinal cord were not very detailed. This
study, which is the first step in our investigations on the role
of glycinergic neurons in spinal sensory processing, was set up
to obtain detailed knowledge on the distribution of spinal
glycinergic neuronal somata at different levels of the spinal
cord. For this purpose, we used non-radioactive in situ
hybridization for GlyT2 mRNA on thick fixed free-floating
sections.
2. Results
2.1. General observations
Light microscopic examination of the sections showed a
bluish reaction product, representing the presence of GlyT2
mRNA, in a limited number of neuronal somata of various
sizes. No staining was found in glial cells or fiber tracts.
Staining was only present in neuronal somata, sometimes
including their primary dendrites. Control sections hybridized
with sense probes did not show any specific labeling.
Themajority of the labeled neuronal somata were found in
the deep dorsal horn and the adjoining intermediate zone
(laminae VII&VIII) of the ventral horn (Fig. 1). In laminae I&II
(Fig. 2A) the number of labeled neuronal somata observed
never exceeded four neurons per section. The few labeled
somata in lamina II were often located close to the border with
lamina III. Laminae III to VI of the dorsal horn contained
several labeled neurons, varying in size from 10 to 30 μm (Fig.
2B). In laminae IV, V&VI, labeled neuronal somata were more
abundant medially than laterally (Figs. 1, 2B). The intermedi-
ate zone of the ventral horn also contained many labeled
somata, including several of the largest labeled somata (Fig. 3).
The large presumed motoneurons in lamina IX were never
labeled. Occasionally a labeled neuron, considerably smaller
than the presumed motoneurons, was present within the
motoneuronal area (Figs. 1, 3A). The grey matter surrounding
the central canal (lamina X) contained few labeled neurons. In
all sections examined, a limited number of labeled neurons
were found scattered in the white matter, close to either the
dorsal or ventral horn (Figs. 1, 2A).
2.2. GlyT2 mRNA labeled neuronal somata in specialized
spinal nuclei
We have examined several specialized nuclei, i.e., groups of
cells that can be distinguished anatomically and usually
subserve specialized functions (Holstege et al., 1996) for a
more detailed description. These nuclei include the lateral
spinal nucleus (LSN), the lateral cervical nucleus (LCN), the
central cervical nucleus, the dorsal nucleus of Clarke, the
intermediomedial nucleus, the intermediolateral nucleus,
and, in the L6 segment, the dorsomedial and dorsolateral
nuclei (Onuf's nucleus). In about 25% of the sections exam-
ined, one or two labeled neurons were identified in the LSN,
which is located in the dorsolateral white matter (Fig. 4). In a
few cases, labeled neurons were also observed in the LCN,
which is present dorsal to the LSN at the C1–C3 level. In
general, in both nuclei the intensity of the labeling was weak.
The other specialized nuclei virtually never contained labeled
neurons. However, several labeled somata were usually
present around these nuclei.
2.3. Quantitative aspects
In all spinal segments examined, around 50% (range 43.7–
70.9%) of the labeled neurons in that segment were located in
the intermediate zone of the ventral horn (laminae VII&VIII),
with the highest percentage (average 70.9%) at level L2 (Table
1). The superficial dorsal horn (laminae I&II), the motoneur-
onal cell groups (lamina IX) and lamina X contained the lowest
percentage of glycinergic neurons (Table 1). A comparison
between the segmental levels for each lamina separately (a
total of 135 comparisons using the Bonferroni post hoc test)
showed that in the large majority of the cases (116) there were
no significant differences between the different segmental
levels. The 19 cases that were significantly different (Table 1)
were found mostly in L2 and S1. At the L2 segmental level, the
average percentage in laminae V&VI (13.5%) was significantly
lower than the percentage obtained for the same laminae in
the other segments analyzed, while the average in laminae
VII&VIII (70.9%) was significantly higher. In S1 lamina IV only
contained 3.3% of the neurons at this level, significantly lower
than most of the other segmental levels, while the average
percentage (64.7%) obtained for laminae VII&VIII was signifi-
cantly higher.
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Fig. 1 – Schematic drawings illustrating the distribution of GlyT2 mRNA labeled (glycinergic) neuronal somata in analyzed
single sections from rat spinal segments C2, C6, T5, L2, L5 and S1. Neurons in the dorsolateral funiculus are located in the lateral
spinal nucleus. Other special nuclei are: intermediomedial nucleus (1), intermediolateral nucleus (2), central cervical nucleus
(3), and dorsal nucleus of Clarke (4).
63B R A I N R E S E A R C H 1 1 4 2 ( 2 0 0 7 ) 6 1 – 6 9
         25
Distribution pattern of glycinergic neuronal somata in the rat spinal cord
When considering the density of the neurons in each
lamina, i.e., the average number of neurons per mm2, the
highest densities are found in laminae V&VI and VII&VIII, and
the lowest densities were found in laminae I, II, IX and X (Fig.
5). A comparison between the segmental levels for each
lamina separately (a total of 120 comparisons using the
Bonferroni post hoc test, excluding the specialized nuclei)
showed that in the large majority of the cases (113) there were
no significant differences between segmental levels. The
exceptions were the density of lamina IV in the S1 segment,
which was significantly different from segments C2, C6, and
L2 (p<0.05); the density of laminae V&VI in S1, which was
significantly different from segment C6 (p<0.05), and the
density of laminae VII&VIII in L2, which was significantly
different from segments T5, L5 and S1 (p<0.05). Since the large
majority of the laminar densities in the different segmental
Fig. 2 – Light micrographs showing glycinergic neuronal
somata as identified by GlyT2mRNA labeling. (A) Few labeled
somata are present in the superficial dorsal horn (segment
C2), with increasing numbers of labeled somata in laminae III
and IV. Note the labeled somata in the white matter (arrows)
and the lateral spinal nucleus (LSN). Scale bar=50 μm. (B)
Glycinergic neuronal somata of various sizes in the deep
dorsal horn and the intermediate zone of the ventral horn.
1: intermediomedial nucleus, DF: dorsal funiculus, *: central
canal. Scale bare=50 μm.
Fig. 3 – Light micrographs showing labeled neuronal somata
in the lumbar ventral horn. (A) Overview of the L5 ventral
horn. Few GlyT2 mRNA labeled neuronal somata are present
in the motoneuronal cell groups (encircled areas). Scale
bar=50 μm. (B) Labeled neuronal somata in lamina VII of the
L5 spinal segment. Note the variability in size of the labeled
neurons. Scale bar=50 μm.
Fig. 4 – Light micrograph showing GlyT2 mRNA labeled
(glycinergic) neuronal somata in the lateral spinal nucleus
(LSN) at spinal segment T5. Scale bar=25 μm.
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levels were not significantly different, the average density for
each lamina(e) was calculated (Fig. 5). This showed that the
densities of laminae I, II, IX and X are each significantly lower
than the densities in the other laminae (p<0.005). The same
holds true for lamina III (p<0.05), except that the density is not
significantly different from lamina IV (p>0.05). The density of
lamina IV is also not significantly different from the density of
VII and VIII (p>0.05). Laminae V&VI have the highest average
density, although not significantly different from laminae
VII&VIII.
3. Discussion
The present study is the first detailed description of the
distribution of GlyT2 mRNA in the spinal cord, using non-
radioactive in situ hybridization on thick paraformaldehyde-
fixed free-floating sections. Previous studies on the distribu-
tion of glycinergic (GlyT2 mRNA) and/or GABAergic (GAD67
mRNA) neuronal somata (Schreihofer et al., 1999; Tanaka and
Ezure, 2004) in the brainstem have confirmed the sensitivity
(Key et al., 2001) of the detection method used in the present
study. In situ hybridization on free-floating 40-μm-thick
sections has the advantage that the sections are easy to
handle because the sections are fixed and much thicker than
slide mounted non-fixed sections. Especially the washing
steps in the procedure are more efficient on free-floating
sections, which, in our hands, lead to a higher signal-to-noise
ratio in comparison with slide mounted sections. The method
used in this study is therefore the most reliable and sensitive
approach presently available to identify spinal glycinergic
neuronal somata. It has the advantage that it can be combined
with other techniques like immunohistochemistry, and neu-
ronal tracing (Stornetta et al., 2005).
Our results show that glycinergic neuronal somata are
concentrated in the deep dorsal horn (laminae V&VI) and the
intermediate zone of the ventral horn (laminae VII&VIII). In
the superficial dorsal horn (laminae I&II), the area around the
central canal (lamina X) and the motoneuronal cell groups
(lamina IX) glycinergic neuronal somata were observed much
less frequently, while laminae III and IV hold an intermediate
position. This pattern is present in all the examined spinal
segments (i.e., C2, C6, T5, L2, L5 and S1), strongly suggesting
that this pattern is constant throughout the spinal cord.
However, our analysis also showed some exceptions to this
Table 1 – Relative laminar distribution of the glycinergic neuronal somata in different segments of the rat spinal cord
Lamina C2 C6 T5 L2 L5 S1
%±SD %±SD %±SD %±SD %±SD %±SD
I 0.3±0.5 0.3±0.4 0.4±1.0 0.2±0.4 0.1±0.3 0.0
II 1.8±1.0 1.2±0.4 0.9±2.2 0.7±0.6 0.6±0.5 1.2±1.0
III 6.3±2.2 4.6±1.4 4.9±2.6 3.9±2.2 4.2±2.4 2.1±1.9
IV 14.1±3.5a 10.3±1.7 9.8±2.7 5.9±1.5 9.7±3.0 3.3±2.0b
V&VI 28.5±2.8 29.5±5.2 18.3±5.0c 13.5±3.4d 31.7±2.8 25.4±5.9
VII&VIII 43.7±6.4 49.0±8.7 54.8±7.9 70.9±2.1e 49.6±6.4 64.7±6.8 f
IX 1.2±1.0 3.2±3.5 2.0±2.3 1.5±1.1 3.1±1.8 1.8±1.8
X 0.5±0.5 0.6±0.6 1.2±1.3 1.4±1.3 0.5±0.9 1.5±2.7
Special nuclei 3.5±1.8 1.3±0.9 7.6±5.8 2.0±1.9 0.3±0.5 0.0
n 606 760 255 720 788 356
For each lamina of the C2, C6, T5, L2, L5 and S1 segments the average percentage (±SD) of the total number of glycinergic neuronal somata is
shown. n: Total number of labeled neuronal somata.
a Lamina IV in C2 is significantly different from the same lamina in L2 (p<0.005).
b Lamina IV in S1 is significantly different from C2, C6, T5, and L5 (p<0.005).
c Laminae V&VI in T5 is significantly different from C2, C6, and L5 (p<0.005).
d Laminae V&VI in L2 from C2, C6, L5, S1 (p<0.005).
e Laminae VII&VIII in L2 from C2, C6, T5, and L5 (p<0.005).
f Laminae VII&VIII in S1 from C2, C6, and L5 (p<0.005).
Fig. 5 – Average density of glycinergic neuronal somata per
lamina in the analyzed segments. An increasing density is
observed in the intermediate zone, while the superficial
laminae, the motoneuronal cell groups (lamina IX) and
lamina X have the lowest density. N/mm2: calculated number
of labeled glycinergic neuronal somata per mm2. *Laminae I,
II, IX and X are significantly different from laminae III, IV,
V&VI, and VIII&VIII (p<0.005). **Lamina III is significantly
different from all the other laminae (p<0.05), except lamina
IV. ***Lamina IV is significantly different from all the other
laminae (p<0.005), except laminae III and VII&VIII.
****Laminae V&VI are significantly different from all other
laminae (p<0.005), except laminae VII&VIII. Error bars
represent ±SD.
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rule, especially at spinal levels L2 (laminae V&VI, and VII&VIII)
and S1 (laminae IV, and VII&VIII). The most simple explana-
tion for this finding is that the laminar boundaries at the L2
and S1 level were identified incorrectly or that their location
leads to relatively large differences in surface area as
compared with the other segments. Especially at the L2
level, a ventral shift of the boundary between laminae V and
VII, would increase the percentage of neurons in laminae V
and decrease the percentage in laminae VII&VIII, likely
resulting in the disappearance of the significant differences
between the L2 and the other segments. Also in S1, which is a
relatively small segment, small changes in boundary delinea-
tion may easily lead to significant changes in the percentages
that were obtained. We therefore consider that the few
significant differences in the laminar percentages that were
found between segments are due to technical reasons, and do
not signify any functional difference in the role of glycinergic
neurons in these segments.
The bulk of the glycinergic neuronal somata was found in
the intermediate zone (laminae VII&VIII). This finding is not
surprising considering that this is the largest area as
compared with the other spinal laminae. Thus even if the
glycinergic neurons were evenly distributed over all the
laminae in a section, the percentage of neurons in laminae
VII&VIII would still be the highest. Therefore, we also
calculated the average density of the glycinergic neurons in
the different laminae. This showed that the superficial dorsal
horn, the motoneuronal cell groups and lamina X have the
lowest density. In case of the superficial dorsal horn, it may be
expected that the density of glycinergic neurons would be
relatively high considering the small surface area of these
laminae. In contrast the density of the superficial laminaewas
very low, which confirms that these laminae are almost
devoid of glycinergic neuronal somata.
The highest percentages of glycinergic neuronal somata in
the various segments were found in laminae, V&VI and
VII&VIII. These laminae also contained the highest densities
of glycinergic neurons, which confirms the specific concen-
tration of glycinergic neurons in these laminae.
In the analyzed specialized nuclei, only the LSN and LCN
contained glycinergic neurons. This finding likely indicates
that some of the widespread descending (Jansen and Loewy,
1997) and ascending (Ding et al., 1995; Keay et al., 1997)
projections originating in the LSN are in part glycinergic.
Only one previous study (Todd and Sullivan, 1990) has
provided a detailed description of glycinergic neuronal
somata in the adult spinal cord with a focus on the superficial
dorsal horn. This study used glycine antibodies in combina-
tion with pre-embedding immunohistochemistry on semi-
thin plastic sections of rat lumbar segments. Their results are
in general agreement with the results of the present study
and show the same distribution pattern: a concentration of
glycinergic neuronal somata in the deep dorsal horn and the
intermediate zone of the ventral horn, while glycinergic
neuronal somata are nearly absent from the superficial dorsal
horn. Our findings further showed that this distribution
pattern is similar in all the examined segments. Since the few
differences that were found in the relative laminar distribu-
tion between some of the segments, are most likely due to
technical reasons, we conclude that the observed distribution
pattern of glycinergic neuronal somata is present throughout
the spinal cord.
The functional significance of the laminar localization of
glycinergic neuronal somata can only be appreciated in
combination with many other data on these neurons, includ-
ing the size of their dendritic tree, their axonal projection area,
the parameters that determine the release of glycine and the
properties of the postsynaptic glycine receptors. The dendritic
tree of spinal neurons may extend into several neighboring
laminae (Willis and Coggeshall, 2003). However, the morphol-
ogy of the dendritic tree of glycinergic neurons is largely
unknown. Similarly, little is known about the axonal arboriza-
tion of glycinergic neurons. Areas that contain very few
glycinergic neuronal somata, as we have shown here for the
superficial dorsal horn (laminae I&II) and the motoneuronal
cell groups (lamina IX), contain many glycinergic terminals
(Rekling et al., 2000; Todd, 1990). It seems likely that the
majority of these terminals is derived from spinal neurons
located in other laminae, while some are derived from
supraspinal sources (Antal et al., 1996; Holstege and Bongers,
1991). A lot more is known about the release properties and
effects of glycine on other neurons. In this respect it is
important to realize that both in the dorsal (Todd and Sullivan,
1990; Todd et al., 1996) and ventral horn (Taal and Holstege,
1994) glycine is often colocalized and co-released with GABA.
However, there are also sets of neurons that contain glycine
without GABA and vice versa, e.g., neurons in the intermediate
zone that presynaptically inhibit Ia afferents on motoneurons
only contain GABA and not glycine (Hughes et al., 2005; Mackie
et al., 2003). In view of all these variables, it is likely that the
glycinergic neurons in a specific lamina fulfill diverse func-
tions. In laminae II–V the action of glycinergic neuronsmay be
focused on the influencing sensory transmission (Willis and
Coggeshall, 2003; Zeilhofer, 2005), while neurons in deeper
laminae may be involved in affecting motor transmission
(Rekling et al., 2000). In addition there are neurons in many of
these laminae that project to supraspinal brain areas and
some of these neurons may use glycine as a transmitter,
although direct evidence for such a glycinergic projection is
presently lacking.
Recently, glycinergic neurons in the spinal cord were also
identified on the basis of the expression of GlyT2, but using a
very different approach, namely by producing transgenicmice
expressing enhanced green fluorescent protein (eGFP) under
the control of the promotor of the GlyT2 gene (Zeilhofer et al.,
2005). This study showed that the large majority of the eGFP
producing neurons in the brain were also immunoreactive for
glycine (in somata, dendrites and terminals) and GlyT2 (in
terminals). However, in the dorsal horn, the area of the spinal
cord examined in this paper, it was found that several glycine
immunoreactive neuronal somata did not express eGFP and
vice versa. In lamina II a subset of neurons was described as
glycine immunoreactive, without expressing eGFP. In this case
our findings in the rat dorsal horn would support the eGFP
expression pattern, since we also found very few neurons in
lamina II expressing GlyT2 mRNA. Whether this would
indicate that there is a subset of neurons in lamina II that
uses glycine as a transmitter without expressing GlyT2, or
whether these cells show a high level of glycine, but do not use
it as a transmitter, is unclear.
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In this study we have identified glycinergic neurons
throughout the spinal cord using GlyT2 mRNA in situ
hybridization. We have shown that glycinergic neurons are
concentrated in laminae III–VIII and provided evidence that
this pattern is constant throughout the spinal cord. These
findings provide a solid anatomical basis for further studies on
the role of glycine in the spinal cord.
4. Experimental procedures
4.1. Tissue preparation
In this studywe used 18maleWistar rats, including six rats for
quantitative analysis. Rats received an overdose of sodium
pentobarbital and were transcardially perfused with 150 ml
saline followed by 750 ml of 4% paraformaldehyde (PFA) in
0.12 M phosphate buffer (PB), pH 7.4. Subsequently, the entire
spinal cord was dissected and left overnight in a RNAse-free
solution of 4% PFA and 30% sucrose dissolved in 0.12 M PB at
4 °C. All the experiments have been approvedby the Rotterdam
Animal Ethics Committee.
4.2. In situ hybridization
All the solutions used in the following steps until the
hybridization step were Diethylpyrocarbonat (DEPC)-treated.
The regions of interest of the spinal cord were cut transver-
sally in 40-μm sections on a freezing microtome and collected
in 0.05 M PB. The sections were then treated with 0.2% glycine
in phosphate-buffered saline (PBS, 5 min), rinsed in PBS, and
then treated (10 min) in PBS containing 0.1 M triethanolamine
(Merck, Germany) pH 8.0 and 0.0025% acetic anhydride (Sigma-
Aldrich, Germany). Sections were then washed in 4× standard
saline citrate (SSC, pH 4.5) and prehybridized for 1 h at 65 °C in
hybridization mixture consisting of 50% formamide, 5× SSC
(pH 4.5), 2% Blocking Reagent (Roche), 0.05% 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate (CHAPS,
Sigma-Aldrich), 1 μg/ml yeast tRNA (tRNA brewer's yeast,
Sigma), 5mM EDTA (pH 8.0), 50 μg/ml Heparin (Sigma-Aldrich),
and 1× Denhardt's solution (Sigma-Aldrich).
The GlyT2 mRNA was obtained from a partial cDNA
template (3.1 kb; a generous gift from Dr. N. Nelson, Tel Aviv
University), encoding GlyT2. The riboprobes were obtained by
linearizing the recombinant plasmids with restriction
enzymes (XbaI for GlyT2 antisense, HindIII for GlyT2 sense)
and transcribed with RNA polymerases (T7 for GlyT2 anti-
sense, T3 for GlyT2 sense) in the presence of digoxigenin (DIG)-
labeled 11-UTP (Roche).
The sections were hybridized for 16–24 h at 65 °C in
hybridization mixture (minus Denhardt's) containing 500–
600 pg/μl of GlyT2 anti-sense riboprobes. Some sections were
hybridized with sense probe at a matched concentration to
serve as control. After hybridization, the sections were
washed in 2× SSC (pH 4.5), followed by three washes of
15 min each in 2× SSC (pH 4.5)/50% formamide at 65 °C, and
finally washed in PBS. The sections were then pre-incubated
(90 min, room temperature) in BSA-blocking solution consist-
ing of PBS, 5% BSA (bovine serum albumin, Fraction V, Roche)
and 0.5% Triton X-100. For detection of DIG, the sections were
incubated in 2% BSA-blocking solution with anti-digoxigenin
antibody conjugated to alkaline phosphatase (Roche) diluted
1:4000 (overnight, 4 °C). Subsequently, the sections were
washed in TBST (0.14 M NaCl, 2.7 mM KCl, 25 mM Tris/HCl
(pH 7.5), and 0.1% Tween-20), followed by NTM (100 mM NaCl,
100mMTris/HCl (pH 9.5), and 50mMMgCl2). The blue reaction
product was produced by the reaction of alkaline phosphatase
with levamisol, NBT (nitroblue tetrazolium; Roche) and BCIP
(5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt;
Roche) for 1.5–2 h at room temperature in the dark. Usually,
the exact reaction time was determined by assessing the
staining in the light microscope. The sections were randomly
mounted on slides, air dried overnight, dehydrated using
absolute ethanol (<0.01%methanol), transferred to xylene and
coverslipped with Permount (Fisher, Hampton, NH).
4.3. Data analysis
Light micrographs were made with a digital camera and
processed using Adobe Photoshop. The images were not
manipulated, except for brightness and contrast.
Analysis was carried out on cervical (C2 and C6), thoracic
(T5), lumbar (L2 and L5), and sacral (S1) segments from six
rats. Between 15 and 20 sections per segment were mounted
on a slide in a random order. In the microscope, the slide
was systematically examined, starting with the first section
in the first row. The first section of the appropriate
segmental level that was encountered was used for analysis.
Occasionally this section appeared damaged during the
procedure or incorrectly mounted, in which case the section
was discarded. Thus a total of 36 sections were analyzed.
Using a camera lucida microscope (Neurolucida, MicroBright-
field Inc., Williston, VT) the outline of the white and grey
matter, the boundaries between the laminae and the contour
of several spinal nuclei were drawn unilaterally (Molander et
al., 1984, 1989), after which the labeled neurons were plotted
in the drawing. A neuron was considered labeled only if the
largest diameter was at least 10 μm, the cell soma contained
a bluish reaction product and a non-stained nucleus was
apparent. The number of plotted neurons per lamina was
expressed as a percentage of the total number of neurons
plotted in that section. The results obtained in the six rats
were averaged for each lamina per segment. The density of
glycinergic neurons per lamina is expressed as the number
of plotted neurons in a lamina divided by the surface area,
expressed in mm2, of that lamina, as calculated by Neuro-
lucida. The results obtained in the six rats were averaged for
each laminar density per segment. The data for both the
laminar distribution and the density of glycinergic neuronal
somata were analyzed by performing the one-way ANOVA
test followed by the Bonferroni post hoc test. p<0.05 was
considered as significant.
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a b s t r a c t
The inhibitory transmitters GABA and glycine play an important role in modulating pain transmission,
both in normal and in pathological situations. In the present study we have combined in situ hybridiza-
tion for identifying spinal neurons that use the transmitter(s) glycine and/or GABA (Gly/GABA neurons)
with immunohistochemistry for c-fos, a marker for neuronal activation. This procedure was used with
acute pain models induced by the injection of capsaicin or formalin; and chronic pain models using Com-
plete Freund’s Adjuvant (CFA, chronic inﬂammation), and the spared nerve injury (SNI) model (neuro-
pathic pain). In all models Gly/GABA neurons were activated as indicated by their expression of c-fos.
The pattern of Gly/GABA neuronal activation was different for every model, both anatomically and quan-
titatively. However, the averaged percentage of activated neurons that were Gly/GABA in the chronic
phase (P20 h survival, 46%) was signiﬁcantly higher than in the acute phase (62 h survival, 34%). In addi-
tion, the total numbers of activated Gly/GABA neurons were similar in both phases, showing that the acti-
vation of non-Gly/GABA (presumed excitatory) neurons in the chronic phase decreased. Finally, morphine
application equally decreased the total number of activated neurons and activated Gly/GABA neurons.
This showed that morphine did not speciﬁcally activate Gly/GABA neurons to achieve nociceptive inhibi-
tion. The present study shows an increased activity of Gly/GABA neurons in acute and chronic models.
This mechanism, together with mechanisms that antagonize the effects of GABA and glycine at the recep-
tor level, may determine the sensitivity of our pain system during health and disease.
 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
Nociceptors convey their information from the periphery to the
spinal cord where they target secondary neurons located in the
superﬁcial (laminae I–II) and deep (laminae III–VI) dorsal horns
[45]. While a subpopulation of these secondary neurons is projec-
tion neurons that relay the nociceptive information to higher cen-
ters [40], the majority are local interneurons [4]. A substantial
number of these interneurons contain the fast inhibitory transmit-
ters GABA and glycine, often colocalized in the same cell [47,48]
and these neurons are directly innervated by primary afferent ﬁ-
bers [10,14]. The importance of GABA and glycine in pain transmis-
sion was shown by blocking glycinergic and/or GABAergic
neurotransmission in naïve animals, which induced many behav-
ioral signs of hypersensitivity as observed in inﬂammatory and
neuropathic pain conditions [38,39,50].
Accordingly, decreased inhibition was found in the spinal cord
during chronic inﬂammatory pain [33,37]. In this condition, glycin-
ergic inhibition in the spinal cord is blocked by a pathway involv-
ing prostaglandin E2 (PGE2). When this PGE2-induced blockade
was prevented (<24 h) the thermal and mechanical sensitizations
of inﬂammatory pain did not appear [52]. During neuropathic pain
there is loss of synaptic inhibition due to a shift in the neuronal
chloride gradient, which reverses the inhibitory effect of GABA into
a depolarizing one [9]. Further, it was recently shown that selective
activation of GABA(A) receptors containing the a2 and/or a3 sub-
units [26] leads to pronounced nociceptive inhibition.
The studies described above underline the importance of gly-
cine and GABA in modulating the spinal processing of nociceptive
information, especially during chronic pain. However, little is
known about the activity of inhibitory neurons, and changes there-
in, during different pain states. For identifying neurons that were
recently activated, the expression of c-fos protein has been used
extensively in the nociceptive system [8], showing that spinal c-
fos expression patterns are correlated with the type, intensity
and duration of nociceptive stimuli [8]. However, data on the acti-
vation patterns of spinal inhibitory neurons during different pain
states are scarce. So far, three studies have [46,54,55] identiﬁed
activated glycinergic and/or GABAergic (Gly/GABA) neurons after
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Abstract
 The inhibitory transmitters GABA and glycine play an important role in modulating 
pain transmission, both in normal and pathological situations. In the present study we have 
combined in situ hybridization for identifying spinal neurons that use the transmitter(s) 
glycine and/or GABA (Gly/GABA neurons) with immunohistochemistry for c-fos, a marker 
for neuronal activation. This procedure was used with acute pain models induced by injec-
tion of capsaicin or formalin; and chronic pain models using Complete Freund’s Adjuvant 
(CFA, chronic inflammation), and the spared nerve injury (SNI) model (neuropathic pain).
 In all models Gly/GABA neurons were activated as indicated by their expression 
of c-fos. The pattern of Gly/GABA neuronal activation was different for every model, both 
anatomically and quantitatively. However, the averaged percentage of activated neurons 
that were Gly/GABA in the chronic phase (≥ 20 hrs survival, 46%) was significantly higher 
than in the acute phase (≤ 2 hrs survival, 34%). In addition, the total numbers of activated 
Gly/GABA neurons were similar in both phases, showing that the activation of non-Gly/
GABA (presumed excitatory) neurons in the chronic phase decreased. Finally, morphine 
application equally decreased the total number of activated neurons and activated Gly/
GABA neurons. This shows that morphine did not specifically activate Gly/GABA neurons 
to achieve nociceptive inhibition.
 The present study shows an increased activity of Gly/GABA neurons in acute and 
chronic models. This mechanism, together with mechanisms that antagonize the effects 
of GABA and glycine at the receptor level, may determine the sensitivity of our pain sys-
tem during health and disease.
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1. Introduction
 Nociceptors convey their information from the periphery to the spinal cord where 
they target secondary neurons located in the superficial (laminae I-II) and deep (laminae 
III-VI) dorsal horn [45]. While a subpopulation of these secondary neurons are projec-
tion neurons that relay the nociceptive information to higher centers [40], the majority 
are local interneurons [4]. A substantial number of these interneurons contain the fast 
inhibitory transmitters GABA and glycine, often colocalized in the same cell [47,48] and 
these neurons are directly innervated by primary afferent fibers [10,14]. The importance 
of GABA and glycine in pain transmission was shown by blocking glycinergic and/or GAB-
Aergic neurotransmission in naïve animals, which induced many behavioral signs of hyper-
sensitivity as observed in inflammatory and neuropathic pain conditions [38,39,50]. 
 Accordingly, decreased inhibition was found in the spinal cord during chronic 
inflammatory pain [33,37]. In this condition, glycinergic inhibition in the spinal cord is 
blocked by a pathway involving prostaglandin E2 (PGE2). When this PGE2 induced block-
ade was prevented (<24 hrs) the thermal and mechanical sensitization of inflammatory 
pain did not appear [52]. During neuropathic pain there is loss of synaptic inhibition due to 
a shift in the neuronal chloride gradient, which reverses the inhibitory effect of GABA into 
a depolarizing one [9]. Further, it was recently shown that selective activation of GABA(A) 
receptors containing the α2 and/or α3 subunits [26] leads to pronounced nociceptive in-
hibition. 
 These studies described above underline the importance of glycine and GABA in 
modulating the spinal processing of nociceptive information, especially during chronic 
pain. However, little is known about the activity of inhibitory neurons, and changes there-
in, during different pain states. For identifying neurons that were recently activated, the 
expression of c-fos protein has been used extensively in the nociceptive system [8], show-
ing that spinal c-fos expression patterns are correlated with the type, intensity and dura-
tion of nociceptive stimuli [8]. However, data on the activation patterns of spinal inhibitory 
neurons during different pain states are scarce. So far, three studies have [46,54,55] iden-
tified activated glycinergic and/or GABAergic (Gly/GABA) neurons after acute nociceptive 
stimulation of the hind paw with capsaicin or formalin. These studies have used immuno-
histochemistry to identify the c-fos protein as well as Gly/GABA neurons. However, pres-
ently available antibodies preferentially label Gly/GABA terminals and have proven diffi-
cult for reliably labeling the somata of Gly/GABA neurons [2,17]. Therefore, in the present 
study we have used in situ hybridization with markers for Gly/GABA neurons. This tech-
nique will identify mRNA for GlyT2 (a marker for glycinergic neurons) [36,41] or GAD67 (a 
marker for GABAergic neurons) [12,24] with a high sensitivity, and can be combined with 
immunohistochemistry for c-fos [42]. Using this approach we set out to investigate the 
activation patterns of spinal Gly/GABA neurons in different acute and chronic pain states. 
For this purpose we determined the number and the percentage of c-fos labeled neurons 
that expressed GABA and/or glycine in acute (capsaicin, formalin) or chronic (inflamma-
tory and neuropathic) pain conditions. In addition, we investigated the effect of morphine 
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application on c-fos expression in Gly/GABA neurons after stimulation with formalin. 
2. Materials and methods
 In this study we used a total of 67 male Wistar rats. All animal experiments were 
approved by the Rotterdam Animal Ethical Committee. 
2.1. Pain models
 Nociceptive stimuli for the capsaicin, formalin and CFA pain models were applied 
to the left foot sole under light anesthesia (2% isofluoran in 30%O
2
/70%N
2
O; 2-3 min). The 
left foot sole was injected with either sterile saline (50μl of 0.9% NaCl, Baxter; 90 min sur-
vival, n=5), capsaicin (50μl of 0.3% N-Vanillylnonanamide, Sigma-Aldrich, diluted in 80% 
saline, 10% Tween-80, and 10% ethanol-100%; 90 min survival, n=5), Complete Freund’s 
Adjuvant (chronic inflammation model; CFA, 100μl; 90 min survival, n=5; 20 hrs survival, 
n=5; 4 days survival, n=5), or 4% paraformaldehyde (PFA diluted in 0.12 M phosphate buf-
fer pH ≈ 7.5; 45 min survival, n=5; 90 min survival, n=5). For induction of neuropathic pain, 
the animals were kept under anesthesia during the whole procedure (20-30 minutes). 
We used the SNI model according to the protocol described in [11]. In short, the three 
branches of the sciatic nerve were exposed above the knee, and the tibial and common 
peroneal branches were ligated and cut 2 mm distal to the ligation, while the sural branch 
was left intact. In the sham model, the three sciatic branches were also exposed but then 
left intact. We used survival times of 2 hrs, 1 wk and 2 wks for the SNI model and their cor-
responding sham models (n=24). In the morphine experiment, the animals received 1.5 
mg of morphine (morphine HCL-3H
2
O) subcutaneously 20 min prior to injection of forma-
lin (50µl of 4 % PFA) in the left foot sole (90 min survival, n=4). The control group received 
1.5 ml of sterile saline instead of morphine (90 min survival, n=4). 
2.2. Behavioral experiments
 The mechanical thresholds of the hind paws were assessed using the Von Frey 
hair monofilaments (Stoelting) in the capsaicin, CFA, and SNI (1 wk and 2 wks) groups. 
Before the start of the experiments, all rats were habituated to the experimenter, the 
experiment room, and a transparent cage (15cm x 15cm; gridded floor) for 5 days. There-
after, prior to each experiment the rats were habituated for 30 minutes to the experiment 
room, and for 10 minutes to the transparent cage. Each Von Frey hair was applied for 2 
seconds at 5 seconds interval, and the threshold was set at 3 evoked responses in a maxi-
mum of 5 applications. The mechanical thresholds were assessed at 60 min after injection 
in the capsaicin group, at 20 hrs (CFA 20 hrs) or 4 days (CFA 4 days) in the CFA group, and 
at 1 wk (SNI 1 wk) and 2 wks (SNI 2 wks) in the SNI group. In the morphine experiment, the 
number of flinches and flutters and the time spent licking the injected paw was measured 
during 60 min after the formalin injection.  
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2.3. Tissue preparation
 At the end of an experiment, the rats received an overdose of sodium pentobar-
bital, and were transcardially perfused with 150 ml saline followed by 750 ml of 4% PFA. 
Thereafter, the lumbar spinal cords were dissected and incubated overnight at 4 ºC in 
RNAse free solution consisting of phosphate buffer (PB), 4% PFA and 30% sucrose. Coronal 
sections were cut at 30 μm with a freezing microtome, collected in 9 separate jars and 
stored in glycerol at -20 ºC. 
2.4. Fluorescent in situ hybridization combined with fluorescent immunohistochemistry
 For fluorescent in situ hybridization (FISH), the partial cDNA templates encoding 
GlyT2 (3.1 kb; a generous gift from Dr. N. Nelson, Tel Aviv University), or GAD67 (3.2 kb; a 
generous gift from Dr. A.J. Tobin and N. Tillakaratne, PhD, UCLA) were used. The recombi-
nant plasmids were linearized, and subsequently riboprobes were transcribed using the 
appropriate RNA polymerases in the presence of fluorescein-labeled 11-UTP (Roche). For 
FISH the protocol described in [19] was applied with the following modifications. Sections 
from a jar were incubated with a mixture of GAD67 and GlyT2 probes in order to identify 
spinal inhibitory neurons (GABAergic and/or glycinergic). After riboprobe hybridization, 
the sections were incubated (48 hours at 4 ºC) with mouse monoclonal anti-fluorescein 
antibody (Roche; 1:500) and rabbit anti-c-fos (1: 4000; Oncogene Research Products, La 
Jolla, CA) in a cocktail of phosphate buffered saline (PBS), 2% milk powder (Profitar Plus, 
Nutricia) and 0.5% Triton X-100. Thereafter, sections were rinsed in PBS and incubated 
with biotinylated goat-anti-mouse (Vector; for detection of fluorescein), and donkey-anti-
rabbit tagged with Cy3 (Jackson) for detection of c-fos antibody in a 2% milk powder cock-
tail for 90 minutes at RT. Subsequently, sections were rinsed in PBS and incubated with 
Avidin-Biotin-Complex (ABC, Vector) tagged with horseradish peroxidase (HRP) for 90 min 
at RT. After rinsing in PBS, a tyramide amplification procedure was performed by reacting 
HRP with H
2
O
2
 and a self prepared FITC tyramide solution as described previously [18]. 
Thereafter, the sections were washed in PB, mounted on slides and cover slipped with 
Vectashield (Vector). 
2.5. Analyzing labeled neurons
 Analysis was carried out on sections from the L4 and L5 lumbar spinal segments. 
Sections for analysis were chosen by starting in the first row of the randomly mounted 
sections and searching for sections from the appropriate segmental level, i.e. from rostral 
L4 to caudal L5. Per rat, the first 5 or 6 sections were analyzed in a Leica fluorescent micro-
scope with a FITC and/or Cy3 filter. Labeling for GlyT2/GAD67 mRNAs (FITC) was consid-
ered as neuronal labeling if the staining was present in the cell soma and the shortest di-
ameter was at least 10μm. In order to investigate colocalization of c-fos (Cy3) with GlyT2/
GAD67 mRNAs (FITC), first c-fos labeling was assessed in a 40x objective. Thereafter, in the 
same focus field, we assessed whether there was labeling for GlyT2/GAD67 mRNA pres-
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ent in the cytoplasm. If in the same focus field, c-fos labeling was surrounded by somatic 
GlyT2/GAD67 mRNA staining, the neuron was counted as a double labeled neuron. Single 
c-fos labeled and c-fos/GlyT2/GAD67 double labeled neurons were plotted by hand in an 
illustrated representation of the appropriate segmental level. In this illustration, the grey 
matter was divided in 10 laminae according to the laminar distribution in the rat [31]. In 
order to correct cell counts for double counting error, we measured the shortest and larg-
est diameter of the nuclei of c-fos labeled neurons and c-fos labeled Gly/GABA neurons in 
laminae I-II, III-VI and VIII-X. The average diameter of the nuclei was calculated by averag-
ing the sum of the shortest and largest diameters, and we then performed corrections 
for sampling bias related to cell size using Abercrombie’s formula as described previously 
[15].Per rat, the average numbers of c-fos and c-fos/Gly/GABA double labeled neurons, 
and the average percentages of double labeled neurons were calculated. Per group, the 
results were averaged and compared with the average results in the other groups. Errors 
in the variations were assessed as standard error of the mean (SEM). The unpaired t-test 
or one-way ANOVA with a Bonferroni post-hoc test was performed for statistical compari-
son between groups. p<0.05 was taken as significant.
3. Results
3.1. General observations
 Fluorescent in situ hybridization (FISH) with a mixture of GlyT2/GAD67 probes 
resulted in cytoplasmic labeling of neurons that contained either GlyT2 mRNA, GAD67 
mRNA or both mRNAs, thus representing neurons that use glycine and/or GABA as 
neurotransmitter(s) (Gly/GABA neurons) (Fig. 1A, B). In the superficial dorsal horn we ob-
served labeled neurons that were relatively small in size. These neurons contain most 
likely GABA and not glycine since glycinergic neurons are scarce in laminae I and II [19,46]. 
Labeled neurons in the deep dorsal and ventral horn were mostly medium to large in size, 
representing neurons using glycine and/or GABA as neurotransmitters [47]. 
 Fluorescent immunohistochemistry (IHC) for c-fos resulted in labeling of nuclei 
with various intensities (Fig. 1C). In the spinal cords of naïve rats c-fos labeled neurons 
were rare, while many were present in the spinal cords of rats that received a nociceptive 
stimulus. Most c-fos labeled neurons were located ipsilateral to the stimulus in the su-
perficial (laminae I-II) and deep (III-VI) dorsal horn and much less in the ventral horn (VII-
X). When FISH was combined with IHC, double labeled neurons were observed in which 
the labeling for c-fos (reddish nucleus) was surrounded by the labeling for GlyT2/GAD67 
mRNA (greenish cytoplasm) (Fig. 1C, D, and E).
Fig. 1. Fluorescence micrographs of lumbar spinal sections showing the distribution of neurons labeled for 
GlyT2 and/or GAD67 mRNAs, and/or neurons labeled for c-fos protein after stimulation with formalin (45 
min). (A and B) Note that labeled neurons in the superficial layers, which are mostly small and somewhat diffi-
cult to see at this magnification, are predominantly GABAergic neurons, while small and large labeled neurons 
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in the deeper laminae are glycinergic and/or GABAergic. (C, D and E) Labeling for c-fos protein in nuclei of neu-
rons in the deep dorsal horn after stimulation with formalin (45 min) combined with labeling for GlyT2 and/
or GAD67 mRNAs. Note that double labeled neurons are yellow. Roman figures indicate laminae; DF: dorsal 
funiculus; Scale bar: 50 µm. 
3.2. Capsaicin, formalin, CFA and SNI pain models
 The effects of nociceptive stimulations were assessed by behavioral analysis us-
ing Von Frey hair monofilaments. As expected, we found that the mechanical threshold 
(grams) was significantly decreased in the capsaicin (33 g before treatment, 3 g after cap-
saicin, p<0.001), chronic inflammation (CFA; 37 g before treatment, 5 g after CFA 1.5 hrs, 
p<0.005; 7 g after CFA 20 hrs, p<0.005; 10 g after CFA 4 days, p<0.01) and neuropathic 
pain (SNI; 27 g before treatment, 2 g after SNI 1 wk, p<0.005; 1 g after SNI 2 wks, p<0.005) 
groups as compared to the mechanical threshold of the same paw before treatment. In the 
sham-SNI groups we did not find a significant decrease in the mechanical threshold (27g 
before treatment, 20 g after sham-SNI 1wk, p>0.05; 19 g after sham-SNI 2 wks, p>0.05) 
3.3. c-fos labeling pattern
 In naïve unstimulated rats we found on average a total 0.5 ± 0.2 c-fos labeled 
neurons per section. In view of this low number, we did not further investigate the colocal-
ization of c-fos in Gly/GABA neurons in naïve rats. Stimulation with capsaicin or formalin 
induced significantly higher average numbers of c-fos labeled neurons per section than 
stimulation with saline (control) (Fig. 2). In the CFA pain model, there were no significant 
differences between the numbers of c-fos labeled neurons obtained at different survival 
times (ANOVA). In the SNI pain model there were no significant differences between the 
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number of c-fos labeled neurons at 1 wk (18 ± 2.8) or 2 wks (14 ± 1.9) after nerve in-
jury, and they were significantly lower (p<0.001, ANOVA) than at 2 hrs after nerve injury 
(Fig. 2). When considering all pain models (Fig. 2), the highest numbers of c-fos labeled 
neurons were found 90 minutes after stimulation wit formalin (53 ± 4) and at 2 hrs after 
spared nerve injury (61 ± 3.6). 
 With respect to the laminar distribution (Table 1A), c-fos labeled neurons were 
approximately equally abundant in laminae I&II and in laminae III-VI in the acute pain 
models (after saline, capsaicin, formalin) and in the acute phases of inflammation and 
neuropathic pain. However, in the chronic phases of inflammation (CFA 20 hrs and 4 days) 
and neuropathic pain (1 wk and 2 wks) the bulk of c-fos labeled neurons was present in 
laminae III-VI (Table 1A). In all pain models, laminae VII-X contained the lowest numbers 
of c-fos labeled neurons.  
3.4. The number of c-fos labeled Gly/GABA neurons
 In the saline, capsaicin and formalin models, the average number of c-fos labeled 
Gly/GABA neurons per section was significantly higher after stimulation with capsaicin 
(11 ± 1.1), 45 and 90 minutes after formalin injection (15 ± 0.8 and 21 ± 1.7, respectively) 
when compared to saline (4 ± 0.3, control) (Fig. 3, Fig. 4 and Fig. 5). These findings indicate 
that a saline injection, which served as control, also induced c-fos expression in spinal Gly/
GABA neurons. 
Fig. 2. Histogram showing the average number of c-fos 
labeled neurons per section in lumbar spinal cord in vari-
ous rat pain models and their controls. Capsaicin, 45 and 
90 minutes after formalin injection induced significantly 
higher numbers of c-fos labeled neurons than the control 
stimulation with saline (ANOVA). The SNI models induced 
significantly higher numbers of c-fos labeled neurons than 
their corresponding sham models (unpaired t-test). * = 
p<0.05; ** = p<0.01; *** = p<0.005; **** = p<0.001.
 In the CFA inflammation model there were no significant differences between the 
numbers of c-fos labeled Gly/GABA neurons at 1.5 hrs (10 ± 2.7), 20 hrs (10 ± 0.4) and 4 
days (10 ± 2.3) after injection of CFA (Fig. 4 and Fig. 5). In the SNI model, the numbers of 
c-fos labeled Gly/GABA neurons were higher in nerve injured than in the corresponding 
sham-SNI operated animals (controls) at all time points (Fig. 4). Further, a significantly 
(p<0.001, ANOVA) higher number  of c-fos labeled Gly/GABA neurons was found at 2 hrs 
after nerve injury (25 ± 3.1) than at 1 wk (8 ± 1.2) or 2 wks (8 ± 1.4). Note that the higher 
         39
Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models
number at 2 hrs after nerve injury is partly explained by the contribution of the operation 
procedure, as shown by the relatively high number of activated Gly/GABA neurons in the 
sham operated animals (Fig. 4). 
Fig. 3. Fluorescence micrographs from lumbar spinal sections showing labeling for c-fos protein and GlyT2/
GAD67 mRNAs. Arrows indicate c-fos labeled neurons that also contained GlyT2 and/or GAD67 mRNAs. (A, B 
and C) Superficial dorsal horn at caudal L4 level of a rat stimulated with capsaicin. (D, E and F) Deep dorsal horn 
at caudal L5 level of a rat with chronic inflammation (CFA 4 days). Asterisk indicates a c-fos labeled neuron that 
was out of focus but also contained GlyT2 and/or GAD67 mRNA. Scale bar: 50 µm.
Fig. 4. Histograms showing the average number of c-fos la-
beled neurons per section that also contained GlyT2 and/
or GAD67 mRNAs (Gly/GABA neurons) in different rat pain 
models. Capsaicin, 45 and 90 minutes after formalin injec-
tion induced significantly higher numbers of c-fos labeled 
Gly/GABA neurons than the control stimulation with sa-
line (ANOVA). The SNI models induced significantly higher 
numbers of c-fos labeled neurons than their corresponding 
sham models (unpaired t-test). * = p<0.05; ** = p<0.01; *** 
= p<0.005; **** = p<0.001.
 When comparing the number of c-fos labeled Gly/GABA neurons in all the pain 
models, there were no significant differences (p>0.05, ANOVA) between the capsaicin (11 
± 1.1) , CFA 1.5 hrs (10 ± 2.7), CFA 20 hrs (10 ± 0.4), CFA 4 days (10 ± 2.3), SNI 1 wk (8 ± 1.2) 
and SNI 2 wks (8 ± 1.2) pain models (Fig. 4, Fig. 5). Further, SNI 2 hrs (25 ± 3.1) induced sig-
nificantly the highest number of c-fos labeled Gly/GABA neurons as compared to all other 
pain models (p<0.05, ANOVA), except for 90 minutes after formalin injection. When con-
sidering the distribution pattern of c-fos labeled Gly/GABA neurons, in most pain models 
the majority of the labeled neurons were located in the deep dorsal horn (III-VI), and with 
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lower percentages in the superficial dorsal horn and in the ventral horn (Table 1B). 
Table 1. Laminar distribution of c-fos 
labeled and c-fos labeled Gly/GABA 
neurons in the various pain models. 
(A, B) Percentages (± SEM) of the total 
number of c-fos labeled (A) or c-fos la-
beled Gly/GABA (B) neurons that were 
located in laminae I-II, III-VI or VII-X 
are shown for each pain model. Note 
that the majority of c-fos labeled and 
c-fos labeled Gly/GABA neurons were 
located in the deep dorsal horn (lami-
nae III-VI), especially in the chronic 
pain models.  
3.5. The percentage of c-fos labeled neurons that were Gly/GABA
 After calculating the average percentages of c-fos labeled neurons that were dou-
ble labeled with Gly/GABA in all the pain models, we found that in the chronic phase of 
the CFA, sham-SNI and SNI models, there were no significant differences (p>0.05, ANOVA) 
between the percentages obtained for the two chronic survival times in each model. Since 
we were interested in possible differences between the acute and chronic phases,   we 
 
Fig. 5. Drawings showing the spinal distribution of c-fos labeled and c-fos labeled Gly/GABA neurons in ran-
domly chosen single sections from the lumbar spinal cord, each from a different pain model. An open circle 
represents a single c-fos labeled neuron, and each filled triangle represents a single c-fos labeled neuron that 
also contained GlyT2/GAD67 mRNAs (Gly/GABA).  90 min after formalin injection and 2 hrs after nerve injury 
induced the highest numbers of c-fos labeled Gly/GABA neurons. Note that in most pain models, the bulk of c-
fos labeled Gly/GABA neurons were located in the deep dorsal horn (laminae III-VI; see also table 1B). In most 
pain models, few c-fos labeled Gly/GABA neurons were located in the ventral horn (laminae VII-X).
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combined in each group the chronic phases (i.e. 20 hrs + 4 days in the CFA model; 1wk 
+ 2wks in the sham-SNI and SNI models). We then compared the result for the chronic 
phase with that of the acute phase in the different models (Fig. 6). This showed that in the 
CFA and SNI models the percentages of c-fos labeled neurons that were Gly/GABA were 
significantly higher in the chronic phases as compared to their acute phases. Also in the 
formalin model there was no significant difference between the two survival times. We 
therefore combined the two results and found that the percentage of c-fos labeled neu-
rons that were Gly/GABA was significantly higher in the formalin model as compared to 
the saline and capsaicin models (Fig. 6).  
 We then averaged the percentages of all the chronic phases in the various mod-
els (i.e. CFA 20 hrs and 4 days; sham-SNI and SNI 1 wk and 2 wks), and compared it with 
the average percentages of all the acute phases (saline, capsaicin, formalin, CFA 1.5 hrs, 
sham-SNI and SNI 2 hrs). As a result we found that in the chronic phase the overall aver-
age percentage of the c-fos labeled neurons that were Gly/GABA was 46% (± 1.5), which 
is significantly higher (p<0.0005; unpaired t-test) than 34% (± 2), the overall percentage 
obtained for the acute phase.
Fig. 6. Histogram showing the average percentages of 
c-fos labeled neurons per section that also contained 
GlyT2/GAD67 mRNA (Gly/GABA). A significantly higher 
percentage was found in the combined formalin (45 + 
90 min) models as compared to the saline and capsa-
icin models (ANOVA). Note that the percentages of c-
fos labeled neurons that were Gly/GABA in the chronic 
phases of the CFA (20 hrs + 4 days), and SNI (1 wk + 
2 wks) models were significantly higher than the cor-
responding acute phases (unpaired t-test). * = p<0.05; 
**** = p<0.001.
Fig. 7. Histograms showing the average numbers (A) or 
percentages (B) of c-fos labeled neurons after formalin 
stimulation in rats pretreated with saline (control, 20 
min) or morphine (20 min). (A) The average number 
per section of c-fos labeled neurons or the average 
number of c-fos labeled neurons containing GlyT2/
GAD67 mRNA (Gly/GABA) after formalin stimulation. 
(B) The percentage of c-fos labeled neurons that were 
Gly/GABA. Note that despite the decrease in the to-
tal number of c-fos labeled Gly/GABA neurons (A), the 
percentage of c-fos labeled neurons that were Gly/
GABA did not change significantly when the rats were 
pretreated with morphine. *: p<0.05
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3.6. Effects of morphine application in the formalin model 
 In order to determine the effect of morphine on the number of c-fos labeled Gly/
GABA neurons we used the formalin pain model. The behavioral analysis confirmed the 
notion that morphine significantly reduced the licking time (saline: 630 sec ± 77, morphine: 
71 s ± 12, p<0.005, unpaired t-test) and the number of fluttering and flinches (saline: 676 ± 
61, morphine: 16 ± 5, p<0.005, unpaired t-test) of the injected paw. After formalin stimula-
tion, the total number of c-fos labeled neurons and the number of c-fos labeled Gly/GABA 
neurons decreased by subcutaneous morphine application when compared to control 
(Fig. 7A). When considering the percentage of c-fos labeled neurons that were Gly/GABA, 
we found no difference between the percentages of the control and the morphine treated 
groups (Fig. 7B).
4. Discussion
 In the present study we have shown that Gly/GABA neurons are activated (i.e. 
expressing c-fos protein) in all the pain models that we have investigated. Our data fur-
ther showed that the percentage of activated neurons that are Gly/GABA is higher in the 
chronic phase (46%) than in the acute phase (34%). Furthermore, the systemic application 
of morphine, preceding formalin injection, reduced the activation of Gly/GABA neurons 
and non-Gly/GABA (presumed excitatory) neurons in an equal manner. These findings 
show that active recruitment of Gly/GABA neurons is inherent to the normal and patho-
logical processing of nociceptive stimuli in the spinal cord.
 
4.1. Technical aspects 
 FISH was used to identify glycinergic neurons by their expression of glycine trans-
porter 2 (GlyT2) mRNA [23,28], and GABAergic neurons were identified by their expres-
sion of the mRNA for the GABA synthesizing enzyme (GAD) [13]. The GAD67 isoform of 
this enzyme is found in the large majority of spinal GABAergic neurons, often together 
with the GAD65 isoform [30]. A few neurons in the ventral horn, involved in presynap-
tic inhibition of 1A afferents only express the GAD65 isoform [20]. These neurons have 
not been identified in the present study, but it is highly unlikely that this has significantly 
affected our results. GABA and glycine are often colocalized in neurons [43,47] and co-
released at synapses [22]. Therefore, we did not attempt to identify glycinergic and GAB-
Aergic neurons separately but rather aimed at labeling them simultaneously. 
 For identifying spinal neurons that were activated in various pain models we have 
used c-fos, an immediate early gene (IEG) that is widely used as a marker for neuronal ac-
tivation in pain research [8]. Our results on the expression of c-fos in various pain models 
are in general agreement with other studies [6,21,29]. Application of GABA and glycine an-
tagonists in naïve animals leads to a hypersensitive spinal cord [38,39]. This indicates the 
presence of a continuous inhibitory tone, which is most likely due to activity in nearby Gly/
GABA neurons [1]. Apparently, the activity of these neurons does not induce significant 
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amounts of c-fos protein, since labeled c-fos neurons are very low in naïve animals. Thus, 
c-fos expression in spinal neurons signals phasic activity associated with active nociceptive 
processing rather than tonic activity associated with the presumed ongoing inhibition in 
the naïve spinal cord. Therefore, the results obtained in the present study are associated 
with the processing of phasic nociceptive stimuli in the different pain models.
4.2. c-fos expressing Gly/GABA neurons 
 In all our pain models, we found that a substantial proportion (ranging between 
24 and 53%) of the activated neurons expressed glycine and/or GABA. It seems likely that 
this activation was induced by nociceptive afferents, which are known to contact Gly/
GABA neurons [5,10,14,16], although indirect activation through interneurons cannot be 
excluded. Previous studies [46,54,55] using different techniques have also shown the acti-
vation of spinal inhibitory neurons by means of c-fos expression after capsaicin or formalin 
stimulation. Our data are in general agreement with the study by Todd et al. [46], however 
we found a lower percentage of activated GABAergic neurons in the superficial dorsal 
horn after capsaicin stimulation when compared to the studies by Zou et al [54,55]. 
 In our study, capsaicin induced a significant increase in the number of Gly/GABA 
activated neurons, when compared to saline. However, the percentages of activated Gly/
GABA neurons after saline (24%) and capsaicin (26%) stimulation were similar. This shows 
that in this paradigm, irrespective of the stimulus intensity (i.e. low after saline and high 
after capsaicin), the number of activated Gly/GABA neurons is proportional to the total 
number of activated neurons. In the formalin model, which typically shows a first and 
second phase in the behavioral response [44], the total number of activated neurons is 
higher at 90 min after formalin injection than at 45 min. Also in this case the percentages 
of activated Gly/GABA neurons were not significantly different at the two time points, 
although, when combined, it was higher than after saline or capsaicin injections. These 
results suggest that in a given pain model the proportion of activated neurons that are 
Gly/GABA remains stable, irrespective of the stimulus intensity. However, when we exam-
ined the CFA experiments we found the reverse situation: the total number of activated 
Gly/GABA neurons was similar at the different time points (i.e. 1.5 hrs, 20 hrs and 4 days), 
while the percentage of activated Gly/GABA neurons was higher in the chronic phase than 
at 1.5 hrs. In the SNI experiments, the total number of activated Gly/GABA neurons de-
clined significantly in the chronic phase, while there was a significant increase in the per-
centage. In the sham-SNI group, in which the operation procedure by itself resulted in a 
significant number of c-fos expressing neurons, the percentage did not increase in the 
chronic phase as compared to the acute phase. We therefore concluded that there was 
no consistent pattern of Gly/GABA neuronal activation when comparing the different pain 
models. However, within a particular pain model there were consistencies in the numbers 
or percentages of activated Gly/GABA neurons.  
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 We then examined the data from another viewpoint by subdividing all pain mod-
els in acute (≤ 2 hrs) and chronic (≥ 20 hrs) phases. Our data showed that in the chronic 
phase the percentage of activated Gly/GABA neurons (46%) was higher than in the acute 
phase (34%). This increase in the percentage in the chronic phases was due to a decrease 
in the total number of activated neurons while the number of activated Gly/GABA neu-
rons remained stable. Assuming that the majority of the non-Gly/GABA activated neurons 
were excitatory, our data show a decline in the number of activated excitatory neurons in 
the chronic phase. 
 Hypersensitivity in chronic pain conditions has been shown to result from loss of 
spinal inhibition due to blockade of glycinergic and GABAergic receptors [53]. At the same 
time, our data indicate an increased activity of inhibitory neurons in chronic pain condi-
tions. Whether the balance between these apparently opposing mechanisms determines 
the sensitivity of spinal neurons for incoming nociceptive stimuli, or whether they act on 
different aspects of pain transmission, is presently unclear. 
4.3. Laminar distribution of c-fos labeled Gly/GABA neurons
 Activated Gly/GABA neurons in the superficial dorsal horn are mainly GABAergic 
[19,46], while activated Gly/GABA neurons in the deep dorsal horn are glycinergic and/
or GABAergic [47]. Deeper located Gly/GABA neurons have been suggested as a source 
of inhibitory input to the superficial dorsal horn [51], which may be lost in chronic pain 
states, leading to touch evoked allodynia. There is also loss of GABAergic inhibition in the 
superficial dorsal horn in chronic neuropathic pain states, which may be due to loss of 
GABAergic interneurons [32,34,35]. Our data showed that the number of activated Gly/
GABA neurons in the deep dorsal horn remained stable over time in the chronic phase, 
while the numbers of presumed excitatory neurons were declining. Thus, our results on 
activated Gly/GABA neurons do not indicate loss of inhibition in chronic pain states due to 
decreased activation of spinal Gly/GABA neurons. 
 It has been suggested that GABAergic neurons in the superficial dorsal horn re-
ceive C-fiber input [16], and are important for regulating the spinal transmission of innoc-
uous and nociceptive information, especially during acute pain [10]. Our data confirm the 
presence of activated Gly/GABA neurons in the superficial dorsal horn, but their numbers 
are low when compared to the number of activated Gly/GABA neurons in the deep dorsal 
horn. 
4.4. The morphine experiment
 After a systemic morphine injection preceding a formalin injection to the hind 
paw, there was a significant reduction in the total number of c-fos labeled neurons and a 
proportional decrease in the number of c-fos labeled Gly/GABA neurons. It seems most 
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likely that most inhibition induced by morphine is due to presynaptic inhibition of primary 
afferents expressing mu-opioid receptors [3]. Postsynaptic mu-opioid receptors in the su-
perficial dorsal horn are expressed preferentially by neurons, mainly in laminae II, that 
are not GABAergic or glycinergic [25]. This would suggest that inhibitory neurons escape 
postsynaptic inhibition by morphine. However, our finding of an equal reduction of c-fos 
expression in Gly/GABA and non-Gly/GABA (presumed excitatory) neurons, indicates that 
the overall effect of the pre- and postsynaptic inhibition induced by morphine is about 
equally strong on inhibitory and excitatory neurons. Similarly, the suggestion [7] that mor-
phine would activate Gly/GABA neurons, especially GABAergic neurons in lamina II, is not 
supported by our findings. Thus, the proportional decrease in the number of c-fos labeled 
Gly/GABA neurons after morphine injection shows that morphine did not specifically re-
cruit spinal Gly/GABA neurons for the inhibition of nociceptive inputs. 
4.5. Conclusions 
 A characteristic feature of the pain models that we have examined is the develop-
ment of hypersensitivity for (in)nocuous stimuli. This phenomenon is due to glutamate 
induced sensitization in spinal neurons [27,49], along with a blockade [53] or reversal [9] 
of inhibitory impulses. We now show that similar numbers of Gly/GABA neurons are ac-
tivated by nociceptive stimuli during acute and chronic pain states, while in chronic pain 
states the activation of presumed excitatory neurons is declining. Therefore it seems most 
likely that the balance between all these mechanisms, and the disturbances therein dur-
ing pathological pain states, will determine the sensitivity of our pain system during health 
and disease.
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Nociceptive stimulation induces expression of
Arc/Arg3.1 in the spinal cord with a preference
for neurons containing enkephalin
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Abstract
Background: In pain processing, long term synaptic changes play an important role, especially during chronic
pain. The immediate early gene Arc/Arg3.1 has been widely implicated in mediating long-term plasticity in
telencephalic regions, such as the hippocampus and cortex. Accordingly, Arc/Arg3.1 knockout (KO) mice show a
deficit in long-term memory consolidation. Here, we identify expression of Arc/Arg3.1 in the rat spinal cord using
immunohistochemistry and in situ hybridization following pain stimuli.
Results: We found that Arc/Arg3.1 is not present in naïve or vehicle treated animals, and is de novo expressed in
dorsal h rn neurons after nociceptive stimulation. Expression of Arc/Arg3.1 was induced in an intensity dependent
manner in neurons that were located in laminae I (14%) and II (85%) of the spinal dorsal horn. Intrathecal injection
of brain derived neurotrophic factor (BDNF) also induced expression of Arc/Arg3.1. Furthermore, 90% of Arc/Arg3.1
expressing neurons also contained the activity marker c-Fos, which was expressed more abundantly.
Preproenkephalin mRNA was found in the majority (68%) of the Arc/Arg3.1 expressing neurons, while NK-1 was
found in only 19% and GAD67 mRNA in 3.6%. Finally, pain behavior in Arc/Arg3.1 KO mice was not significantly
different from their wild type littermates after application of formalin or after induction of chronic inflammatory
pain.
Conclusions: We conclude that Arc/Arg3.1 is preferentially expressed in spinal enkephalinergic neurons after
nociceptive stimulation. Therefore, our data suggest that Arc/Arg3.1 dependent long term synaptic changes in
spinal pain transmission are a feature of anti-nociceptive, i.e. enkephalinergic, rather than pro-nociceptive neurons.
Background
The experience of pain is usually initiated by the acti-
vation of nociceptors, which are the peripheral termi-
nations of nociceptive ganglion neurons. The central
projections of these neurons enter the dorsal horn of
the spinal cord to terminate on second order neurons
[1]. After strong nociceptive stimulation these neurons
may show an enhanced responsiveness to afferent
inputs, which may last for several hours [2-4]. The
mechanism underlying this enhanced responsiveness is
similar to that of long-term potentiation (LTP) [5],
which is a form of activity dependent plasticity that
has been investigated extensively in other parts of the
CNS, especially in the hippocampus [6]. Another form
of activity dependent plasticity is long-term depression
(LTD), a state of decreased sensitivity of neurons.
Whether LTP or LTD is produced in the spinal noci-
ceptive system depends on many variables, including
the type of activity in nociceptive afferents [2]. For
long term changes to become persistent it is essential
that activity regulated genes, including immediate early
genes (IEG), orchestrate a cascade of transcriptions
and subsequent protein synthesis [7]. The first IEG
that was found to be strongly increased in spinal neu-
rons after a nociceptive stimulus is c-Fos [8]. This IEG
is now widely used for the identification of activated
nociceptive neurons [9]. Other IEGs that have been
implicated in plastic changes are c-Jun, Jun-d, Krox 24
and Homer 1a [10,11]. Recently it has become clear
that in cortex, hippocampus and other higher brain
centers, the IEG named Arc/Arg3.1 (activity regulated
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Whether LTP or LTD is produced in the spinal noci-
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that was found to be strongly increased in spinal neu-
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cytoskeleton-associated protein/activity regulated gene
3.1) plays a crucial role in activity dependent synaptic
plasticity [12]. Moreover, Arc/Arg3.1 is critically
involved in processes essential for synaptic structural
rearrangement such as LTP, LTD and homeostatic
scaling of AMPA receptors [13,14]. These mechanisms
are also essential in spinal processing [15], and dys-
functional forms of activity dependent plasticity such
as LTP and LTD that lead to persistent changes in
neuronal sensitivity, may underlie chronic pain disor-
ders [16]. Therefore, in this study we set out to investi-
gate the role of Arc/Arg3.1 in nociceptive processing
in the spinal cord.
Our findings show that Arc/Arg3.1 is not expressed at
detectable levels in naïve spinal cord. However, after
peripheral nociceptive stimulation we found de novo
expression of Arc/Arg3.1 in a limited number of neu-
rons in the superficial dorsal horn, depending on the
type of stimulus. Further, Arc/Arg3.1 is predominantly
expressed in spinal interneurons located in lamina II
and many of these neurons also contain the opioid neu-
rotransmitter enkephalin. Finally, we found that the pain
behavior in Arc/Arg3.1 knockout (KO) mice after noci-
ceptive stimuli was not significantly different from their
wild type (WT) littermates.
Results
General observations
In the spinal cord of naïve rats and mice there was no
detectable expression of Arc/Arg3.1 mRNA or protein
when using in situ hybridization (ISH) and immuno-
histochemistry (IHC), respectively. However, after
application of a peripheral nociceptive stimulus to the
hind paw, Arc/Arg3.1 was expressed in a limited num-
ber of cells in the superficial layers of the lumbar dor-
sal horn. ISH using the alkaline phosphatase (AP)
reaction produced a bluish/brownish reaction product
in the cytoplasm and in some occasions in the nucleus
and primary dendrites of Arc/Arg3.1 mRNA expressing
neurons (Fig. 1A,B). Arc/Arg3.1 protein, visualized by
bright field IHC, was present primarily in the cyto-
plasm, occasionally combined with nuclear labeling or
labeling in proximal dendrites (Fig. 1C). Applying
fluorescent IHC for Arc/Arg3.1 protein produced very
similar labeling characteristics. In order to ascertain
that Arc/Arg3.1 is expressed in neurons rather than in
glial cells, we combined FISH for Arc/Arg3.1 mRNA
with fluorescent IHC for NeuN, which is a specific
marker for neuronal cells (Fig. 1D). It was found
that 95% ± 1.3 (SEM) of the cells expressing Arc/
Arg3.1 mRNA also expressed NeuN (99% ± 0.4 for
Figure 1 Arc/Arg3.1 is only expressed in the superficial dorsal horn. Light micrographs showing the distribution of neurons expressing Arc/
Arg3.1 mRNA (A, B) or protein (C) in the rat spinal dorsal horn after peripheral stimulation with 25% mustard oil gauze wrapped around one
hind paw for 2 hours. Note that many of the Arc/Arg3.1 labeled neurons are located in laminae I&II, and very few labeled neurons are present
below lamina II. D, Fluorescent micrograph showing the expression of Arc/Arg3.1 mRNA and its colocalization with the neuronal marker NeuN.
Arrowheads indicate Arc/Arg3.1 mRNA and NeuN double labeled neurons. Scale bar: 50 μm (A and D); 25 μm (B); 100 μm (C).
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25% MO/1 h, n = 4; 95% ± 3.3 for 25% MO/2 hrs, n =
5; 94% ± 2.8 for CFA for 1.5 hrs, n = 4).
For both ISH and IHC, we observed that the intensity
of the labeled neurons varied in a single section. We did
not observe any labeling indicative of localization of
Arc/Arg3.1 in intermediate or distal dendrites. Although
labeling patterns obtained with ISH and IHC were iden-
tical, labeling efficiency was higher for ISH than for
IHC. Therefore, ISH was used for the quantification of
neurons expressing Arc/Arg3.1. The specificity of our
detection techniques was assessed by omitting the
probes/primary antibodies in the ISH and IHC proce-
dures, respectively, and by applying ISH and IHC on
spinal tissue of Arc/Arg3.1 KO mice. These experiments
did not show any labeling in the spinal cord. ISH per-
formed on cortex of naïve rats showed Arc/Arg3.1
mRNA labeling in the cortex and the hippocampus as
previously reported [17].
Distribution and quantification of Arc/Arg3.1 mRNA
expressing neurons in the spinal cord following
nociceptive stimulation
Several types of nociceptive stimuli applied to the hind
paw induced Arc/Arg3.1 mRNA expressing neurons on
the ipsilateral side (Fig. 2) but not on the contralateral
side of the lumbar superficial dorsal horn. A single sub-
cutaneous injection of capsaicin resulted in the lowest
average number of labeled neurons per section (2.6 ± 0.6
SEM, n = 6), while wrapping the paw in a gauze soaked
with 25% mustard oil (MO) for 2 hrs induced the highest
number of neurons (50 ± 3.5 SEM, n = 5). On average,
lamina II accounted for 85% ± 3.5 of the labeled neurons,
while lamina I (14% ± 3.2) and III (0.6% ± 0.4) contained
the remaining labeled neurons. The other laminae very
rarely contained labeled neurons.
Expression of Arc/Arg3.1 mRNA following nociceptive
stimulation occurs in a subset of c-Fos labeled neurons
and is intensity dependent
The number of neurons expressing the neuronal acti-
vation marker c-Fos or Arc/Arg3.1 mRNA was
counted in separate sections treated with IHC or ISH,
respectively. c-Fos labeled neurons outnumbered Arc/
Arg3.1 mRNA labeled neurons (Fig. 3A), except after 2
hrs mustard oil stimulation when about equal number
of neurons were labeled. FISH and fluorescent IHC
were applied to simultaneously visualize Arc/Arg3.1
mRNA and c-Fos protein, respectively (Fig. 3B). When
data from the 25% mustard oil and the CFA groups
were taken together (Fig. 3C), 90% ± 6.8 of the Arc/
Arg3.1 mRNA expressing neurons also contained c-Fos
protein. In order to determine whether the number of
Arc/Arg3.1 expressing neurons was stimulus intensity
dependent, rats received a single application (by brush)
of either 10% (n = 5) or 50% (n = 5) mustard oil on
one hind paw. It was found that 50% MO induced sig-
nificantly higher numbers of Arc/Arg3.1 mRNA posi-
tive neurons that 10% mustard oil (Fig. 4A). The
number of c-Fos labeled neurons showed a similar sig-
nificant increase.
Temporal expression of Arc/Arg3.1 mRNA in an acute and
a chronic pain model
As a model for acute pain, 25% MO soaked gauze was
wrapped around one hind paw, with survival times
ranging from 25 min to 8 hrs. The number of Arc/
Arg3.1 mRNA expressing neurons increased over time,
reached a peak at 4 hours and then declined (Fig. 4B).
The distribution of labeled neurons remained
unchanged over time. As a model for chronic pain
CFA was injected in the hind paw, with survival times
ranging from 1.5 hrs to 60 hrs. Temporal expression of
Arc/Arg3.1 mRNA was highest at 1.5 hrs post injection
and then gradually declined (Fig. 4C). No expression of
Arc/Arg3.1 mRNA was found at survival times of 10
hrs and longer. The number of c-Fos expressing neu-
rons was increased at all survival times. In the spared
nerve injury (SNI) model for neuropathic pain, expres-
sion of Arc/Arg3.1 mRNA was only observed at two
hours after the operation. Arc/Arg3.1 mRNA was not
expressed 1 week or 2 weeks after the operation (not
shown) when the neuropathic pain symptoms, i.e.
mechanical and thermal hyperalgesia and allodynia,
had developed. There was no significant difference in
the number of Arc/Arg3.1 mRNA labeled neurons
between the SNI and sham operated group (p>0.05,
unpaired t-test) (Fig. 4D).
Figure 2 Several types of nociceptive stimuli induce Arc/Arg3.1
mRNA in the ipsilateral superficial dorsal horn. Histogram
showing the number of Arc/Arg3.1 mRNA labeled neurons after
each specific nociceptive stimulus. Error bars represent ± SEM.
Hossaini et al. Molecular Pain 2010, 6:43
http://www.molecularpain.com/content/6/1/43
Page 3 of 13
         95
Nociceptive stimulation induces expression of Arc/Arg3.1 in the spinal cord with a preference for neurons containing enkephalin
Arc/Arg3.1 mRNA is expressed in specific subpopulations
of dorsal horn neurons
In this experiment, the colocalization of Arc/Arg3.1
with various neuronal markers was investigated (Fig.
5A-E). We found that about a fifth of Arc/Arg3.1
mRNA positive neurons also express the NK-1 recep-
tor (CFA 1.5 hrs: 21.7% ± 7.6, n = 4; MO25%/2 hrs:
17% ± 3.4, n = 5) (Fig. 6). Less than 10% of Arc/
Arg3.1 mRNA expressing neurons also expressed PKC-
g protein (CFA 1.5 hrs: 7.7% ± 3.7, n = 4; MO25%/1h:
9.3% ± 3.8, n = 4). Further, Arc/Arg3.1 mRNA expres-
sing neurons showed a low level of co-existence with
calbindin (CFA 1.5 hrs: 9.7% ± 1.4, n = 4; MO25%/1h:
10.5% ± 2.6, n = 4).
In order to identify Arc/Arg3.1 in inhibitory neurons,
FISH for GAD67 mRNA, the specific marker for
GABAergic neurons, and fluorescent IHC for Arc/
Arg3.1 protein were combined. Very few of the Arc/
Arg3.1 labeled neurons were GABAergic (CFA 3 hrs:
1.7% ± 0.8, n = 4; MO25%/2 hrs: 4.5% ± 0.8, n = 5;
MO25%/4 hrs: 4.5% ± 1.5, n = 4) (Fig. 6). Preproenke-
phalin mRNA is a marker for the subpopulation of
enkephalinergic neurons in the spinal cord. Interestingly,
a large majority of the Arc/Arg3.1 positive neurons also
expressed preproenkephalin mRNA (CFA 3 hrs: 74.2% ±
9.2, n = 4; MO25%/2 hrs: 61.5% ± 2.6, n = 4; MO25%/4
hrs: 68.1% ± 3, n = 4) (Fig. 6).
Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA
expression
Intrathecal injection of brain-derived neurotrophic fac-
tor (BDNF) induced Arc/Arg3.1 mRNA expression in
the superficial dorsal horn neurons (10 ± 1.7/section, n
= 6). We found that 45% ± 8 of Arc/Arg3.1 mRNA
labeled neurons were located in lamina I and 55% ± 8
in lamina II. 93.6% ± 2.5 of Arc/Arg3.1 mRNA labeled
neurons expressed NeuN, 55.6% ± 9.1 expressed c-Fos,
and 16.8% ± 6.4% expressed NK-1. Since it has been
shown [18] that administration of BDNF together with
NBQX, which is an AMPA receptor blocker, increases
Arc/Arg3.1 mRNA expression in cortical neurons, we
injected BDNF intrathecally together with NBQX. This
combination resulted in 13.8 ± 2.9 Arc/Arg3.1 mRNA
labeled neurons/section (n = 6) (Fig. 7A), which was not
significantly different from intrathecal BDNF injection
alone (unpaired t-test). c-Fos expression after BDNF +
NBQX injection was also not significantly different from
BDNF injection alone (p= 0.08 for lamina II) (Fig. 7B).
Intrathecal injection of vehicle (n = 2) or NBQX (n = 2)
alone did not induce Arc/Arg3.1 mRNA expression in
Figure 3 The number of neurons expressing c-Fos outnumber Arc/Arg3.1 mRNA labeled neurons. A, Histogram showing the number of
neurons labeled for c-Fos or Arc/Arg3.1 mRNA following various nociceptive stimuli. capsaicin, n = 6; CFA1.5 hrs, n = 4; MO25%-2 hrs, n = 4;
MO25%-4 hrs, n = 4. B, Fluorescent micrograph showing Arc/Arg3.1 mRNA and/or c-Fos protein labeled neurons in spinal dorsal horn after
stimulation with 25% mustard oil for 2 hours. Arrows indicate Arc/Arg3.1 mRNA labeled neurons that were not in focus and therefore not
included in the analysis. Arrow heads indicate Arc/Arg3.1 mRNA and c-Fos protein labeled neurons. C, Histogram showing the percentage of
Arc/Arg3.1 mRNA labeled neurons that also express the neuronal activation marker c-Fos. Scale bar: 50 μm. Error bars represent ± SEM.
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the spinal cord. Furthermore, we found that intrathecal
injection with NMDA (n = 2), which served as a positive
control, also induced Arc/Arg3.1 expression in the dor-
sal horn (not shown).
Pain behavior in the Arc/Arg3.1 KO mice
Mechanical and thermal thresholds
Freely moving Arc/Arg3.1 knockout (KO) mice did not
display any overt behavioral abnormalities in compari-
son with their wild type (WT) littermates, as reported
previously [13]. With respect to pain behavior, the
mechanical thresholds and hot plate withdrawal laten-
cies were tested. We found that the mechanical thresh-
olds in Arc/Arg3.1 KO mice were not significantly
different from their WT littermates (Fig. 8A). However,
in the hotplate test Arc/Arg3.1 KO mice showed
significantly longer withdrawal latencies than WT mice
(Fig. 8B).
Acute pain: formalin test
Subcutaneous injection of formalin in the hind paw
induced a two-phased pain behavior in both WT and Arc/
Arg3.1 KO mice, consisting of licking and fluttering of the
injected paw. In both groups, the first phase was apparent
in the first 10 minutes after injection, and the second
phase began 25 minutes after injection with licking as the
prominent behavior. No significant difference (repeated-
measures ANOVA, p>0.05) was found between the WT
and Arc/Arg3.1 KO mice in licking or fluttering behavior
(Fig. 9A,B). Also the total licking time (WT: 200 sec. ± 34
(SEM); KO: 275 sec. ± 49 (SEM); p>0.05, unpaired t-test)
nor the total numbers of flutters (WT 100 ± 21 (SEM);
KO 128 ± 32 (SEM); p>0.05, unpaired t-test) were
Figure 4 Arc/Arg3.1 expression is stimulus intensity dependent and is present only in the acute phase of chronic inflammatory and
neuropathic pain. A, Histogram showing the numbers of Arc/Arg3.1 mRNA or c-Fos protein labeled neurons at 2 hours after a brush applied
stimulation with either 10% (n = 5) or 50% (n = 5) mustard oil. * = p < 0.05; ** = p < 0.005 (unpaired t-test). B, Time course of Arc/Arg3.1 mRNA
and c-Fos protein expression after stimulation with 25% mustard oil gauze wrapped around one hind paw for different survival times. 25 min, n
= 4; 45 min, n = 4; 1 h, n = 4; 2 hrs, n = 5; 4 hrs, n = 4; 8 hrs, n = 4. C, Time course of Arc/Arg3.1 mRNA and c-Fos protein expression after CFA
injection in the hind paw. 1.5 hrs, n = 4; 3 hrs, n = 4; 4 hrs, n = 4; 10 hrs, n = 4; 20 hrs, n = 4; 60 hrs, n = 4. D, The number of Arc/Arg3.1 mRNA
labeled neurons 2 hours after sham operation (n = 3) or after cutting the common peroneal and tibial nerves in the SNI model (n = 3). Error
bars represent ± SEM.
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Figure 5 Arc/Arg3.1 is expressed in a subpopulation of superficial dorsal horn neurons with a preference for neurons containing
enkephalin. A-E, Fluorescent micrographs showing neurons in the superficial dorsal horn that express Arc/Arg3.1 mRNA (A-C) or protein (D and
E) and markers that identify neurons expressing the neurokinin-1 receptor (NK1), protein kinase C gamma (PKC-g), Calbindin, GAD67 mRNA
(GABAergic neurons), or preproenkephalin mRNA (enkephalinergic neurons) respectively. The following nociceptive stimuli were used. A, CFA,
survival time 1.5 hrs, B and C: Mustard oil 25% gauze wrapped, survival time 1 h, D and E, Mustard oil 25% gauze wrapped, survival time 2 h.
Arrow heads indicate Arc/Arg3.1 labeled neurons that also express one of the markers mentioned above. Scale bar: 50 μm.
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significantly different. In addition, c-Fos expression due to
the formalin injection did not appear different from the c-
Fos expression in the WT mice.
Chronic pain: inflammation
Induction of chronic inflammation by CFA injection in
the hind paw resulted in decreased mechanical thresh-
olds of the injected paw (Fig. 10A). A repeated measures
ANOVA did not reveal any significant differences
between WT and Arc/Arg3.1 KO mice regarding the
mechanical or thermal thresholds at any time point (Fig.
10A,B).
Discussion
In this study we have used in situ hybridization (ISH) and
immunohistochemistry (IHC) to show that nociceptive sti-
mulation induced Arc/Arg3.1 mRNA and protein in the
superficial dorsal horn of the spinal cord. Both techniques
specifically identified Arc/Arg3.1 since standard controls,
most notably nociceptively stimulated spinal cord of Arc/
Arg3.1 knockout (KO) mice, did not show any specific
labeling. In naïve or vehicle treated animals expression of
Arc/Arg3.1 mRNA and protein was absent in the spinal
cord, in agreement with a study using RT-PCR [19]. This
strongly indicates that in the spinal cord a nociceptive sti-
mulus induces de novo expression of Arc/Arg3.1, in con-
trast with other areas of the nervous system, like
hippocampus [17] and cortex [20].
Arc/Arg3.1 mRNA and protein were induced in the
superficial dorsal horn in the acute phases of all pain
models that we tested, i.e. after nociceptive stimulation
with capsaicin, CFA, formalin and mustard oil. Injection
of CFA induces an inflammatory process [21] that leads
to the release of cytokines and other local messengers,
all of which may activate different types of receptors on
nociceptive fibers. Capsaicin, however, specifically acti-
vates nociceptive fibers expressing the transient receptor
potential vanilloid-1 (TRPV1) [22]. Further, mustard oil
and formalin both specifically activate the TRPA1 recep-
tor, although formalin may exert TRPA1-independent
effects at higher concentrations [23,24]. The number of
neurons producing Arc/Arg3.1 mRNA varied in the dif-
ferent pain models, and increasing the intensity of the
pain stimulus resulted in an increased number of neu-
rons expressing Arc/Arg3.1 as shown in the mustard oil
experiments. Therefore, our data indicate that the num-
ber of neurons expressing Arc/Arg3.1 depends on the
intensity of the stimulus, but is not limited to the activa-
tion of one specific receptor on peripheral nerves.
Neurons expressing Arc/Arg3.1 in the spinal cord are
most likely driven by direct input from afferent
Figure 6 Histogram showing the averaged percentages of
neurons expressing Arc/Arg3.1(induced after various
nociceptive stimuli, as in fig. 5), that co-express either NK1,
PKC-g, Calbindin, GAD67 mRNA or preproenkephalin mRNA.
Error bars represent ± SEM. For details, see text.
Figure 7 Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA expression in spinal dorsal horn. A and B, The averaged number of
neurons that express Arc/Arg3.1 mRNA (A) or c-Fos protein (B) after intrathecal injection with BDNF or BDNF together with NBQX. Error bars
represent ± SEM.
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nociceptive fibers that use glutamate as their main neu-
rotransmitter [25]. Apart from glutamate and various
neuropeptides, these fibers may also contain growth fac-
tors like BDNF [26] or GDNF [27]. We found that
intrathecal injection of NMDA or BDNF induced Arc/
Arg3.1 mRNA in spinal dorsal horn neurons. This is in
line with Arc/Arg3.1 expression in cultured neurons fol-
lowing BDNF application [18]. The same study showed
a significantly enhanced expression of Arc/Arg3.1
mRNA when NBQX, a potent AMPA receptor blocker,
was applied together with BDNF. However, in the pre-
sent study a significant increase in the number of Arc/
Arg3.1 mRNA expressing neurons could not be con-
firmed after intrathecal injection of BDNF and NBQX
together. Taken together, our findings are in line with
the idea that release of glutamate and/or BDNF from
activated nociceptive fibers are at least partly responsible
for Arc/Arg3.1 induction in the spinal dorsal horn.
Following nociceptive stimulation, Arc/Arg3.1 was
often expressed in activated neurons as identified by c-
Fos. Especially after nociceptive stimulation with capsai-
cin, and after chronic inflammatory pain, the number of
neurons expressing Arc/Arg3.1 is low as compared to
those showing c-Fos expression. This finding may be
interpreted to indicate that Arc/Arg3.1 is only expressed
in activated neurons that received the strongest input
from nociceptive fibers. This assumption is in line with
our finding that Arc/Arg3.1 expression is intensity
dependent. On the other hand, there may be specific
subpopulations of spinal nociceptive neurons that are
capable of producing Arc/Arg3.1, while others are not.
In search of such a neuronal subpopulation that specifi-
cally expressed Arc/Arg3.1, we focused on neurons that
were characterized by the expression of the neurokinin-
1 (NK-1) receptor, Protein Kinase C gamma (PKC-g),
calbindin, GAD67 or preproenkephalin. We found a
high percentage of Arc/Arg3.1 expressing neurons (68%)
to contain preproenkephalin, while percentages of colo-
calization with other markers were less prominent (19%
for NK-1; 8.5% for PKC-g; 3.6% for GAD67; 10% for cal-
bindin). NK-1 expressing neurons project to supraspinal
sites [28] and are essential for the initiation and mainte-
nance of chronic neuropathic and inflammatory pain
[29], and neurons expressing PKC-g are considered criti-
cally important for the development of neuropathic pain
after peripheral nerve injury [30]. The finding that only
a small number of Arc/Arg3.1 positive neurons also
expressed NK-1 or PKC-g indicates that Arc/Arg3.1 is
Figure 8 Naïve Arc/Arg3.1 knockout (KO) mice showed
significantly longer response times on the hotplate than their
naïve wild type (WT) littermates. A and B, Histogram showing
the mechanical threshold (A) and thermal withdrawal latency (B) of
Arc/Arg3.1 KO and WT mice, assessed with the Von Frey and the
hotplate test, respectively. Error bars represent ± SEM. *: p < 0.05,
unpaired t-test; n = 4 for A and for B.
Figure 9 Arc/Arg3.1 KO mice do not differ from WT mice concerning licking or fluttering of the paw injected with formalin. A and B,
Graphs showing the time spent licking (A) and the number of flutters (B) after formalin injection in the hind paw during an observation period
of 55 minutes. Error bars represent ± SEM. Differences were not significant (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
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not strongly involved in pain processing by the NK-1 or
PKC-g subpopulations of dorsal horn neurons. This is
remarkable since especially the NK-1 expressing neu-
rons projecting to the parabrachial area or periaqueduc-
tal grey show LTP formation after high or low
frequency stimulation, respectively [31]. Our finding
indicates that Arc/Arg3.1 dependent long term changes
may occur preferentially in local interneurons rather
than in projection neurons. Further, we found low colo-
calization with GAD67, the marker for GABAergic neu-
rons, indicating that the expression of Arc/Arg3.1 is low
in the total subpopulation of dorsal horn inhibitory neu-
rons since glycinergic neurons are virtually absent in the
superficial dorsal horn [32-34], and, if present, also con-
tain GABA [35]. In the hippocampal and neocortical
neurons expression of Arc/Arg3.1 in GABAergic posi-
tive neurons is also low but this is not the case in the
dorsal striatum [20]. Together, NK-1, PKC-g and/or pre-
proenkephalin constitute more than 90% of the Arc/
Arg3.1 expressing neurons. Since to date there is no evi-
dence for the colocalization of these substances with
each other, we conclude that Arc/Arg3.1 is preferentially
expressed in the subpopulation of enkephalinergic neu-
rons. Preproenkephalin mRNA is the precursor of both
Met- and Leu-enkephalin, which are both expressed by
neurons in the spinal cord and mainly exert their effect
on the δ-opioid receptor (DOR) [36]. Also, preproenke-
phalin mRNA in the spinal cord is increased after per-
ipheral inflammation and is also present in neurons that
express c-Fos after nociceptive stimuli [37]. Further,
using VgluT2 immunohistochemistry for identifying glu-
tamatergic terminals, it was shown [38] that 85% of the
enkephalin containing terminals in the dorsal horn use
glutamate as transmitter. However, a study [39] using
cultured dorsal horn neurons showed 42% colocalization
of immunohistochemically identified GAD and enkepha-
lin. A more recent study [40] using preproenkephalin
green fluorescent protein transgenic mice, showed that
43% of the fluorescent enkephalin neurons also
expressed immunohistochemically identified GABA.
Colocalization of enkephalin with VgluT2 was not
explored in these studies. Since we found a low level of
colocalization of Arc/Arg3.1 with GABAergic neurons,
it is not unlikely that several of the enkephalinergic neu-
rons in the spinal cord that express Arc/Arg3.1 also use
glutamate as a transmitter. The functional role of gluta-
mate in these fibers is unclear, since it is not known
whether they activate inhibitory or excitatory (i.e. anti-
or pro-nociceptive) circuits in the spinal cord, nor is it
known under which circumstances enkephalin and/or
glutamate is released from these fibers. Since the activa-
tion of the delta opioid receptor (DOR), through which
enkephalin exerts its effect, decreases pain behavior dur-
ing chronic peripheral inflammation [41], we tend to
conclude that the overall effect of Arc/Arg3.1 expressing
enkephalinergic neurons is anti-nociceptive.
In order to understand the functional role of Arc/
Arg3.1 in enkephalinergic neurons at the behavioral
level, we employed Arc/Arg3.1 KO mice and their WT
littermates. The only significant difference between
these mice was that in the hotplate test the thermal
threshold of naïve Arc/Arg3.1 KO mice was significantly
higher as compared to naïve WT mice. This finding is
difficult to interpret since naïve WT mice, like their KO
littermates, do not show Arc/Arg3.1 expression in the
spinal cord. One explanation may be that there is a very
low basal expression of Arc/Arg3.1 that we and others
[19] were not able to detect, and that the permanent
lack of Arc/Arg3.1 in the KO mice may have altered
spinal processing of nociceptive thermal stimuli over
time. Alternatively there may be supraspinal changes in
nociceptive processing. After nociceptive stimuli, we did
not find any difference in the pain behavior between the
KO and WT mice in the formalin test and chronic
inflammatory pain model. We therefore conclude that
Arc/Arg3.1 KO mice do not show a clear phenotypic
change that can be attributed to pain transmission in
the spinal cord.
Figure 10 No differences in mechanical and thermal thresholds between the Arc/Arg3.1 KO and WT mice during the time course of
inflammatory pain. A and B, Graphs showing mechanical (A) and thermal (B) thresholds after CFA injection in one hind paw of Arc/Arg3.1 KO
and WT mice. Differences were not significant at any time point (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
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Several studies have shown that in hippocampus
knockdown of Arc/Arg3.1 leads to enhanced LTP in the
early phase but impaired consolidation of LTP and long
term depression (LTD) in the late phase [13]. In the
spinal cord, LTP is one of the major components of
central sensitization [16], especially in lamina I project-
ing neurons [31]. LTP leads to enhanced responsiveness
of spinal nociceptive neurons, which is important for
maintenance of hyperalgesia and allodynia during acute
and chronic pain. Our finding that Arc/Arg3.1 KO mice
develop hypersensitivity in acute and chronic pain mod-
els in the same way as their WT littermates, suggests
that the LTP formation that contributes to central sensi-
tization and subsequent developing hyperalgesia is unaf-
fected by the lack of Arc/Arg3.1. It seems therefore that
Arc/Arg3.1 is not critically involved in LTP as occurring
in the dorsal horn projection neurons, which in line
with our result that few NK-1 positive neurons express
Arc/Arg3.1.
The low number of spinal projection neurons that
express Arc/Arg3.1 may be explained by the fact that, in
contrast to other areas of the brain, structural long-term
changes in the excitability of these spinal neurons are
counterproductive if they persist after the healing pro-
cess has been completed. Our finding that Arc/Arg3.1 is
expressed predominantly in enkephalinergic neurons
may suggest that in these neurons long term changes
are actually consolidated. However, Arc/Arg3.1 KO mice
that lack consolidation of long term changes show nor-
mal pain behavior. This would not exclude that enke-
phalinergic neurons, which have an inhibitory effect on
pain transmission, may serve as an anti-nociceptive
mechanism against strong nociceptive inputs that may
occur in the future.
Conclusions
Our data show that Arc/Arg3.1, which is critically
involved in consolidating long term structural changes
in the forebrain, is preferentially induced in spinal enke-
phalinergic neurons after nociceptive stimulation. This
finding suggests that Arc/Arg3.1 dependent memory
formation in spinal pain transmission is a predominant
feature of neurons, which are anti-nociceptive rather
than pro-nociceptive.
Methods
Animal experiments
In this study we used 99 male Wistar rats and 16 Arc/
Arg3.1 KO mice and their wild type littermates.
Rats
50 μl of 0.3% capsaicin (Sigma-Aldrich) solution consist-
ing of 80% saline, 10% Tween-80, and 10% ethanol 100%
(n: 6; survival: 1.5 hrs) or 100 μl of Complete Freund’s
Adjuvant (CFA, Sigma-Aldrich; n: 24; survival: 1.5 hrs, 3
hrs, 4 hrs, 10 hrs, 20 hrs, 60 hrs) was injected in a hind
paw under anesthesia with 2% isofluorane in 30%O2/70%
N2O. In experiments applying mustard oil (MO) (Allyli-
sothiocyanat, Merck) the animals were kept under
anesthesia during entire survival time and subsequent
perfusion. For 25% MO application (n: 25; survival: 25
min, 45 min, 1 h, 2 hrs, 4 hrs, 8 hrs) the left paw was
shaved and wrapped in a gauze soaked with MO and
then covered with foil. For application of 10% (n: 5; survi-
val: 2 hrs) and 50% (n: 5, survival: 2 hrs) MO, the left paw
was shaved and MO was applied once at the beginning of
the experiment using a brush. For the experiments using
intrathecal injections, the same protocol was used as
described in [42]. Brain-derived neurotrophic factor
(BDNF, 10 μg, Tocris) was injected intrathecally in a total
injection volume of 40 μl (n: 6; survival: 75 min). In
another experiment, 5 μg of 1,2,3,4-tetrahydro-6-nitro-
2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX,
Tocris) was injected concomitantly with BDNF (n: 6; sur-
vival: 75 min). For control intrathecal experiments, 25
nmol N-Methyl-d-asparate (NMDA; Sigma, St. Louis,
MO; n: 2; survival: 75 min), or only vehicle (1% bovine
serum albumin in 0.025 M phosphate buffer; n: 2; survi-
val: 75 min) or only NBQX (n: 2; survival: 75 min) was
injected intrathecally. After the injections, the rats were
placed back in their cages. For induction of neuropathic
pain, the spared nerve injury (SNI) model and a control
operation were used [43]. In short, the sciatic nerve was
exposed and the three branches were isolated. The tibial
and the common peroneal branches were ligated and
then cut while the sural nerve was left intact (n: 9; survi-
val: 2 hrs, 7 days, 14 days). As a control, the sciatic nerve
was only exposed and isolated (n:7; survival: 2 hrs, 7 days,
14 days).
Arc/Arg3.1 KO and WT mice
All mice were habituated for 5 days to the experimenter,
the experiment room, and the transparent cage that was
used for the Von Frey measurements. Thereafter, prior
to each experiment the mice were habituated for 30
minutes to the room in which the behavioral experi-
ments took place.
Von Frey experiment before each Von Frey measure-
ment, the mice were allowed to habituate to a transpar-
ent cage (15 cm × 15 cm with a gridded floor) for 10
minutes. We used calibrated von Frey filaments, which
were applied for 2 seconds at 5 seconds interval, and
the threshold was set at 3 evoked responses in a maxi-
mum of 5 applications.
Hotplate test the thermal thresholds were assessed by
measuring the time a mouse spent on the hotplate (51°
C) before showing a response like fluttering or licking of
the hind paw, or jumping. Immediately after a response
or after maximally 45 seconds, the mouse was taken off
the hotplate.
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The formalin pain model the mice were restrained by
the experimenter and 15 μl of formalin, i.e. a freshly
made solution of 4% paraformaldehyde (PFA) in phos-
phate buffer (PB), was injected subcutaneously in the
left hind paw. The number of flutters and the time
spent licking of the injected paw were measured during
55 minutes post-injection. After 90 minutes the mice
were perfused and the tissue was processed as described
below. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
The CFA pain model 25 μl of CFA was injected in a
hind paw of restrained mice and thereafter the mechani-
cal and thermal thresholds were assessed at 1.5 h, 4 hrs,
1 d, 3 d, 4 d, 8 d, 14 d, 21 d, 28 d, 34 d, and 42 d post-
injection. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
Statistical analysis An unpaired t-test or a repeated
measures ANOVA was performed, p < 0.05 was taken
as significant.
Examination of the Arc/Arg3.1 KO mice spinal tissue
After experiments the mice were sacrificed and further
processed for immunohistochemistry (IHC) or in situ
hybridization (ISH). Histological examination of Arc/
Arg3.1 KO mice spinal cord did not reveal any morpho-
logical abnormalities in comparison with their WT
littermates.
Tissue preparation
At the end of the survival times the animals received an
overdose of sodium pentobarbital and were transcar-
dially perfused with 100 ml saline (rats) or 10 ml (mice)
followed by 750 ml of 4% PFA (rats) or 50 ml (mice)
dissolved in 0.12 M phosphate buffer (PB), pH 7.4. The
spinal cord was dissected and left overnight in a solution
of 4% PFA and 30% sucrose at 4°C. Subsequently, sec-
tions were cut (30 μm) on a freezing microtome and
collected in RNAse-free PB. Serial sections were cut and
collected in 9 separate jars, and therefore sections in
one jar were at least 270 μm apart. The sections were
kept in a solution of 40% glycerol, 40% ethyleenglycol
and 20% RNAse-free PB for long-term storage at -20°C.
In situ hybridization and immunohistochemistry
The partial cDNA templates encoding the following
mRNAs were used: Arc/Arg3.1 (3.5 kb, full length probe
encoding the mus musculus Arc/Arg3.1 gene, GeneID:
11838; Image Clone number: 3498057), GAD67 (3.2 kb;
a generous gift from Dr. A.J. Tobin, UCLA), preproen-
kephalin (0.95 kb, a generous gift from Dr. S.L. Sabol,
NIH). The riboprobes were obtained by linearizing the
recombinant plasmids with the appropriate restriction
enzymes and RNA polymerases. The transcription was
performed in the presence of digoxigenin (DIG)- or
fluorescein-labeled 11-UTP (Roche). ISH based on
alkalic phosphatase (AP) reaction was performed follow-
ing the protocol described previously [32]. For fluores-
cent in situ hybridization (FISH) the following
modifications were applied to the protocol. After ribop-
robe hybridization, the detection of DIG or fluorescein
was achieved with sheep polyclonal anti-Dig antibody
(Roche) or mouse monoclonal anti-fluorescein antibody
(Roche), respectively (1:500; 48 hours at 4°C in phos-
phate buffer saline (PBS), 2% milk powder and 0.5% Tri-
ton X-100). Thereafter, the anti-DIG or anti-fluorescein
primary antibodies were detected using biotinylated rab-
bit-anti-goat (Vector) or goat-anti-mouse (Vector),
respectively. Subsequently, the sections were incubated
with Avidin-Biotin-Complex (ABC, Vector) tagged with
horseradish peroxidase (HRP). A tyramide amplification
procedure was performed by reacting HRP with H2O2
and a self made FITC tyramide according to protocol
described in [44]. Thereafter, the sections were washed
in PBS and processed for fluorescent IHC using the fol-
lowing antibodies diluted in 2% milk power solution:
rabbit anti-Arc (1/3000; a generous gift from Dr. D.
Kuhl), rabbit anti-c-Fos (1: 40.000; Oncogene Research
Products, La Jolla, CA), rabbit anti-neurokinin-1 (NK1;
1:5000; Advanced Targeting System, CA, USA), rabbit
anti-calbindin (1:7000; Swant, Switzerland), rabbit anti-
PKC-g (1/750; Santa Cruz), and mouse anti-neuronal
nuclei (NeuN) monoclonal antibody (1:5000, Chemicon).
These primary antibodies were detected with Cy3 tagged
fluorescent secondary antibodies donkey-anti-rabbit or
donkey-anti-mouse (1:200). Thereafter, the section were
washed in PB and mounted on slides and coverslipped
with Vectashield (Vector).
Data analysis
Analysis was carried out on L4 and L5 segments of the
spinal cord, except for the BDNF experiments, in which
also S1 and S2 segments were included in the analysis.
Slides were systematically examined starting from the
first section in the first row for the appropriate segmen-
tal level. The first 5 to 6 sections that were encountered
and were not damaged during the procedure were
included in the analysis [42]. For illustrations, light
micrographs were made with a digital camera and con-
focal images with a Zeis LSM 510 confocal laser scan-
ning microscope and a 20× objective. The images were
processed using Adobe Photoshop and were not
manipulated, except for brightness and contrast. Quanti-
tative analysis of Arc/Arg3.1 mRNA positive neurons
based on AP-ISH was achieved using a camera lucida
microscope (Neurolucida, Microbrightfield Inc., Willis-
ton, VT). The grey and white matter and the boundaries
between the laminae were drawn according to [45] and
labeled neurons were identified only if the largest dia-
meter was at least 10 μm, and the cell soma contained a
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bluish/brownish product. Labeled neurons were
expressed as the average number of labeled neurons per
section.
For double labeling based on FISH combined with
fluorescent IHC, confocal images were analyzed using
the Zeis LSM image browser. For each section, the dor-
sal horn showing Arc/Arg3.1 labeled neurons was ana-
lyzed in a vertical plane consisting of 9 slices with an
optical thickness of 2.46-2.76 μm. Every fifth section
was analyzed for double labeled neurons. For markers
that label the cytoplasm, the criterion was that the dia-
meter of a profile was at least 10 μm to be counted as a
neuron. For statistical analysis, an unpaired t-test was
performed, and p < 0.05 considered significant.
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Chapter VII
 In this thesis we have identified the location of glycinergic neurons in the spi-
nal cord and investigated the activation pattern of spinal glycinergic and GABAergic (Gly/
GABA) neurons in various acute and chronic pain states. Further, we have identified spi-
nal Gly/GABA neurons in the area around the central canal that project to the RVM, and 
we have investigated the expression pattern of Arc/Arg3.1 in naive spinal cord and after 
stimulation with nociceptive stimuli. Finally, with respect to descending pathways we have 
investigated the distribution pattern of Gly/GABA neurons in the RVM that project to the 
spinal cord. The following general discussion will first focus on the role of spinal Gly/GABA 
neurons in the naive spinal cord, and during spinal nociception. Thereafter, we will focus 
on the expression of Arc/Arg3.1 in the spinal cord and long-term memory consolidation in 
nociceptive pathways. Finally, we will discuss the role of the descending projection of Gly/
GABA neurons in the RVM and their role in the inhibitory control of spinal nociception.
1. The role of spinal glycinergic and GABAergic neurons in pain inhibition
 In the 1960’s it was shown for the first time that glycine and GABA act as inhibitory 
neurotransmitters in the central nervous system [3, 44]. Glycine is an amino acid produced 
from serine by the enzyme serine hydroxymethyltransferase, which is not specific for gly-
cinergic neurons. Further, glycine is an important transmitter in the spinal cord and the 
brainstem, but is not found in higher levels of the nervous system, where GABA is the main 
inhibitory transmitter [6, 39, 69]. The inhibitory effect of glycine is produced by the glycine 
receptor, a ligand gated chloride channel, opening of which leads to membrane hyperpo-
larization [41]. GABA is an amino acid that is produced from glutamic acid by the enzyme 
glutamic acid decarboxylase (GAD) [81]. GAD is only present in neurons that use GABA as 
their transmitter and can therefore be used for the identification of GABAergic neurons 
[14, 40]. GABA acts on GABA receptors of which there are two main types: GABA-A and 
GABA-B receptors. GABA-A receptors are ligand gated chloride channels, the opening of 
which leads to membrane hyperpolarization. GABA-B receptors, on the other hand, are 
G-protein coupled receptors, which are indirectly linked to a potassium channel, that also 
has a hyperpolarizing effect on the membrane [53]. Glycine and GABA are often colocal-
ized in spinal neurons [48], both in the dorsal [86, 87] and ventral horn [82]. In accordance, 
physiological studies have shown that glycine and GABA and are co-released at synapses 
[36]. Only few populations of spinal neurons use only glycine or only GABA as their inhibi-
tory neurotransmitter [24, 87]. They include neurons in the superficial dorsal horn, which 
are predominantly GABAergic since there are few glycinergic neurons in these laminae, as 
we have shown in chapter 2. Furthermore, in the ventral horn there are specific GABAergic 
neurons that express GAD65, which is one of the isoforms of GAD and often colocalized 
with the other isoform GAD67, that are involved in the presynaptic inhibition of muscle 
spindle afferents on motoneurons [31]. Next to the inhibitory input provided by these Gly/
GABA interneurons, there is also inhibitory input from descending glycinergic and GAB-
Aergic terminals originating from Gly/GABA neurons in the RVM [2, 5, 49, 56]. The termi-
nals of these Gly/GABA projections contact projection neurons in the superficial layers [2], 
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interneurons in the deeper layers (laminae III-VI), and also neurons located in the ventral 
horn [28, 29]. Taken together, glycinergic and GABAergic neurotransmission in the spinal 
cord is either produced by spinal Gly/GABA interneurons or by Gly/GABA neurons in the 
RVM with projections to the spinal cord.
1.1. The naive spinal cord
 Abolishing glycinergic or GABAergic neurotransmission in the naive spinal cord 
results in many behavioral signs of hypersensitivity as observed in neuropathic and inflam-
matory pain conditions [75, 78, 97]. This finding indicates that nociceptive spinal neurons, 
including projections neurons, are active in the absence of a nociceptive stimulus, and 
there is the necessity for a continuous glycine and GABA induced inhibition of nociceptive 
neurons in order to block their activity in the naive animal. It is unclear which Gly/GABA 
neurons, i.e. spinal interneurons and/or RVM projection neurons, are the source of this 
inhibitory control. Although there is evidence of descending Gly/GABA terminals contact-
ing spinal dorsal horn neurons [2], and for inhibitory effects after RVM stimulation [50], 
it remains unclear whether Gly/GABA projection neurons in the RVM are involved in the 
tonic inhibition of the naive spinal cord. Similarly, the role of spinal inhibitory neurons 
in this tonic inhibition of nociceptive neurons in the naive spinal cord is not clear. C-fos 
protein, which is an immediate early gene that is widely used as a marker for neuronal 
activation [32], is expressed by spinal neurons that are activated by a nociceptive stimulus 
[22]. In the naive spinal cord, c-fos is only expressed by very few neurons [9], suggesting 
the absence of active inhibitory neurons in the naive spinal cord. Thus, based on c-fos 
activation, it seems that spinal Gly/GABA neurons do not play a role in inhibiting nocicep-
tive spinal neurons in the naive animal. This apparent contradiction may be resolved when 
it is assumed that c-fos expression in spinal neurons is induced by phasic activity rather 
than tonic activity. Therefore, the lack of c-fos expression in the naive spinal cord would 
not necessarily imply the absence of active Gly/GABA neurons. Apparently, these neurons 
only start to express c-fos when they become activated after a nociceptive stimulus, which 
leads to a sudden strong increase in their activity. In conclusion, spinal inhibitory neurons, 
whether or not in combination with descending inhibitory neurons, probably play a role 
in inhibiting nociceptive neurons in the naive spinal cord but the mechanisms underlying 
this inhibition are still unclear. 
1.2. Nociceptive activated spinal cord
1.2.1. Ipsilateral pain stimulation
 In the past decade, is has become increasingly clear that glycine and GABA play 
an important role in controlling spinal nociceptive processing. For example, during chronic 
inflammatory pain glycinergic inhibition is blocked in the spinal cord by a pathway that 
involves prostaglandin E2 (PGE2) [58, 72], a process which underlies the development 
of thermal and mechanical hyperalgesia [98]. Further, activation of selective subunits of 
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the GABA receptor, i.e. the α2 and/or α3, result in pronounced pain inhibition in chronic 
pain states [42]. During neuropathic pain states, there is evidence for reduced GABAergic 
inhibition in the superficial dorsal, which may [57] or may not [65, 66] be due to loss of 
GABAergic interneurons. At the same time there is loss of synaptic inhibition due to a shift 
in the chloride gradient, which reverses the inhibitory effect of GABA into a depolarizing 
one [11]. 
 Despite the knowledge on the involvement of inhibitory neurotransmission in spi-
nal nociceptive processing, there are few data about the role of  Gly/GABA interneurons 
in the loss of spinal inhibition and their activation pattern in acute and chronic pain states 
[85, 101, 102]. In chapter 3 of this thesis, we have investigated the activation pattern of 
spinal Gly/GABA neurons in various acute and chronic pain states affecting one hindpaw 
by determining the number and the percentage of c-fos activated neurons that were Gly/
GABA on the ipsilateral side. We found that the percentage of c-fos activated neurons that 
was inhibitory was higher (46%) in chronic (≥ 20hrs) pain states as compared to  acute (≤ 
2hrs) pain states (34%). This increase in percentage was caused by a reduction in the num-
ber of c-fos expressing non-Gly/GABA neurons in chronic pain states while the number of 
c-fos expressing Gly/GABA neurons remained stable. This finding indicates that in chronic 
pain states there is a relatively increased activation of Gly/GABA neurons. However, as 
mentioned earlier, several studies have shown a loss of inhibitory transmissions in the 
spinal cord during chronic inflammatory and neuropathic pain [99]. A possible explanation 
may be that the activated Gly/GABA neurons that we found are not functional, because 
the effects of the glycine and GABA they release is blocked at the synaptic level or that 
there effect is reversed (see above). Another explanation may be that the activated Gly/
GABA neurons serve as a compensation, albeit insufficient, of the apparent loss of inhibi-
tory neurotransmissions in other pathways during chronic pain states. Yet another view 
would be that the expression of c-fos occurs in Gly/GABA neurons involved in phasic activ-
ity, while the loss of inhibition occurs in tonically active Gly/GABA neurons, which are not 
identified by the expression of c-fos. Finally it may be argued, that the activated Gly/GABA 
neurons are involved in another role, unrelated to the inhibition of pain transmission in 
the dorsal horn, e.g. related to inhibition of motoneurons. Next to the activity of spinal 
interneurons, there are also glycinergic and GABAergic inputs by descending pathways 
from the RVM to the spinal cord [2, 50]. Therefore, it is possible that the activity in these 
inhibitory descending pathways is decreased, counteracting the effect of the activated 
Gly/GABA neurons that we have indentified during chronic pain states.
 In conclusion, in chronic pain states there is loss of synaptic inhibition in the spinal 
cord while at the same time there are c-fos activated spinal Gly/GABA neurons, and pos-
sibly inhibitory input by descending pathways from the RVM. Whether all these inhibitory 
inputs are blocked, resulting in the observed loss of spinal inhibition in chronic pain states, 
or whether their activation is induced by the loss of spinal inhibition but fail to compen-
sate for that loss is currently unclear. 
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1.2.2. Contralateral pain stimulation
 In chapter IV of this thesis we have shown that the number of activated Gly/GABA 
neurons is increased after a capsaicin injection in the hindpaw of rats which have chronic 
inflammatory or neuropathic pain in the other hindpaw. This indicates that a unilateral 
chronic pain state increases the excitability of Gly/GABA neurons on the contralateral side 
of the spinal cord. As a result a subsequent pain stimulus on that side will activate a larger 
number of Gly/GABA neurons, relative to non-Gly/GABA neurons. Previous studies have 
shown that primary afferent fibers not only result in ipsilateral activation of the spinal 
cord, but also in contralateral activation by polysynaptic mechanisms [27]. Further, it has 
been shown that an one sided noxious stimulation induces c-fos activation of spinal neu-
rons on the contralateral side [9], and that the number of c-fos expressing neurons is 
increased after a second stimulus on that contralateral side [45, 46]. In accordance, it was 
shown recently by means of autofluorescent flavoprotein imaging that there is activity 
on the contralateral side of the spinal cord immediately after an ipsilateral nociceptive 
stimulation [37]. The following question now arises: what is the functional meaning of the 
activation and the increased excitability that develops on the contralateral side? One pos-
sible explanation may be that it is important for survival: when a body part is injured on 
one side, the same body part on the contralateral side must remain functional despite the 
injuries and possible new injuries to that body part. In this situation, an enhancement of 
the local inhibition of nociception would be beneficial for a proper function of that body 
part [63, 70]. However, in these situations it is likely that the PAG-RVM system, that con-
trols spinal pain transmission through its descending projections to the dorsal horn [26], 
will also become involved. Therefore it is likely that changes that we have observed on the 
contralateral side of an injury, are the result of changes in the activity and excitability of 
local spinal neurons as well as neurons in the RVM. Taken together our findings show that 
the excitability and subsequent activation pattern of Gly/GABA neurons on one side of the 
spinal cord are affected by painful events on the contralateral side, while the underlying 
mechanisms need further investigation.
2. Long-term memory consolidation in spinal nociceptive pathways
 Central sensitization plays a important role in the development and the mainte-
nance of hyperalgesia and allodynia after nociceptive stimuli. There are three mechanisms 
that underlie the central sensitization [94, 95]. In the first place there is wind-up, a form 
of activity dependant plasticity, resulting in the increase of action potential output of dor-
sal horn neurons. Wind-up is induced by and only manifest during a train of repeated 
low-frequency C-fiber or nociceptor stimuli [12, 52, 55, 83] and occurs only at the active 
synapse (homosynaptic). For example, when a noxious thermal or mechanical stimulus 
with a constant intensity is repeatedly applied to the skin, wind up of spinal neurons in-
duces an increase in pain with each successive stimulus, while the intensity of the noxious 
stimuli is constant [68]. 2) A second mechanism is heterosynaptic central sensitization. In 
this case the increased excitability of spinal nociceptive dorsal horn neurons, elicited by 
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a brief and intense nociceptive stimulus, results in the activation of dorsal horn neurons 
by primary afferent inputs that are normally subthreshold [10, 51, 96]. This form of cen-
tral sensitization is heterosynaptic, meaning that that the potentiation of synaptic output 
not only applies to the synapses that were activated by the initiating stimulus, but also 
to other synapses not activated by the initiating stimulus [76]. At the behavioral level, 
this heterosynaptic potentiation is the underlying cause of secondary hyperalgesia and 
allodynia in the area around the primary injury site [77]. A third mechanism is known as 
long-term potentiation (LTP), a process at the homosynaptic level which results in an in-
creased efficacy of excitatory primary afferent input [34, 92]. It has been shown that this 
LTP induced enhancement of monosynaptic excitatory synaptic responses lasts for days to 
weeks, is NMDA receptor dependent, and leads to the phosphorylation of AMPA recep-
tors and the recruitment of new AMPA receptors into the cell membrane [71, 90]. It is gen-
erally assumed that most processes inherent to LTP formation in cortical and hippocampal 
neurons are probably similar to the LTP-related processes occurring in spinal nociceptive 
neurons [35]. Taken together, there is evidence for nociception induced homosynaptic and 
heterosynaptic enhancement of spinal nociceptive neuronal excitability, and LTP based 
long-term consolidation of synaptic changes in spinal nociceptive pathways, and all these 
mechanisms contribute to central sensitization.  
 In this thesis we have investigated the expression pattern of Arc/Arc3.1 mRNA 
and protein in the rat spinal cord after nociceptive stimuli, and determined the pain be-
havior in Arc/Arg3.1 knockout (KO) mice. Arc/Arg3.1, an immediate early gene (IEG), was 
first identified and extensively investigated in cortex and hippocampus [8, 21, 64, 73, 74], 
where it plays an essential role in long-term memory consolidation by regulating AMPA re-
ceptor trafficking [7]. Consequently, knockdown of Arc/Arg3.1 results in the loss of LTP and 
long term depression (LTD), and the loss of long-term memory while short term memory 
is unchanged [64]. In chapter 6 we showed that Arc/Arg3.1 is de novo expressed after a 
nociceptive stimulus and that the expression of Arc/Arg3.1 is intensity dependent, i.e. a 
stronger nociceptive stimulus induces a higher number of Arc/Arg3.1 expressing neurons. 
We further found that Arc/Arg3.1 is predominantly expressed in enkephalinergic inter-
neurons, and not in NK1 receptor expressing projection neurons, that relay nociceptive 
signals to supraspinal levels, nor in Gly/GABA interneurons that are likely involved in the 
local inhibition of spinal pain transmission. In line with this lack of expression in the most 
important neurons of the spinal nociceptive system, we found that the Arc/Arg3.1 KO 
mice showed no changes in their pain behavior to acute (formalin) and chronic (inflam-
mation) pain stimuli as compared to their wild type littermates. This strongly suggests 
that the important “memory molecule” Arc/Arg3.1 is not crucially involved in the long-
term consolidation of “pain memory”, i.e. the changes that occur during inflammatory and 
neuropathic pain states. This finding may reflect a special property of pain memory in the 
spinal cord, which is that it should be reversible and not lead to permanent changes. In 
functional terms: if an injured part of our body remained sensitized to non-noxious (allo-
dynia) and noxious (hyperalgesia) stimuli, we would be forced to maintain the protection 
of an injured area long after the healing process of that area had been completed. Instead, 
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central sensitization in the spinal cord that develops post injury slowly subsides with tis-
sue healing, resulting in the disappearance of hyperalgesia and allodynia in and around 
the area of tissue injury. As a consequence the functional organization of the spinal cord, 
and the sensitivity of the healed area of injury, will return to the normal pre-injury situa-
tion. Since Arc/Arg3.1 is involved in establishing permanent changes in synaptic strength, 
its absence from spinal nociceptive projection neurons, as well as Gly/GABA expressing 
spinal neurons, is in line with the idea that permanent changes in the spinal pain system 
are unfavorable for its proper function. However, there is one group of neurons that did 
express Arc/Arg3.1 after nociceptive activation: the enkephalin expressing neurons. This 
indicates that these neurons will develop permanent changes after nociceptive activation 
and become more sensitive for incoming nociceptive stimuli for a long period of time. As a 
consequence, these enkephalinergic neurons, which are a minority of the c-fos activated 
neurons, may become more easily activated when the injured area would be injured a 
second time. Since enkephalin exerts an inhibitory effect on pain transmission in the dor-
sal horn [17, 61], this would mean that a subsequent injury would be less painful then the 
previous one. If this effect is strong enough, it would be possible to test this hypothesis in 
Arc/Arg3.1 KO mice. However, due to a limited availability of these mice, were not able to 
put this to the test. 
 In conclusion, our results indicate that Arc/Arg3.1 in the spinal cord is not involved 
in the development of pain behavior in the formalin and chronic inflammation models. 
This indicates that mechanisms that produce central sensitization in the spinal cord do not 
lead to long-term changes that outlast the healing period. In that sense, LTP in the spinal 
cord is different from other areas of the central nervous system (CNS), where long term 
consolidation of synaptic changes is a prerequisite for memory formation. 
3. Inhibitory projections from the RVM to the spinal cord
 Next to the spinal interneurons, descending projections from the RVM are also 
important in modulating spinal nociception [16], as activation of these projections leads 
to facilitation or inhibition of spinal nociceptive transmission [15]. The facilitating effect 
of the RVM on spinal nociception is induced by the ON cells [4, 15, 25], while inhibition 
of spinal nociception by descending RVM projections is mainly achieved by OFF cell acti-
vation [15, 26], with simultaneous inhibition of the ON cells. Many studies have focused 
on the transmitters involved in producing the effects of the descending RVM projections 
and most of the neuropeptides that were identified showed a facilitating effect, including 
cholecystokinin [43, 89] and neurotensin [60, 79, 88, 89]. With respect to the inhibitory 
projections from the RVM, it was believed for a long time that the transmitter involved 
was serotonin [23, 33, 38, 47]. However, more recently it became clear that serotonin may 
also induce facilitation of spinal pain transmission [62, 84, 100] and that serotonin was not 
localized in ON or OFF cells, but in Neutral cells, which show an activity pattern unrelated 
to nociceptive stimulation [18, 67]. Thus, if serotonin is not present in the OFF cells, which 
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is then the main transmitter, producing direct inhibition on spinal nociception? There is 
evidence that glycine and GABA are released in the dorsal horn upon RVM stimulation [49, 
50, 80], but is has not been established from which terminals, i.e. descending projections 
or local spinal interneurons. In fact there are several mechanisms that may result in the 
inhibition of spinal nociception, including direct inhibition of projection neurons in the 
dorsal horn [91, 93], opioid dependent inhibition of transmitter release by primary noci-
ceptive afferents [19], direct inhibition of nociceptive neurons in the dorsal horn [13, 20] 
and the activation of inhibitory interneurons in the dorsal horn [1, 54, 80]. In an electron 
microscopical study [2], which combined anterograde tracing from the RVM with glycine 
and GABA immunohistochemistry, it was shown that in the dorsal horn glycine and GABA 
were present in terminals that were labeled from the RVM. In chapter 6 we have shown, 
using retrograde tracing from the spinal cord with fluorescent in situ hybridization for 
GABA and glycine, that 44% of the neurons projecting to the spinal dorsal horn are indeed 
Gly/GABA. Thus, based on this anatomical evidence, it seems very likely that Gly/GABA 
neurons represent the OFF cells. Whether this means that glutamate is the likely fast ex-
citatory transmitter in the ON cells (next to various neuropeptides) remains unclear. 
 In chapter 6 we have also shown that there are Gly/GABA neurons in the spinal 
cord, located in the area around the central canal (CC), that project to the RVM. This path-
way is the only projection from the spinal cord to a supraspinal structure (i.e. the RVM) 
that contains the fast inhibitory transmitters GABA and glycine. This finding shows that the 
spinal cord is not merely “passing on” information to higher structures, but is also involved 
in the inhibition of specific supraspinal nuclei, like the RVM. Within the same spinal area 
around the CC there are also neurons that use opioids such as enkephalin and dynorphin 
[59] that project to supraspinal sites including the RVM. Enkephalin is frequently colocal-
ized with GABA in the spinal cord [30], therefore it is not excluded that the opioids in 
these neurons act as modulators that are colocalized with fast transmitters like GABA and 
glycine, and thus represent the same neurons that we have identified as Gly/GABA. It is 
presently unclear which type(s) of neurons in the RVM are inhibited by these connections 
and whether or not they act as feedback loops involved in the control of the nociceptive 
transmission in the spinal cord. Taken together, our finding of glycinergic and GABAergic 
ascending pathways from the spinal cord to the RVM, shows that the idea of the spinal 
cord as a relay station for sensory information, should be adapted to include the existence 
of inhibitory connections, controlling the activity of supraspinal structures, like RVM. 
4. Final conclusions
 In this thesis we have shown that spinal Gly/GABA neurons have specific activation 
pattern in acute and chronic pain states. Whether these activated Gly/GABA neurons can 
compensate for the loss of inhibitory neurotransmission during chronic pain, or whether 
they are involved in another process inherent to chronic pain states is unclear. Our inves-
tigation on the spinal expression of Arc/Arg3.1 indicates that Arc/Arg3.1 based long-term 
memory consolidation is not predominant in the spinal cord. This finding is in line with 
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our suggestion that long-term consolidation of synaptic activity in the spinal cord is unfa-
vorable as it would lead to a hypersensitive spinal cord with permanent hyperalgesia and 
allodynia even after tissue healing. Further, our findings provide strong evidence for the 
involvement of RVM Gly/GABA projection neurons in spinal processing. However, whether 
Gly/GABA projection neurons are the OFF cells that have been characterized to inhibit 
spinal nociception, or that they are a specific subset of neurons, next to OFF cell popula-
tion remains to be determined. Finally, the existence of reciprocal inhibitory connections 
between the RVM and the spinal cord suggest that the spinal cord may, via a feed-back 
loop, be able to modulate RVM neurons in order to alter its own neurons that are under 
control of descending RVM pathways.  Taken together our findings further underline the 
importance of Gly/GABA neurons in the spinal cord and the brainstem for controlling the 
feeling we all know: pain
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 In this thesis we have employed fluorescent in situ hybridization (FISH) in order 
to identify neurons in the spinal cord and the brainstem that use glycine or gamma-ami-
no butyric acid (GABA) or both transmitters (Gly/GABA neurons). With this technique we 
have made a detailed analysis of the localization of glycinergic cell somata in the spinal 
cord (Chapter 2). In the subsequent experiments we have combined FISH with the retro-
grade tracing technique, using fluorescent microspheres, or with the fluorescent immu-
nohistochemistry technique for identifying various proteins, including c-fos, a marker for 
neuronal activation.
 In Chapter 3 it is demonstrated that spinal Gly/GABA neurons have specific acti-
vation patterns in acute, chronic inflammatory and neuropathic pain. Furthermore, the 
averaged percentage of activated neurons that were Gly/GABA in the chronic phase (≥20h 
survival, 46%) was significantly higher than in the acute phase (≤2h survival, 34%). Mor-
phine application equally decreased the total number of activated neurons and activated 
Gly/GABA neurons. This showed that morphine did not specifically activate Gly/GABA 
neurons to achieve nociceptive inhibition. Since there is evidence for an overall loss of 
spinal inhibitory neurotransmissions in chronic pain states, we conclude that the effect of 
the activated Gly/GABA neurons is insufficient to produce an overall increase in inhibition 
during these chronic pain states. 
 In Chapter 4 we have shown that a chronic pain state in the hind paw on one side 
leads to increased excitability of Gly/GABA neurons located on the contralateral side of 
the spinal cord, since a pain stimulus on that contralateral side resulted in an increased 
number of activated Gly/GABA neurons. 
 In Chapter 5 we have used FISH combined with fluorescent retrograde tracing. 
The results showed that about 40% of the neurons in the rostral ventromedial medulla 
(RVM) that project to the cervical spinal cord were Gly/GABA, i.e. containing either gly-
cine or GABA or both transmitters. From the projections of the RVM to the lumbar dorsal 
horn 43% were Gly/GABA and this percentage was 35% for the projections to the lumbar 
ventral horn. In the caudal medulla, relatively few neurons projecting to the lumbar dorsal 
horn were Gly/GABA (5%), while this percentage was much higher (19%) for projections 
to the ventral horn. The percentages obtained for GABA and glycine separately were very 
similar to those obtained for Gly/GABA. These findings show that virtually all of the Gly/
GABA projections to the spinal cord contain both transmitters and that the projections to 
the dorsal horn originate preferentially in the RVM. In this chapter we have also shown 
the presence of spinal Gly/GABA neurons located in the area around the central canal that 
project to the RVM. This inhibitory ascending pathway, which is the only inhibitory (Gly/
GABA) pathway from the spinal cord to the brainstem identified up to now, might allow 
the spinal cord to modulate the RVM, thereby controlling the descending control of the 
RVM on spinal pain processing. 
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 In Chapter 6 we have investigated in the spinal cord the role of Arc/Arg3.1, an im-
mediate early gene that is essential for long-term memory consolidation in cortical and 
hippocampal neurons. Arc/Arg3.1 is not present in the naive spinal cord, but is de novo 
expressed by nociceptive stimuli. The majority (68%) of the Arc/Arg3.1 expressing neu-
rons contained enkephalin, while only 19% were neurokinin-1 expressing projection neu-
rons and 3.6% were inhibitory (GABA) neurons. These findings showed that Arc/Arg3.1 
is expressed in only a few projection and inhibitory neurons, which belong to the most 
important neurons of the spinal pain system. Accordingly Arc/Arg3.1 knockout mice did 
not show any changes in their pain behavior after formalin injection and after induction of 
chronic inflammation. These findings suggest that long term memory consolidation is not 
required and may even hamper normal functioning of the nociceptive system. 
 Taken together, this thesis gives a detailed analysis of the distribution pattern of 
activated Gly/GABA neurons in the spinal cord during different pain states as well as the 
distribution of Gly/GABA neurons in the RVM that project to the spinal cord. The expres-
sion pattern of Arc/Arg3.1 during different pain states substantiates the idea that long 
term synaptic changes in the spinal pain system, including the Gly/GABA neurons, are un-
favorable for the normal functioning of spinal pain transmission. Thus our findings further 
underline the importance of Gly/GABA neurons in the spinal cord and the brainstem for 
controlling the feeling we all know: pain. 
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 In dit proefschrift hebben we gebruik gemaakt van de fluorescerende in situ hy-
bridizatie (FISH) techniek om de neuronen in het ruggenmerg en de hersenstam te iden-
tificeren die glycine of gamma-amino boterzuur (GABA) of beide transmitters bevatten 
(Gly/GABA neuronen). Met deze techniek hebben we een gedetailleerde analyse gemaakt 
van de localisatie van de glycinerge neuronen in het ruggenmerg (Hoofdstuk 2). In de 
volgende experimenten hebben we de FISH techniek gecombineerd met de retrograde 
neuronale opsporingstechniek met behulp van fluorescerende micro-bolletjes of met de 
fluorescende immunohistochemie techniek om verschillende eiwitten te identificeren, 
waaronder c-fos, het eiwit dat geactiveerde neuronen labelt.
 In Hoofdstuk 3 wordt aangetoond dat Gly/GABA neuronen in het ruggenmerg vol-
gens een specifiek patroon geactiveerd worden gedurende acute pijn, chronische ontstek-
ingspijn en neuropathische pijn. Het gemiddelde percentage geactiveerde Gly/GABA neu-
ronen was significant hoger in de chronische fase (≥20h overleving, 46%) vergeleken met 
de acute phase (≤2h overleving, 34%). De toediening van morfine verminderde het totale 
aantal geactiveerde neuronen en het totaal aantal geactiveerde Gly/GABA neuronen in 
dezelfde mate. Dit laat zien dat de pijnonderdrukking door morfine niet tot stand kwam 
door het activeren van Gly/GABA neuronen. Op grond van aanwijzingen dat de totale 
mate van pijnonderdrukking in het ruggenmerg minder wordt gedurende chronische pijn, 
kan worden geconcludeerd dat het effect van de geactiveerde Gly/GABA neuronen onvol-
doende is om gedurende chronische pijn een toename van pijnonderdrukking te bewerk-
stelligen. 
 In Hoofdstuk 4 laten we zien dat chronische pijn aan de achterpoot aan één kant, 
leidt tot een verhoogde prikkelbaarheid van Gly/GABA neuronen aan de andere kant van 
het ruggenmerg, aangezien een pijnprikkel aan die andere kant resulteerde in een ver-
hoogd aantal geactiveerde Gly/GABA neuronen. 
 In Hoofdstuk 5 hebben we de FISH techniek gecombineerd met de retrograde neu-
ronale opsporingstechniek. De resultaten lieten zien dat ongeveer 40% van de neuronen 
in de rostral ventromediale medulla (RVM) die naar het cervicale ruggenmerg project-
eerden Gly/GABA bevatten, ofwel dat deze neuronen of glycine of GABA of beide trans-
mitters bevatten. Van de projecties van de RVM naar de lumbale dorsale hoorn waren 43% 
Gly/GABA en wat betreft de projecties naar de lumbale ventrale hoorn was dit percentage 
35%. De ventrale medulla, caudaal van de RVM, bevatte relatief weinig neuronen met 
Gly/GABA (5%), die naar de lumbale dorsale hoorn projecteerden, terwijl dit percentage 
veel hoger lag (19%) voor de neuronen met projecties naar de lumbale ventrale hoorn. 
De percentages die werden verkregen voor GABA en glycine apart waren vrijwel gelijk 
aan de bovengenoemde percentages voor Gly/GABA. Samengevat kan gesteld worden dat 
nagenoeg alle projecties van de RVM en caudale medulla naar het ruggenmerg zowel gly-
cine als GABA bevatten en dat de projecties naar de dorsale hoorn voornamelijk afkomstig 
zijn van de RVM. In dit hoofdstuk hebben we ook laten zien dat er Gly/GABA neuronen 
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aanwezig zijn rond het centrale kanaal van het ruggenmerg die naar de RVM projecteren. 
Deze baan van het ruggenmerg naar de hersenstam is de enige opstijgende baan, met een 
remmend (Gly/GABA) effect, die tot nu toe bekend is. Waarschijnlijk kan deze baan de 
RVM beïnvloeden en daarmee de afdalende banen van de RVM controleren, die op hun 
beurt de pijnverwerking in het ruggenmerg controleren.  
 Hoofdstuk 6 laat in het ruggenmerg het onderzoek zien aangaande Arc/Arg3.1, 
een snel afgeschreven genproduct dat in de cortex en de hippocampus neuronen essen-
tieel is voor het vastleggen van het lange termijn herinneringen. Arc/Arg3.1 is normaliter 
niet aanwezig in het ruggenmerg, maar wordt pas tot expressie gebracht als er een pi-
jnprikkel wordt toegediend. De meeste neuronen die Arc/Arg3.1 tot expressie brengen 
bevatten enkephaline (68%), terwijl slechts 19% de neurokinine-1 receptor (kenmerkend 
voor projectie neuronen) tot expressie brengen en 3.6% waren GABA neuronen, die een 
remmende werking hebben. Deze bevindingen tonen aan dat Arc/Arg3.1 slechts in enkele 
projectie-neuronen en remmende neuronen tot expressie komt, terwijl die neuronen be-
horen tot de belangijkste in het pijnsysteem van het ruggenmerg. In overeenstemming 
hiermee lieten Arc/Arg3.1 knockout muizen dan ook geen veranderingen zien in hun pi-
jngedrag na injectie van formaline en gedurende chronische infectie. Deze bevindingen 
geven aan dat het vastleggen van “pijnherinneringen” voor de lange termijn niet noodza-
kelijk of zelfs hinderlijk zijn voor het normaal functionerende pijn systeem.
 Samengevat kan gesteld worden dat dit proefschrift een gedetailleerde analyse 
geeft van zowel de organisatie patronen van geactiveerde Gly/GABA neuronen in het rug-
genmerg bij verschillende oorzaken van pijn, als ook de verdeling van de organisatie van 
de Gly/GABA neuronen in de RVM en caudale medulla, die naar het ruggenmerg pro-
jecteren. Het expressie patroon van Arc/Arg3.1 gedurende de verschillende oorzaken van 
pijn verschaft een basis aan het idee dat het vastleggen van synaptische veranderingen 
voor de lange termijn in het pijnsysteem, daarbij inbegrepen de Gly/GABA neuronen, on-
gunstig zijn voor het normaal functionerende pijnsysteem in het ruggenmerg. Deze bevin-
dingen benadrukken nogmaals het belang van Gly/GABA neuronen in het ruggenmerg en 
de hersenstam voor het controleren van het gevoel dat we allemaal kennen: pijn.
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 Het is 22.56 uur op een donderdagavond in een stilstaande trein op het centraal 
station in Breda. Het is zoals gewoonlijk een regelrechte chaos op de Nederlandse spoor-
wegen en de ergernis van de reizigers trekt als een dampige mist over de spoorwegen. 
Moedig had ik besloten om vanavond na mijn avonddienst op de spoedeisende hulp in 
het Amphiaziekenhuis toch naar huis terug te reizen, maar mijn moed is nergens meer 
te bekennen en de stilstaande trein maakt me onrustig. Dan maar aan mijn dankwoord 
beginnen:
 Allereerst wil ik mijn promotor Prof. Chris de Zeeuw bedanken. Alhoewel wij maar 
een paar minuten met elkaar hebben gesproken in de afgelopen zeven jaar en de meeste 
zaken tussen ons via Joan zijn verlopen wil ik je hierbij bedanken voor de steun op de ach-
tergrond en meedelen dat je ambities mij aan het denken hebben gezet. Hierbij wil ik ook 
graag de rest van de leden van de promotiecommissie bedanken voor de tijd die ze hebben 
genomen om mijn proefschrift te lezen en vragen te formuleren.
 Mijn copromotor en begeleider Dr. J.C. Holstege. Beste Joan, we hebben wonder-
lijk genoeg meer dan zeven jaar met elkaar samengewerkt en evenredig aan het aantal 
jaren, evenzoveel artikelen geschreven. Ik ben in de afgelopen jaren veel veranderd en 
jij bent een van de weinigen geweest die daar invloed op heeft gehad. Je ongezouten 
mening, dat vaak de waarheid weerspiegelde, heb ik altijd op prijs gesteld. Vaak had je 
aan begeleiding je handen vol aan mij, en in de wetenschap was mijn enthousiasme vaak 
ongericht, maar gelukkig was jij er om me de goede richting in te sturen. Je kennis over 
het pijnsysteem heeft me vaak verrast, en je manier van aanpak om een vraagstuk te be-
antwoorden heeft mij veel bijgeleerd. Verder, het feit dat een artikel minstens 25x her-
geschreven moest worden laat zien hoe perfectionistisch jij bent of hoe slecht ik ben. De 
wetenschappelijke en niet-wetenschappelijke gebeurtenissen die wij in de afgelopen jaren 
hebben meegemaakt is een unieke en leerzame ervaring geweest. Het is niet makkelijk 
om volledig te zijn in mijn bewoordingen maar het komt er op neer dat ik een geweldige 
tijd heb gehad en ik wil je hierbij bedanken voor je hulp en geduld. Aangezien we vaak fi-
losofische gesprekken hebben gevoerd, zal ik mijn dank maar eindigen met het volgende: 
‘Perceptie maakt wetenschap mogelijk, en wetenschap is een feitelijke handgreep om te 
sublimeren. Maar gelukkig is sublimatie een droom binnen dromen.’ Ps. Ik moet wel toe-
geven dat het nog steeds jeukt dat we geen paper over ‘Jeuk’ hebben gepubliceerd.
 Beste Elize! In de afgelopen jaren heb ik ontelbare keren ‘Elize’ geroepen en altijd 
werd dat met een vriendelijke lach beantwoord. Jij bent zeker de onmisbare schakel in het 
histologielab, en zonder jouw kennis had ik het op bepaalde momenten niet kunnen red-
den. Hierbij wens ik je in de komende jaren veel plezier op het histolab, en geniet van je 
jaarlijkse reizen naar de meest exotische plekken op de aarde. 
 Erika, bedankt voor de vele leuke gesprekken. Jouw gevoel voor humor komt re-
delijk dicht in de buurt van die van Joan en ergens denk ik dat jouw vele jaren op het lab, 
en je samenwerking met Joan aan het begin van je carrière, wel degelijk van invloed zijn 
geweest. Als je de Masterstudenten ooit zat wordt, geef me dan een seintje, want dan 
kunnen we ons toneelstuk uitproberen. Mandy, Loes, en Edith, jullie ook bedankt voor jul-
lie hulp in de afgelopen jaren, en nog veel plezier op de afdeling in de aankomende jaren.
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 Liron, als jij niet op de afdeling was verschenen zouden de afgelopen twee jaar 
voor mij heel moeilijk zijn geweest. Jij bent een chirurg die wetenschappenlijk is inge-
steld, een Kosovaar van top tot teen en gekleed volgens de regels van de Italiaanse mode. 
Jouw Balkanese mentaliteit gecombineerd met mijn Perzische mentaliteit heeft veel leuke 
momenten opgeleverd in de late avonduren op het lab; onze manier om de wetenschap-
pelijke tegenslagen van de dag te verteren. Dit was vooral het geval in het eerste jaar toen 
we alle immunotechnieken aan de gang moesten krijgen en hierdoor hebben wij ook een 
sterke vriendschap opgebouwd. Je experimenten lopen nu goed en voor je het weet begin 
jij ook aan het dankwoord van jouw proefschrift! En bedankt dat je mijn paranimf wilt zijn!
 Somesh, jij arriveerde op het juiste moment! In het laatste jaar hadden Liron en ik 
het allebei zwaar, maar met jouw hulp konden we weer alles aan. De drie dagen in Milaan 
waren goed genoeg om weer maanden vooruit te kunnen. Bedankt voor je hulp met mijn 
onderzoek en de vriendschap die we hieraan hebben overgehouden. Veel succes met je 
nieuwe huis en tot volgende week waarschijnlijk! 
 Beste Sebastian, wij rolden het Master of Neuroscience programma binnen in het 
tweede jaar nadat het gestart was. We hebben drie soorten knockout muizen ‘gepijnigd’ 
maar uiteindelijk hebben zij óns gepijnigd. Wat waren we toch gemotiveerd aan het begin 
en wat waren wij toch gedemotiveerd aan het eind! Wat wij waren toch naïeve Masterstu-
denten aan het begin en verbitterde Masterstudenten aan het eind. Maar het blijven leuke 
tijden! Vooral de memorabele ‘formaline test’ in het kleine donkere kamertje waarbij de 
slapeloosheid van ons evenredig was aan die van de muizen. Veel succes met je opleiding 
tot Psychiater en hopelijk zal ik in de toekomst niet tegenover jou komen te zitten, want 
dan is er iets goed misgegaan!
 Querido John! Yo tu prometido que yo dar gracias en Español, et yo cumplir de 
promesa usanta Van Dale diccionario. Muchas gracias por leccionas de Español, entre-
tenids y algunas veces locos tiempos en laboratorio. Nosotros tenemos abiertas mentas, 
y esporo que encontrara en futuro en zona differente del medicina, y estoy curisio que 
serás. Yo me parece Español un bello lengua, y en cuanto más tiempos en mi vida ap-
prendé Español. Hasta luego amigo!
 Verder wil ik Tom Ruigrok bedanken voor de nuttige discussies en je hulp met 
de plotmicroscoop in de afgelopen jaren. Het is wel een ouderwetse ding, maar je kan 
er ongenaakbare anatomiedata mee genereren. Veel succes in de komende jaren met je 
onderzoek. 
 Beste Joost! Ik heb bewondering voor je opvallende toewijding en enthousiasme 
voor wetenschap naast je baan als Neuroloog. Ik moet eerlijk toegeven dat neurologie niet 
bovenaan mijn lijst van specialisaties staat. Maar de toekomst is net zo onvoorspelbaar 
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1.1. The definition of pain
 In the 17th century, René Descartes, who is generally considered as the ‘father of 
modern philosophy’, was one of the first in history to inquire into the feeling of pain on a 
rational (scientific) basis. Some of his philosophical reasoning, like his theory on the du-
alistic nature of humans with a clear separation between the mind and the body, are still 
found in our culture today. Several of his other statements, e.g. that animals do not have 
a mind and therefore are not able to feel pain, are now generally considered as outdated. 
Nevertheless, his view on the transmission of pain [6], represented as the pulling of a 
thread (Fig. 1), and on the functional importance of pain are not completely at odds with 
current views on pain transmission.
Fig. 1:“For example, if the fire A is close to 
the foot B, the small particles of fire, which 
as you know move very swiftly, are able to 
move as well the part of the skin which they 
touch on the foot. In this way, by pulling at 
the little thread cc, which you see attached 
there, they at the same instant open e, 
which is the entry for the pore d, which is 
where this small thread terminates; just as, 
by pulling one end of a cord, you ring a bell 
which hangs at the other end.... Now when 
the entry of the pore, or the little tube, de, 
has thus been opened, the animal spirits 
flow into it from the cavity F, and through it 
they are carried partly into the muscles 
which serve to pull the foot back from the 
fire, partly into those which serve to turn 
the eyes and the head to look at it, and 
partly into those which serve to move the 
hands forward and to turn the whole body 
for its defense.”
 Painful stimuli are indeed detected by specialized fibers in the skin and transmit 
their information to the spinal cord [56], and from there to higher centers of the central 
nervous system [23]. Furthermore, pain serves as a warning system leading to retraction 
of our body from the source of physical danger. Since Descartes’ time and especially in 
the last century, there has been a tremendous increase in research on pain. The Interna-
tional Association for the study of Pain (IASP), founded in the 1973, describes pain as ‘An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’. This definition points out that pain, while 
serving as a warning system of our body, is in essence a feeling with a major emotional 
impact. This makes pain a prominent part of our daily live, especially for patients with 
chronic pain. 
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1.2. The pain system
 The feeling of pain is generally initiated by the activation of specialized primary 
afferents, termed nociceptors, which innervate the skin [56] but also the majority of the 
internal organs [8, 74], with clinically notable exceptions like the liver, the lungs, and the 
brain. Nociceptors are activated by actual or potential damaging stimuli directed to our 
body  and hence require our immediate attention. Activated nociceptors convey their in-
formation to the spinal cord, or, when our face is involved, to the brainstem [24, 80]. 
In the spinal cord and the brainstem, nociceptors establish the first synapse in the pain 
system by contacting second order nociceptive neurons [76]. There are two main types 
of nociceptive fibers, namely slow conducting unmyelinated C-fibers that are responsible 
for the dull aching pain, and fast conducting myelinated Aδ-fibers that are responsible for 
acute pin prick-like pain [22, 72]. C-fibers contact nociceptive neurons located in lamina I 
and especially lamina II, while Aδ-fibers project to secondary nociceptive neurons mainly 
in laminae I, IV and V [76]. Subsequently, via crossing axons of the second order neurons 
nociceptive information is conducted contralaterally to various nuclei in the brainstem, 
the midbrain and the thalamus by way of the antero-lateral system [23]. 
 The antero-lateral system contains several important ascending pathways includ-
ing projections to: 1) the thalamus, i.e. spinothalamic tract (STT) [23]; 2) the homeostatic 
control regions in the medulla and the brainstem, i.e. spinomedullary, spinopontine and 
spinomesencephalic pathways that project to the regions of catecholamine cell groups 
(A1-A7) [23, 68], the parabrachial nucleus (PB) [10, 14, 26], the periaqueductal grey (PAG) 
[82], and the reticular formation of the medulla and pons [9]; 3) the hypothalamus (the 
spinohypothalamic tract, SHT) and the ventral part of the forebrain [17]. In addition there 
are projections to the forebrain, originating in the brainstem, which include the anterior 
cingulate cortex (ACC), the insular cortex (IC) and the prefrontal cortex [23]. Further, there 
are also nociceptive projections to the SI and SII regions in the somato-sensory cortex, 
mainly through the thalamus [15]. While the projections to the somato-sensory cortex 
are primarily involved in identifying the location and intensity of the nociceptive stimulus 
[48, 49, 60], the projections to the limbic forebrain provide the basis for the emotional 
impact of the nociceptive stimulus [7, 31, 51, 79]. Collectively, these various supraspinal 
structures that are involved in pain processing are known as the pain matrix [11, 63]. The 
pain matrix, which includes sensory, motor, cognitive and emotional parts of the brain, 
emphasizes that the feeling of pain is a multidimensional percept, in line with the fact that 
pain is of essential importance in our daily lives. 
1.3. Hyperalgesia and allodynia: increased sensitivity to pain stimuli
 As experienced in daily life, an injury usually leads to a direct painful sensation. 
However, when the initial pain has subsided and the healing process has started, the area 
of injury often becomes more sensitive to both noxious and non-noxious stimuli. This con-
dition, in which a non-noxious stimulus is perceived as painful (referred to as allodynia) 
and a noxious stimulus causes more pain than normal (referred to as hyperalgesia) [12, 45, 
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85] is important, since both allodynia and hyperalgesia will make a subject to protect the 
injured area, thus aiding the healing process. The increased sensitivity of the injured area 
to non-noxious and noxious stimuli is the result of an increased sensitivity of nociceptors 
in the periphery (peripheral or primary sensitization) as well as neurons in the spinal cord 
(central or secondary sensitization) [83, 86]. In addition, descending pathways originating 
in the brainstem further facilitate this process by modulating the sensitivity of the spinal 
nociceptive neurons [66, 81]. 
1.4. Chronic pain
 The feeling of pain usually subsides with the disappearance of the nociceptive 
stimuli during the healing time. However, when an injury becomes chronic the associ-
ated pain, including allodynia and hyperalgesia, will persist. For example, during chronic 
arthritis the joints are affected by chronic inflammation [52], and the patients suffering 
from such a disease complain of a nagging pain in the affected joints, together with limi-
tations of their movements due to their painfulness. Treatment is directed at eliminating 
or decreasing the inflammation process and suppressing the pain, using analgesics [75]. 
Another major cause of chronic pain is the so-called neuropathic pain, which develops 
after nerve injury, e.g. after transection by trauma or surgery, or after ischemic events 
[21]. Post-injury, there is ectopic firing in the damaged nerve, increased sensitivity of spi-
nal nociceptive neurons, and altered descending control originating in the brainstem [5, 
37, 59]. All these changes lead to spontaneous pain without the presence of a noxious 
stimulus at the injured area, often accompanied by allodynia and hyperalgesia [16, 84]. 
More so than chronic inflammatory pain, neuropathic pain is notoriously difficult to treat 
with even the strongest analgesics [5]. Both chronic inflammatory and neuropathic pain 
are seriously debilitating conditions that affects millions of people worldwide [19]. Thus, 
research dedicated to the understanding of the processes underlying chronic inflamma-
tory and neuropathic pain is of essential importance for patients in need of pain relief. 
1.5. Pain inhibition at the spinal cord level
1.5.1. Spinal inhibitory interneurons
 Incoming nociceptive fibers not only contact projection neurons that relay the in-
formation to higher centers but also local excitatory and inhibitory interneurons [18, 27]. 
These interneurons are involved in controlling the spinal sensitivity to incoming nocicep-
tive stimuli [41, 78, 90], and are therefore believed to contribute to the maintenance of 
chronic pain states [90]. Recently, it has been shown that glial cells, especially microglia, 
are also involved in gating the sensitivity for nociceptive stimuli, especially during neuro-
pathic pain [13, 44, 69]. Thus, spinal projections neurons, local interneurons and glial cells 
form an intricate network that controls the nociceptive information that is conveyed to 
supraspinal sites, thereby strongly influencing the pain that is experienced. 
 Inhibitory neurons use the fast neurotransmitters glycine and/or GABA as their 
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inhibitory neurotransmitter(s) [2, 46]. The importance of GABA and glycine in pain trans-
mission was shown by blocking glycinergic and/or GABAergic neurotransmission in naïve 
animals, which induced many behavioral signs of hypersensitivity as observed in inflam-
matory and neuropathic pain conditions [70, 71, 87]. Accordingly, decreased inhibition 
was found in the spinal cord during chronic inflammatory pain [58, 64], as glycinergic inhi-
bition in the spinal cord was blocked by a pathway involving prostaglandin E2 (PGE2) [90]. 
During neuropathic pain there is loss of synaptic inhibition due to a shift in the neuronal 
chloride gradient, which reverses the inhibitory effect of GABA into a depolarizing one 
[13]. Further, it was recently shown that selective activation of GABA(A) receptors contain-
ing the α2 and/or α3 subunits leads to pronounced nociceptive inhibition in chronic pain 
states [50]. These findings underline the importance of glycine and GABA in modulating 
the spinal processing of nociceptive information, especially during chronic pain.
1.5.2. Rostral ventromedial medulla 
 Next to the influence exerted by spinal interneurons, the spinal nociceptive sys-
tem is also under control of descending projections originating in the brainstem, espe-
cially from the locus coeruleus and subcoeruleus, and the rostral ventromedial medulla 
(RVM) [29, 36, 81]. The RVM, which is largely located in the pons, is predominantly un-
der control of PAG that is located in the midbrain [36]. In turn, PAG receives projections 
from several cortical and subcortical structures such as the ACC, IC, hypothalamus and the 
amygdala (Amy) [3, 67, 89]. The first evidence that descending pathways are able to con-
trol pain transmission in the spinal cord was provided in 1976 [55] by producing analgesia 
with electrical stimulation of the PAG, without affecting the animal’s response to most 
other environmental stimuli. Since the PAG has no direct projections to the dorsal horn 
[53], its effects are produced through its connections with the RVM, which has extensive 
projection to the spinal dorsal horn [30, 36]. Therefore, the PAG-RVM circuitry is of critical 
importance for the descending control of pain transmission in the spinal cord. 
 It has been shown that microinjection of morphine into the Amy, IC, PAG or RVM 
produces analgesia, while the analgesic effect of systemic administered opioids is abol-
ished by microinjection of opioid antagonists into these sites [88]. With respect to the 
RVM, it has been shown that electrical stimulation of the RVM produces direct inhibition 
of spinal nociception [65], which is also produced by microinjection of excitatory amino 
acids into the RVM [29]. Further, there is enhancement of descending inhibition from the 
RVM in animals with chronic inflammatory pain induced by injection of complete Freund’s 
adjuvant (CFA) [65]. Next to descending inhibition, RVM also facilitates spinal nociception, 
i.e. enhancing of nociceptive transmission, in inflammatory and neuropathic pain models 
resulting in hyperalgesia and allodynia [81]. Thus, the PAG-RVM system is capable of inhib-
iting and facilitating spinal nociception in certain pain models through RVM projections to 
the spinal dorsal horn.  
 The existence of a parallel inhibitory and facilitatory output from the RVM suggest 
that there are distinct neurons in the RVM that are involved in inhibiting or facilitating spi-
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nal nociception. In the RVM there are indeed three different, physiologically characterized, 
neuronal cell types that project to the dorsal horn and have distinct noxious stimulus de-
pendent activity patterns. The ON-cells, which enter a period of activity before execution 
of a withdrawal reflex from a noxious heat, and have a net facilitatory effect on nocicep-
tion [29]. The OFF-cells, which enter a period of silence before execution of a withdrawal 
reflex and have a net inhibitory effect on nociception [35]. The third group, which was 
termed neutral cells, was classified by exclusion. These cells have no characteristic noxious 
stimulus dependent activity pattern and therefore are most likely not involved in the acute 
modulation of nociception [29, 54]. With respect to their neurochemical characteristics, 
there is still no convincing evidence which neurotransmitters the ON- and OFF-cells use to 
induce facilitation and inhibition, respectively [28, 57]. For a long time it was believed that 
serotonin was the neurotransmitter that induced pain inhibition at spinal level [33, 43]. 
However, later on other studies have shown the involvement of serotonin in facilitating 
spinal nociception [77], and that a subgroup of the neutral cells contain  serotonin rather 
than the OFF-cells [32, 61]. Anterograde tracing from the RVM area, combined with GABA 
and glycine immunohistochemistry (IHC) at the ultrastructural level [20, 38, 39, 40] has 
shown that the terminals of the RVM fibers in the spinal dorsal horn contain glycine and 
GABA [1]. Up to now it is not clear whether these transmitters are present exclusively in 
the OFF-cells and whether the ON-cells, which have a facilitatory effect on pain transmis-
sion in the dorsal horn  use glutamate as their neurotransmitter [28, 57]. 
1.6. Aim of this PhD project
 Spinal neurons that use GABA and/or glycine as their inhibitory neurotransmit-
ters (Gly/GABA neurons) play important roles in spinal nociception. Most likely, Gly/GABA 
neurons in the RVM that project to the spinal dorsal horn are also important in modulat-
ing spinal nociception, although up to now there is lack of evidence for their expression in 
OFF-cells and their involvement in spinal nociception. It has proven difficult to stain glycin-
ergic and GABAergic neurons since using IHC to identify glycine, GABA, or their transmem-
brane transporters results in weak soma labeling and intense terminal labeling [4, 34, 42]. 
Therefore, the method of choice for identifying these inhibitory neurons is in situ hybrid-
ization (ISH), which will identify the mRNA of proteins that are specific for neurons that 
use glycine or GABA as their transmitter. Since mRNA is present in the cell soma and not 
in the terminals, ISH well label exclusively the cell somata of these neurons. In our studies 
we have used the glycine transporter 2 (GlyT2) [62, 73] to specifically identify the somata 
of glycinergic neurons, and glutamic acid decarboxylase (GAD) 67 [25, 47] to identify the 
somata of GABAergic neurons
 In this PhD project, we have combined fluorescent ISH (FISH) for GlyT2 and GAD67 
mRNA with fluorescent IHC, and with fluorescent tracing. Using these techniques we have 
investigated the activity patterns of Gly/GABA neurons in the spinal cord as well as the 
descending projections from the RVM. In Chapter 2 we have described the distribution 
pattern of spinal glycinergic neuronal somata in the rat spinal cord. In Chapter 3 the activa-
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tion pattern of spinal inhibitory neurons in acute and chronic pain states was investigated. 
In Chapter 4 we have determined the activation pattern of spinal inhibitory neurons after 
stimulation with capsaicin in rats with chronic inflammatory or neuropathic pain, and in 
Chapter 5 the distribution pattern of RVM neurons that are inhibitory and project to the 
spinal cord was investigated. In addition, we have identified a new pathway that projects 
to the RVM that is inhibitory and originates in the spinal cord. In Chapter 6 we have de-
scribed the expression pattern of the immediate early gene Arc/Arg3.1 in the rat spinal 
cord in various acute and chronic pain models, with a focus on inhibitory Gly/GABA and 
enkephalinergic neurons, as well as the neurokinin-1 expressing nociceptive projection 
neurons. Further, we have determined the behavioral response of Arc/Arg3.1 knockout 
mice to acute and chronic pain stimuli. Finally, in the general discussion, Chapter 7, we 
discuss the various findings in a broader perspective.
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Glycine transporter 2 (GlyT2) mRNA is exclusively expressed in glycinergic neurons, and is
presently considered a reliable marker for glycinergic neuronal somata. In this study, we
have performed non-radioactive in situ hybridization to localize GlyT2 mRNA in fixed free-
floating sections of cervical (C2 and C6), thoracic (T5), lumbar (L2 and L5) and sacral (S1)
segments of the rat spinal cord. The results showed that in all segments the majority of the
GlyT2 mRNA labeled (glycinergic) neuronal somata was present in the deep dorsal horn and
the intermediate zone (laminae III–VIII), with around 50% (range 43.7–70.9%) in laminae
VII&VIII. In contrast, the superficial dorsal horn, the motoneuronal cell groups and the area
around the central canal contained only few glycinergic neuronal somata. The density
(number of glycinergic neuronal somata per mm2) was also low in these areas, while the
highest densities were found in laminae V to VIII. The lateral spinal nucleus and the lateral
cervical nucleus also contained a limited number of glycinergic neurons.
Our findings showed that the distribution pattern of the glycinergic neuronal somata is
similar in all the examined segments. The few differences that were found in the relative
laminar distribution between someof the segments, aremost likely due to technical reasons.
We therefore conclude that the observed distribution pattern of glycinergic neuronal somata
is present throughout the spinal cord. Our findings further showed that the non-radioactive
in situ hybridization technique for identifying GlyT2mRNA in fixed free-floating sections is a
highly efficient tool for identifying glycinergic neurons in the spinal cord.
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1. Introduction
Strong evidence that the amino acid glycine is acting as a
neurotransmitter in themammalian spinal cord was provided
for the first time in 1965 (Aprison and Werman, 1965). In
subsequent years glycine became established as the main
inhibitory neurotransmitter in the caudal region of the central
nervous system (CNS), next to the amino acid γ-aminobutyric
acid (GABA). Glycinergic neurons are abundantly present in
the spinal cord, brainstem and cerebellum (Borowsky et al.,
1993; Luque et al., 1995), but scarce in rostral parts of the CNS,
like the diencephalon and hippocampus (Rampon et al., 1996;
Song et al., 2006).
The main strategies for identifying neurons that use an
amino acid as neurotransmitter are based on the localization
of the transmitter, its biosynthetic enzyme, or its transporter.
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Antibodies against glycine have been used most frequently to
identify glycinergic neurons (Campistron et al., 1986; Rampon
et al., 1996; Todd and Sullivan, 1990). In general, glycine
antibodies preferentially stain glycinergic terminals because
they contain a high concentration of glycine, while soma
labeling is much weaker. However, in recent reports (Allain et
al., 2006; Song et al., 2006; Zeilhofer et al., 2005) a glycine
antibody was used that was directed against paraformalde-
hyde-fixed glycine (Pow et al., 1995), resulting in a much
improved staining of neuronal somata in addition to axons
and terminals. The use of antibodies against the biosynthetic
enzyme that produces glycine in the brain, serine hydroxy-
methyltransferase, has never been reported, probably because
the activity of this enzyme is correlated with the general pool
of glycine (Daly and Aprison, 1974), rather than with the
transmitter pool. Similarly the vesicle transporter that trans-
ports glycine also transports GABA, and therefore cannot be
used for identifying glycinergic neurons only (Chaudhry et al.,
1998). However, glycine transporter 2 (GlyT2), one of the GlyTs
(Zafra et al., 1995a,b), is present exclusively in the plasma
membrane of glycinergic neurons (Jursky and Nelson, 1995;
Luque et al., 1995), where it is primarily involved in the
reuptake of synaptically released glycine (Betz et al., 2006).
GlyT1, on the other hand, is exclusively present in glial cells
(Adams et al., 1995; Zafra et al., 1995a,b). Since GlyT2 is the
only marker that is present exclusively in glycinergic neurons
(Poyatos et al., 1997; Spike et al., 1997), and GlyT2 antibodies
preferentially label glycinergic terminals rather than somata
(Jursky and Nelson, 1995; Spike et al., 1997), GlyT2 in situ
hybridization is the method of choice for identifying glyciner-
gic neuronal somata. GlyT2 mRNA has been identified
previously in the spinal cord by means of radioactive in situ
hybridization (Zafra et al., 1995a). Since these studies
described GlyT2 mRNA distribution throughout the CNS, the
descriptions of the spinal cord were not very detailed. This
study, which is the first step in our investigations on the role
of glycinergic neurons in spinal sensory processing, was set up
to obtain detailed knowledge on the distribution of spinal
glycinergic neuronal somata at different levels of the spinal
cord. For this purpose, we used non-radioactive in situ
hybridization for GlyT2 mRNA on thick fixed free-floating
sections.
2. Results
2.1. General observations
Light microscopic examination of the sections showed a
bluish reaction product, representing the presence of GlyT2
mRNA, in a limited number of neuronal somata of various
sizes. No staining was found in glial cells or fiber tracts.
Staining was only present in neuronal somata, sometimes
including their primary dendrites. Control sections hybridized
with sense probes did not show any specific labeling.
Themajority of the labeled neuronal somata were found in
the deep dorsal horn and the adjoining intermediate zone
(laminae VII&VIII) of the ventral horn (Fig. 1). In laminae I&II
(Fig. 2A) the number of labeled neuronal somata observed
never exceeded four neurons per section. The few labeled
somata in lamina II were often located close to the border with
lamina III. Laminae III to VI of the dorsal horn contained
several labeled neurons, varying in size from 10 to 30 μm (Fig.
2B). In laminae IV, V&VI, labeled neuronal somata were more
abundant medially than laterally (Figs. 1, 2B). The intermedi-
ate zone of the ventral horn also contained many labeled
somata, including several of the largest labeled somata (Fig. 3).
The large presumed motoneurons in lamina IX were never
labeled. Occasionally a labeled neuron, considerably smaller
than the presumed motoneurons, was present within the
motoneuronal area (Figs. 1, 3A). The grey matter surrounding
the central canal (lamina X) contained few labeled neurons. In
all sections examined, a limited number of labeled neurons
were found scattered in the white matter, close to either the
dorsal or ventral horn (Figs. 1, 2A).
2.2. GlyT2 mRNA labeled neuronal somata in specialized
spinal nuclei
We have examined several specialized nuclei, i.e., groups of
cells that can be distinguished anatomically and usually
subserve specialized functions (Holstege et al., 1996) for a
more detailed description. These nuclei include the lateral
spinal nucleus (LSN), the lateral cervical nucleus (LCN), the
central cervical nucleus, the dorsal nucleus of Clarke, the
intermediomedial nucleus, the intermediolateral nucleus,
and, in the L6 segment, the dorsomedial and dorsolateral
nuclei (Onuf's nucleus). In about 25% of the sections exam-
ined, one or two labeled neurons were identified in the LSN,
which is located in the dorsolateral white matter (Fig. 4). In a
few cases, labeled neurons were also observed in the LCN,
which is present dorsal to the LSN at the C1–C3 level. In
general, in both nuclei the intensity of the labeling was weak.
The other specialized nuclei virtually never contained labeled
neurons. However, several labeled somata were usually
present around these nuclei.
2.3. Quantitative aspects
In all spinal segments examined, around 50% (range 43.7–
70.9%) of the labeled neurons in that segment were located in
the intermediate zone of the ventral horn (laminae VII&VIII),
with the highest percentage (average 70.9%) at level L2 (Table
1). The superficial dorsal horn (laminae I&II), the motoneur-
onal cell groups (lamina IX) and lamina X contained the lowest
percentage of glycinergic neurons (Table 1). A comparison
between the segmental levels for each lamina separately (a
total of 135 comparisons using the Bonferroni post hoc test)
showed that in the large majority of the cases (116) there were
no significant differences between the different segmental
levels. The 19 cases that were significantly different (Table 1)
were found mostly in L2 and S1. At the L2 segmental level, the
average percentage in laminae V&VI (13.5%) was significantly
lower than the percentage obtained for the same laminae in
the other segments analyzed, while the average in laminae
VII&VIII (70.9%) was significantly higher. In S1 lamina IV only
contained 3.3% of the neurons at this level, significantly lower
than most of the other segmental levels, while the average
percentage (64.7%) obtained for laminae VII&VIII was signifi-
cantly higher.
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Fig. 1 – Schematic drawings illustrating the distribution of GlyT2 mRNA labeled (glycinergic) neuronal somata in analyzed
single sections from rat spinal segments C2, C6, T5, L2, L5 and S1. Neurons in the dorsolateral funiculus are located in the lateral
spinal nucleus. Other special nuclei are: intermediomedial nucleus (1), intermediolateral nucleus (2), central cervical nucleus
(3), and dorsal nucleus of Clarke (4).
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When considering the density of the neurons in each
lamina, i.e., the average number of neurons per mm2, the
highest densities are found in laminae V&VI and VII&VIII, and
the lowest densities were found in laminae I, II, IX and X (Fig.
5). A comparison between the segmental levels for each
lamina separately (a total of 120 comparisons using the
Bonferroni post hoc test, excluding the specialized nuclei)
showed that in the large majority of the cases (113) there were
no significant differences between segmental levels. The
exceptions were the density of lamina IV in the S1 segment,
which was significantly different from segments C2, C6, and
L2 (p<0.05); the density of laminae V&VI in S1, which was
significantly different from segment C6 (p<0.05), and the
density of laminae VII&VIII in L2, which was significantly
different from segments T5, L5 and S1 (p<0.05). Since the large
majority of the laminar densities in the different segmental
Fig. 2 – Light micrographs showing glycinergic neuronal
somata as identified by GlyT2mRNA labeling. (A) Few labeled
somata are present in the superficial dorsal horn (segment
C2), with increasing numbers of labeled somata in laminae III
and IV. Note the labeled somata in the white matter (arrows)
and the lateral spinal nucleus (LSN). Scale bar=50 μm. (B)
Glycinergic neuronal somata of various sizes in the deep
dorsal horn and the intermediate zone of the ventral horn.
1: intermediomedial nucleus, DF: dorsal funiculus, *: central
canal. Scale bare=50 μm.
Fig. 3 – Light micrographs showing labeled neuronal somata
in the lumbar ventral horn. (A) Overview of the L5 ventral
horn. Few GlyT2 mRNA labeled neuronal somata are present
in the motoneuronal cell groups (encircled areas). Scale
bar=50 μm. (B) Labeled neuronal somata in lamina VII of the
L5 spinal segment. Note the variability in size of the labeled
neurons. Scale bar=50 μm.
Fig. 4 – Light micrograph showing GlyT2 mRNA labeled
(glycinergic) neuronal somata in the lateral spinal nucleus
(LSN) at spinal segment T5. Scale bar=25 μm.
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levels were not significantly different, the average density for
each lamina(e) was calculated (Fig. 5). This showed that the
densities of laminae I, II, IX and X are each significantly lower
than the densities in the other laminae (p<0.005). The same
holds true for lamina III (p<0.05), except that the density is not
significantly different from lamina IV (p>0.05). The density of
lamina IV is also not significantly different from the density of
VII and VIII (p>0.05). Laminae V&VI have the highest average
density, although not significantly different from laminae
VII&VIII.
3. Discussion
The present study is the first detailed description of the
distribution of GlyT2 mRNA in the spinal cord, using non-
radioactive in situ hybridization on thick paraformaldehyde-
fixed free-floating sections. Previous studies on the distribu-
tion of glycinergic (GlyT2 mRNA) and/or GABAergic (GAD67
mRNA) neuronal somata (Schreihofer et al., 1999; Tanaka and
Ezure, 2004) in the brainstem have confirmed the sensitivity
(Key et al., 2001) of the detection method used in the present
study. In situ hybridization on free-floating 40-μm-thick
sections has the advantage that the sections are easy to
handle because the sections are fixed and much thicker than
slide mounted non-fixed sections. Especially the washing
steps in the procedure are more efficient on free-floating
sections, which, in our hands, lead to a higher signal-to-noise
ratio in comparison with slide mounted sections. The method
used in this study is therefore the most reliable and sensitive
approach presently available to identify spinal glycinergic
neuronal somata. It has the advantage that it can be combined
with other techniques like immunohistochemistry, and neu-
ronal tracing (Stornetta et al., 2005).
Our results show that glycinergic neuronal somata are
concentrated in the deep dorsal horn (laminae V&VI) and the
intermediate zone of the ventral horn (laminae VII&VIII). In
the superficial dorsal horn (laminae I&II), the area around the
central canal (lamina X) and the motoneuronal cell groups
(lamina IX) glycinergic neuronal somata were observed much
less frequently, while laminae III and IV hold an intermediate
position. This pattern is present in all the examined spinal
segments (i.e., C2, C6, T5, L2, L5 and S1), strongly suggesting
that this pattern is constant throughout the spinal cord.
However, our analysis also showed some exceptions to this
Table 1 – Relative laminar distribution of the glycinergic neuronal somata in different segments of the rat spinal cord
Lamina C2 C6 T5 L2 L5 S1
%±SD %±SD %±SD %±SD %±SD %±SD
I 0.3±0.5 0.3±0.4 0.4±1.0 0.2±0.4 0.1±0.3 0.0
II 1.8±1.0 1.2±0.4 0.9±2.2 0.7±0.6 0.6±0.5 1.2±1.0
III 6.3±2.2 4.6±1.4 4.9±2.6 3.9±2.2 4.2±2.4 2.1±1.9
IV 14.1±3.5a 10.3±1.7 9.8±2.7 5.9±1.5 9.7±3.0 3.3±2.0b
V&VI 28.5±2.8 29.5±5.2 18.3±5.0c 13.5±3.4d 31.7±2.8 25.4±5.9
VII&VIII 43.7±6.4 49.0±8.7 54.8±7.9 70.9±2.1e 49.6±6.4 64.7±6.8 f
IX 1.2±1.0 3.2±3.5 2.0±2.3 1.5±1.1 3.1±1.8 1.8±1.8
X 0.5±0.5 0.6±0.6 1.2±1.3 1.4±1.3 0.5±0.9 1.5±2.7
Special nuclei 3.5±1.8 1.3±0.9 7.6±5.8 2.0±1.9 0.3±0.5 0.0
n 606 760 255 720 788 356
For each lamina of the C2, C6, T5, L2, L5 and S1 segments the average percentage (±SD) of the total number of glycinergic neuronal somata is
shown. n: Total number of labeled neuronal somata.
a Lamina IV in C2 is significantly different from the same lamina in L2 (p<0.005).
b Lamina IV in S1 is significantly different from C2, C6, T5, and L5 (p<0.005).
c Laminae V&VI in T5 is significantly different from C2, C6, and L5 (p<0.005).
d Laminae V&VI in L2 from C2, C6, L5, S1 (p<0.005).
e Laminae VII&VIII in L2 from C2, C6, T5, and L5 (p<0.005).
f Laminae VII&VIII in S1 from C2, C6, and L5 (p<0.005).
Fig. 5 – Average density of glycinergic neuronal somata per
lamina in the analyzed segments. An increasing density is
observed in the intermediate zone, while the superficial
laminae, the motoneuronal cell groups (lamina IX) and
lamina X have the lowest density. N/mm2: calculated number
of labeled glycinergic neuronal somata per mm2. *Laminae I,
II, IX and X are significantly different from laminae III, IV,
V&VI, and VIII&VIII (p<0.005). **Lamina III is significantly
different from all the other laminae (p<0.05), except lamina
IV. ***Lamina IV is significantly different from all the other
laminae (p<0.005), except laminae III and VII&VIII.
****Laminae V&VI are significantly different from all other
laminae (p<0.005), except laminae VII&VIII. Error bars
represent ±SD.
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rule, especially at spinal levels L2 (laminae V&VI, and VII&VIII)
and S1 (laminae IV, and VII&VIII). The most simple explana-
tion for this finding is that the laminar boundaries at the L2
and S1 level were identified incorrectly or that their location
leads to relatively large differences in surface area as
compared with the other segments. Especially at the L2
level, a ventral shift of the boundary between laminae V and
VII, would increase the percentage of neurons in laminae V
and decrease the percentage in laminae VII&VIII, likely
resulting in the disappearance of the significant differences
between the L2 and the other segments. Also in S1, which is a
relatively small segment, small changes in boundary delinea-
tion may easily lead to significant changes in the percentages
that were obtained. We therefore consider that the few
significant differences in the laminar percentages that were
found between segments are due to technical reasons, and do
not signify any functional difference in the role of glycinergic
neurons in these segments.
The bulk of the glycinergic neuronal somata was found in
the intermediate zone (laminae VII&VIII). This finding is not
surprising considering that this is the largest area as
compared with the other spinal laminae. Thus even if the
glycinergic neurons were evenly distributed over all the
laminae in a section, the percentage of neurons in laminae
VII&VIII would still be the highest. Therefore, we also
calculated the average density of the glycinergic neurons in
the different laminae. This showed that the superficial dorsal
horn, the motoneuronal cell groups and lamina X have the
lowest density. In case of the superficial dorsal horn, it may be
expected that the density of glycinergic neurons would be
relatively high considering the small surface area of these
laminae. In contrast the density of the superficial laminaewas
very low, which confirms that these laminae are almost
devoid of glycinergic neuronal somata.
The highest percentages of glycinergic neuronal somata in
the various segments were found in laminae, V&VI and
VII&VIII. These laminae also contained the highest densities
of glycinergic neurons, which confirms the specific concen-
tration of glycinergic neurons in these laminae.
In the analyzed specialized nuclei, only the LSN and LCN
contained glycinergic neurons. This finding likely indicates
that some of the widespread descending (Jansen and Loewy,
1997) and ascending (Ding et al., 1995; Keay et al., 1997)
projections originating in the LSN are in part glycinergic.
Only one previous study (Todd and Sullivan, 1990) has
provided a detailed description of glycinergic neuronal
somata in the adult spinal cord with a focus on the superficial
dorsal horn. This study used glycine antibodies in combina-
tion with pre-embedding immunohistochemistry on semi-
thin plastic sections of rat lumbar segments. Their results are
in general agreement with the results of the present study
and show the same distribution pattern: a concentration of
glycinergic neuronal somata in the deep dorsal horn and the
intermediate zone of the ventral horn, while glycinergic
neuronal somata are nearly absent from the superficial dorsal
horn. Our findings further showed that this distribution
pattern is similar in all the examined segments. Since the few
differences that were found in the relative laminar distribu-
tion between some of the segments, are most likely due to
technical reasons, we conclude that the observed distribution
pattern of glycinergic neuronal somata is present throughout
the spinal cord.
The functional significance of the laminar localization of
glycinergic neuronal somata can only be appreciated in
combination with many other data on these neurons, includ-
ing the size of their dendritic tree, their axonal projection area,
the parameters that determine the release of glycine and the
properties of the postsynaptic glycine receptors. The dendritic
tree of spinal neurons may extend into several neighboring
laminae (Willis and Coggeshall, 2003). However, the morphol-
ogy of the dendritic tree of glycinergic neurons is largely
unknown. Similarly, little is known about the axonal arboriza-
tion of glycinergic neurons. Areas that contain very few
glycinergic neuronal somata, as we have shown here for the
superficial dorsal horn (laminae I&II) and the motoneuronal
cell groups (lamina IX), contain many glycinergic terminals
(Rekling et al., 2000; Todd, 1990). It seems likely that the
majority of these terminals is derived from spinal neurons
located in other laminae, while some are derived from
supraspinal sources (Antal et al., 1996; Holstege and Bongers,
1991). A lot more is known about the release properties and
effects of glycine on other neurons. In this respect it is
important to realize that both in the dorsal (Todd and Sullivan,
1990; Todd et al., 1996) and ventral horn (Taal and Holstege,
1994) glycine is often colocalized and co-released with GABA.
However, there are also sets of neurons that contain glycine
without GABA and vice versa, e.g., neurons in the intermediate
zone that presynaptically inhibit Ia afferents on motoneurons
only contain GABA and not glycine (Hughes et al., 2005; Mackie
et al., 2003). In view of all these variables, it is likely that the
glycinergic neurons in a specific lamina fulfill diverse func-
tions. In laminae II–V the action of glycinergic neuronsmay be
focused on the influencing sensory transmission (Willis and
Coggeshall, 2003; Zeilhofer, 2005), while neurons in deeper
laminae may be involved in affecting motor transmission
(Rekling et al., 2000). In addition there are neurons in many of
these laminae that project to supraspinal brain areas and
some of these neurons may use glycine as a transmitter,
although direct evidence for such a glycinergic projection is
presently lacking.
Recently, glycinergic neurons in the spinal cord were also
identified on the basis of the expression of GlyT2, but using a
very different approach, namely by producing transgenicmice
expressing enhanced green fluorescent protein (eGFP) under
the control of the promotor of the GlyT2 gene (Zeilhofer et al.,
2005). This study showed that the large majority of the eGFP
producing neurons in the brain were also immunoreactive for
glycine (in somata, dendrites and terminals) and GlyT2 (in
terminals). However, in the dorsal horn, the area of the spinal
cord examined in this paper, it was found that several glycine
immunoreactive neuronal somata did not express eGFP and
vice versa. In lamina II a subset of neurons was described as
glycine immunoreactive, without expressing eGFP. In this case
our findings in the rat dorsal horn would support the eGFP
expression pattern, since we also found very few neurons in
lamina II expressing GlyT2 mRNA. Whether this would
indicate that there is a subset of neurons in lamina II that
uses glycine as a transmitter without expressing GlyT2, or
whether these cells show a high level of glycine, but do not use
it as a transmitter, is unclear.
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In this study we have identified glycinergic neurons
throughout the spinal cord using GlyT2 mRNA in situ
hybridization. We have shown that glycinergic neurons are
concentrated in laminae III–VIII and provided evidence that
this pattern is constant throughout the spinal cord. These
findings provide a solid anatomical basis for further studies on
the role of glycine in the spinal cord.
4. Experimental procedures
4.1. Tissue preparation
In this studywe used 18maleWistar rats, including six rats for
quantitative analysis. Rats received an overdose of sodium
pentobarbital and were transcardially perfused with 150 ml
saline followed by 750 ml of 4% paraformaldehyde (PFA) in
0.12 M phosphate buffer (PB), pH 7.4. Subsequently, the entire
spinal cord was dissected and left overnight in a RNAse-free
solution of 4% PFA and 30% sucrose dissolved in 0.12 M PB at
4 °C. All the experiments have been approvedby the Rotterdam
Animal Ethics Committee.
4.2. In situ hybridization
All the solutions used in the following steps until the
hybridization step were Diethylpyrocarbonat (DEPC)-treated.
The regions of interest of the spinal cord were cut transver-
sally in 40-μm sections on a freezing microtome and collected
in 0.05 M PB. The sections were then treated with 0.2% glycine
in phosphate-buffered saline (PBS, 5 min), rinsed in PBS, and
then treated (10 min) in PBS containing 0.1 M triethanolamine
(Merck, Germany) pH 8.0 and 0.0025% acetic anhydride (Sigma-
Aldrich, Germany). Sections were then washed in 4× standard
saline citrate (SSC, pH 4.5) and prehybridized for 1 h at 65 °C in
hybridization mixture consisting of 50% formamide, 5× SSC
(pH 4.5), 2% Blocking Reagent (Roche), 0.05% 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate (CHAPS,
Sigma-Aldrich), 1 μg/ml yeast tRNA (tRNA brewer's yeast,
Sigma), 5mM EDTA (pH 8.0), 50 μg/ml Heparin (Sigma-Aldrich),
and 1× Denhardt's solution (Sigma-Aldrich).
The GlyT2 mRNA was obtained from a partial cDNA
template (3.1 kb; a generous gift from Dr. N. Nelson, Tel Aviv
University), encoding GlyT2. The riboprobes were obtained by
linearizing the recombinant plasmids with restriction
enzymes (XbaI for GlyT2 antisense, HindIII for GlyT2 sense)
and transcribed with RNA polymerases (T7 for GlyT2 anti-
sense, T3 for GlyT2 sense) in the presence of digoxigenin (DIG)-
labeled 11-UTP (Roche).
The sections were hybridized for 16–24 h at 65 °C in
hybridization mixture (minus Denhardt's) containing 500–
600 pg/μl of GlyT2 anti-sense riboprobes. Some sections were
hybridized with sense probe at a matched concentration to
serve as control. After hybridization, the sections were
washed in 2× SSC (pH 4.5), followed by three washes of
15 min each in 2× SSC (pH 4.5)/50% formamide at 65 °C, and
finally washed in PBS. The sections were then pre-incubated
(90 min, room temperature) in BSA-blocking solution consist-
ing of PBS, 5% BSA (bovine serum albumin, Fraction V, Roche)
and 0.5% Triton X-100. For detection of DIG, the sections were
incubated in 2% BSA-blocking solution with anti-digoxigenin
antibody conjugated to alkaline phosphatase (Roche) diluted
1:4000 (overnight, 4 °C). Subsequently, the sections were
washed in TBST (0.14 M NaCl, 2.7 mM KCl, 25 mM Tris/HCl
(pH 7.5), and 0.1% Tween-20), followed by NTM (100 mM NaCl,
100mMTris/HCl (pH 9.5), and 50mMMgCl2). The blue reaction
product was produced by the reaction of alkaline phosphatase
with levamisol, NBT (nitroblue tetrazolium; Roche) and BCIP
(5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt;
Roche) for 1.5–2 h at room temperature in the dark. Usually,
the exact reaction time was determined by assessing the
staining in the light microscope. The sections were randomly
mounted on slides, air dried overnight, dehydrated using
absolute ethanol (<0.01%methanol), transferred to xylene and
coverslipped with Permount (Fisher, Hampton, NH).
4.3. Data analysis
Light micrographs were made with a digital camera and
processed using Adobe Photoshop. The images were not
manipulated, except for brightness and contrast.
Analysis was carried out on cervical (C2 and C6), thoracic
(T5), lumbar (L2 and L5), and sacral (S1) segments from six
rats. Between 15 and 20 sections per segment were mounted
on a slide in a random order. In the microscope, the slide
was systematically examined, starting with the first section
in the first row. The first section of the appropriate
segmental level that was encountered was used for analysis.
Occasionally this section appeared damaged during the
procedure or incorrectly mounted, in which case the section
was discarded. Thus a total of 36 sections were analyzed.
Using a camera lucida microscope (Neurolucida, MicroBright-
field Inc., Williston, VT) the outline of the white and grey
matter, the boundaries between the laminae and the contour
of several spinal nuclei were drawn unilaterally (Molander et
al., 1984, 1989), after which the labeled neurons were plotted
in the drawing. A neuron was considered labeled only if the
largest diameter was at least 10 μm, the cell soma contained
a bluish reaction product and a non-stained nucleus was
apparent. The number of plotted neurons per lamina was
expressed as a percentage of the total number of neurons
plotted in that section. The results obtained in the six rats
were averaged for each lamina per segment. The density of
glycinergic neurons per lamina is expressed as the number
of plotted neurons in a lamina divided by the surface area,
expressed in mm2, of that lamina, as calculated by Neuro-
lucida. The results obtained in the six rats were averaged for
each laminar density per segment. The data for both the
laminar distribution and the density of glycinergic neuronal
somata were analyzed by performing the one-way ANOVA
test followed by the Bonferroni post hoc test. p<0.05 was
considered as significant.
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a b s t r a c t
The inhibitory transmitters GABA and glycine play an important role in modulating pain transmission,
both in normal and in pathological situations. In the present study we have combined in situ hybridiza-
tion for identifying spinal neurons that use the transmitter(s) glycine and/or GABA (Gly/GABA neurons)
with immunohistochemistry for c-fos, a marker for neuronal activation. This procedure was used with
acute pain models induced by the injection of capsaicin or formalin; and chronic pain models using Com-
plete Freund’s Adjuvant (CFA, chronic inﬂammation), and the spared nerve injury (SNI) model (neuro-
pathic pain). In all models Gly/GABA neurons were activated as indicated by their expression of c-fos.
The pattern of Gly/GABA neuronal activation was different for every model, both anatomically and quan-
titatively. However, the averaged percentage of activated neurons that were Gly/GABA in the chronic
phase (P20 h survival, 46%) was signiﬁcantly higher than in the acute phase (62 h survival, 34%). In addi-
tion, the total numbers of activated Gly/GABA neurons were similar in both phases, showing that the acti-
vation of non-Gly/GABA (presumed excitatory) neurons in the chronic phase decreased. Finally, morphine
application equally decreased the total number of activated neurons and activated Gly/GABA neurons.
This showed that morphine did not speciﬁcally activate Gly/GABA neurons to achieve nociceptive inhibi-
tion. The present study shows an increased activity of Gly/GABA neurons in acute and chronic models.
This mechanism, together with mechanisms that antagonize the effects of GABA and glycine at the recep-
tor level, may determine the sensitivity of our pain system during health and disease.
 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
Nociceptors convey their information from the periphery to the
spinal cord where they target secondary neurons located in the
superﬁcial (laminae I–II) and deep (laminae III–VI) dorsal horns
[45]. While a subpopulation of these secondary neurons is projec-
tion neurons that relay the nociceptive information to higher cen-
ters [40], the majority are local interneurons [4]. A substantial
number of these interneurons contain the fast inhibitory transmit-
ters GABA and glycine, often colocalized in the same cell [47,48]
and these neurons are directly innervated by primary afferent ﬁ-
bers [10,14]. The importance of GABA and glycine in pain transmis-
sion was shown by blocking glycinergic and/or GABAergic
neurotransmission in naïve animals, which induced many behav-
ioral signs of hypersensitivity as observed in inﬂammatory and
neuropathic pain conditions [38,39,50].
Accordingly, decreased inhibition was found in the spinal cord
during chronic inﬂammatory pain [33,37]. In this condition, glycin-
ergic inhibition in the spinal cord is blocked by a pathway involv-
ing prostaglandin E2 (PGE2). When this PGE2-induced blockade
was prevented (<24 h) the thermal and mechanical sensitizations
of inﬂammatory pain did not appear [52]. During neuropathic pain
there is loss of synaptic inhibition due to a shift in the neuronal
chloride gradient, which reverses the inhibitory effect of GABA into
a depolarizing one [9]. Further, it was recently shown that selective
activation of GABA(A) receptors containing the a2 and/or a3 sub-
units [26] leads to pronounced nociceptive inhibition.
The studies described above underline the importance of gly-
cine and GABA in modulating the spinal processing of nociceptive
information, especially during chronic pain. However, little is
known about the activity of inhibitory neurons, and changes there-
in, during different pain states. For identifying neurons that were
recently activated, the expression of c-fos protein has been used
extensively in the nociceptive system [8], showing that spinal c-
fos expression patterns are correlated with the type, intensity
and duration of nociceptive stimuli [8]. However, data on the acti-
vation patterns of spinal inhibitory neurons during different pain
states are scarce. So far, three studies have [46,54,55] identiﬁed
activated glycinergic and/or GABAergic (Gly/GABA) neurons after
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Abstract
 The inhibitory transmitters GABA and glycine play an important role in modulating 
pain transmission, both in normal and pathological situations. In the present study we have 
combined in situ hybridization for identifying spinal neurons that use the transmitter(s) 
glycine and/or GABA (Gly/GABA neurons) with immunohistochemistry for c-fos, a marker 
for neuronal activation. This procedure was used with acute pain models induced by injec-
tion of capsaicin or formalin; and chronic pain models using Complete Freund’s Adjuvant 
(CFA, chronic inflammation), and the spared nerve injury (SNI) model (neuropathic pain).
 In all models Gly/GABA neurons were activated as indicated by their expression 
of c-fos. The pattern of Gly/GABA neuronal activation was different for every model, both 
anatomically and quantitatively. However, the averaged percentage of activated neurons 
that were Gly/GABA in the chronic phase (≥ 20 hrs survival, 46%) was significantly higher 
than in the acute phase (≤ 2 hrs survival, 34%). In addition, the total numbers of activated 
Gly/GABA neurons were similar in both phases, showing that the activation of non-Gly/
GABA (presumed excitatory) neurons in the chronic phase decreased. Finally, morphine 
application equally decreased the total number of activated neurons and activated Gly/
GABA neurons. This shows that morphine did not specifically activate Gly/GABA neurons 
to achieve nociceptive inhibition.
 The present study shows an increased activity of Gly/GABA neurons in acute and 
chronic models. This mechanism, together with mechanisms that antagonize the effects 
of GABA and glycine at the receptor level, may determine the sensitivity of our pain sys-
tem during health and disease.
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1. Introduction
 Nociceptors convey their information from the periphery to the spinal cord where 
they target secondary neurons located in the superficial (laminae I-II) and deep (laminae 
III-VI) dorsal horn [45]. While a subpopulation of these secondary neurons are projec-
tion neurons that relay the nociceptive information to higher centers [40], the majority 
are local interneurons [4]. A substantial number of these interneurons contain the fast 
inhibitory transmitters GABA and glycine, often colocalized in the same cell [47,48] and 
these neurons are directly innervated by primary afferent fibers [10,14]. The importance 
of GABA and glycine in pain transmission was shown by blocking glycinergic and/or GAB-
Aergic neurotransmission in naïve animals, which induced many behavioral signs of hyper-
sensitivity as observed in inflammatory and neuropathic pain conditions [38,39,50]. 
 Accordingly, decreased inhibition was found in the spinal cord during chronic 
inflammatory pain [33,37]. In this condition, glycinergic inhibition in the spinal cord is 
blocked by a pathway involving prostaglandin E2 (PGE2). When this PGE2 induced block-
ade was prevented (<24 hrs) the thermal and mechanical sensitization of inflammatory 
pain did not appear [52]. During neuropathic pain there is loss of synaptic inhibition due to 
a shift in the neuronal chloride gradient, which reverses the inhibitory effect of GABA into 
a depolarizing one [9]. Further, it was recently shown that selective activation of GABA(A) 
receptors containing the α2 and/or α3 subunits [26] leads to pronounced nociceptive in-
hibition. 
 These studies described above underline the importance of glycine and GABA in 
modulating the spinal processing of nociceptive information, especially during chronic 
pain. However, little is known about the activity of inhibitory neurons, and changes there-
in, during different pain states. For identifying neurons that were recently activated, the 
expression of c-fos protein has been used extensively in the nociceptive system [8], show-
ing that spinal c-fos expression patterns are correlated with the type, intensity and dura-
tion of nociceptive stimuli [8]. However, data on the activation patterns of spinal inhibitory 
neurons during different pain states are scarce. So far, three studies have [46,54,55] iden-
tified activated glycinergic and/or GABAergic (Gly/GABA) neurons after acute nociceptive 
stimulation of the hind paw with capsaicin or formalin. These studies have used immuno-
histochemistry to identify the c-fos protein as well as Gly/GABA neurons. However, pres-
ently available antibodies preferentially label Gly/GABA terminals and have proven diffi-
cult for reliably labeling the somata of Gly/GABA neurons [2,17]. Therefore, in the present 
study we have used in situ hybridization with markers for Gly/GABA neurons. This tech-
nique will identify mRNA for GlyT2 (a marker for glycinergic neurons) [36,41] or GAD67 (a 
marker for GABAergic neurons) [12,24] with a high sensitivity, and can be combined with 
immunohistochemistry for c-fos [42]. Using this approach we set out to investigate the 
activation patterns of spinal Gly/GABA neurons in different acute and chronic pain states. 
For this purpose we determined the number and the percentage of c-fos labeled neurons 
that expressed GABA and/or glycine in acute (capsaicin, formalin) or chronic (inflamma-
tory and neuropathic) pain conditions. In addition, we investigated the effect of morphine 
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application on c-fos expression in Gly/GABA neurons after stimulation with formalin. 
2. Materials and methods
 In this study we used a total of 67 male Wistar rats. All animal experiments were 
approved by the Rotterdam Animal Ethical Committee. 
2.1. Pain models
 Nociceptive stimuli for the capsaicin, formalin and CFA pain models were applied 
to the left foot sole under light anesthesia (2% isofluoran in 30%O
2
/70%N
2
O; 2-3 min). The 
left foot sole was injected with either sterile saline (50μl of 0.9% NaCl, Baxter; 90 min sur-
vival, n=5), capsaicin (50μl of 0.3% N-Vanillylnonanamide, Sigma-Aldrich, diluted in 80% 
saline, 10% Tween-80, and 10% ethanol-100%; 90 min survival, n=5), Complete Freund’s 
Adjuvant (chronic inflammation model; CFA, 100μl; 90 min survival, n=5; 20 hrs survival, 
n=5; 4 days survival, n=5), or 4% paraformaldehyde (PFA diluted in 0.12 M phosphate buf-
fer pH ≈ 7.5; 45 min survival, n=5; 90 min survival, n=5). For induction of neuropathic pain, 
the animals were kept under anesthesia during the whole procedure (20-30 minutes). 
We used the SNI model according to the protocol described in [11]. In short, the three 
branches of the sciatic nerve were exposed above the knee, and the tibial and common 
peroneal branches were ligated and cut 2 mm distal to the ligation, while the sural branch 
was left intact. In the sham model, the three sciatic branches were also exposed but then 
left intact. We used survival times of 2 hrs, 1 wk and 2 wks for the SNI model and their cor-
responding sham models (n=24). In the morphine experiment, the animals received 1.5 
mg of morphine (morphine HCL-3H
2
O) subcutaneously 20 min prior to injection of forma-
lin (50µl of 4 % PFA) in the left foot sole (90 min survival, n=4). The control group received 
1.5 ml of sterile saline instead of morphine (90 min survival, n=4). 
2.2. Behavioral experiments
 The mechanical thresholds of the hind paws were assessed using the Von Frey 
hair monofilaments (Stoelting) in the capsaicin, CFA, and SNI (1 wk and 2 wks) groups. 
Before the start of the experiments, all rats were habituated to the experimenter, the 
experiment room, and a transparent cage (15cm x 15cm; gridded floor) for 5 days. There-
after, prior to each experiment the rats were habituated for 30 minutes to the experiment 
room, and for 10 minutes to the transparent cage. Each Von Frey hair was applied for 2 
seconds at 5 seconds interval, and the threshold was set at 3 evoked responses in a maxi-
mum of 5 applications. The mechanical thresholds were assessed at 60 min after injection 
in the capsaicin group, at 20 hrs (CFA 20 hrs) or 4 days (CFA 4 days) in the CFA group, and 
at 1 wk (SNI 1 wk) and 2 wks (SNI 2 wks) in the SNI group. In the morphine experiment, the 
number of flinches and flutters and the time spent licking the injected paw was measured 
during 60 min after the formalin injection.  
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2.3. Tissue preparation
 At the end of an experiment, the rats received an overdose of sodium pentobar-
bital, and were transcardially perfused with 150 ml saline followed by 750 ml of 4% PFA. 
Thereafter, the lumbar spinal cords were dissected and incubated overnight at 4 ºC in 
RNAse free solution consisting of phosphate buffer (PB), 4% PFA and 30% sucrose. Coronal 
sections were cut at 30 μm with a freezing microtome, collected in 9 separate jars and 
stored in glycerol at -20 ºC. 
2.4. Fluorescent in situ hybridization combined with fluorescent immunohistochemistry
 For fluorescent in situ hybridization (FISH), the partial cDNA templates encoding 
GlyT2 (3.1 kb; a generous gift from Dr. N. Nelson, Tel Aviv University), or GAD67 (3.2 kb; a 
generous gift from Dr. A.J. Tobin and N. Tillakaratne, PhD, UCLA) were used. The recombi-
nant plasmids were linearized, and subsequently riboprobes were transcribed using the 
appropriate RNA polymerases in the presence of fluorescein-labeled 11-UTP (Roche). For 
FISH the protocol described in [19] was applied with the following modifications. Sections 
from a jar were incubated with a mixture of GAD67 and GlyT2 probes in order to identify 
spinal inhibitory neurons (GABAergic and/or glycinergic). After riboprobe hybridization, 
the sections were incubated (48 hours at 4 ºC) with mouse monoclonal anti-fluorescein 
antibody (Roche; 1:500) and rabbit anti-c-fos (1: 4000; Oncogene Research Products, La 
Jolla, CA) in a cocktail of phosphate buffered saline (PBS), 2% milk powder (Profitar Plus, 
Nutricia) and 0.5% Triton X-100. Thereafter, sections were rinsed in PBS and incubated 
with biotinylated goat-anti-mouse (Vector; for detection of fluorescein), and donkey-anti-
rabbit tagged with Cy3 (Jackson) for detection of c-fos antibody in a 2% milk powder cock-
tail for 90 minutes at RT. Subsequently, sections were rinsed in PBS and incubated with 
Avidin-Biotin-Complex (ABC, Vector) tagged with horseradish peroxidase (HRP) for 90 min 
at RT. After rinsing in PBS, a tyramide amplification procedure was performed by reacting 
HRP with H
2
O
2
 and a self prepared FITC tyramide solution as described previously [18]. 
Thereafter, the sections were washed in PB, mounted on slides and cover slipped with 
Vectashield (Vector). 
2.5. Analyzing labeled neurons
 Analysis was carried out on sections from the L4 and L5 lumbar spinal segments. 
Sections for analysis were chosen by starting in the first row of the randomly mounted 
sections and searching for sections from the appropriate segmental level, i.e. from rostral 
L4 to caudal L5. Per rat, the first 5 or 6 sections were analyzed in a Leica fluorescent micro-
scope with a FITC and/or Cy3 filter. Labeling for GlyT2/GAD67 mRNAs (FITC) was consid-
ered as neuronal labeling if the staining was present in the cell soma and the shortest di-
ameter was at least 10μm. In order to investigate colocalization of c-fos (Cy3) with GlyT2/
GAD67 mRNAs (FITC), first c-fos labeling was assessed in a 40x objective. Thereafter, in the 
same focus field, we assessed whether there was labeling for GlyT2/GAD67 mRNA pres-
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ent in the cytoplasm. If in the same focus field, c-fos labeling was surrounded by somatic 
GlyT2/GAD67 mRNA staining, the neuron was counted as a double labeled neuron. Single 
c-fos labeled and c-fos/GlyT2/GAD67 double labeled neurons were plotted by hand in an 
illustrated representation of the appropriate segmental level. In this illustration, the grey 
matter was divided in 10 laminae according to the laminar distribution in the rat [31]. In 
order to correct cell counts for double counting error, we measured the shortest and larg-
est diameter of the nuclei of c-fos labeled neurons and c-fos labeled Gly/GABA neurons in 
laminae I-II, III-VI and VIII-X. The average diameter of the nuclei was calculated by averag-
ing the sum of the shortest and largest diameters, and we then performed corrections 
for sampling bias related to cell size using Abercrombie’s formula as described previously 
[15].Per rat, the average numbers of c-fos and c-fos/Gly/GABA double labeled neurons, 
and the average percentages of double labeled neurons were calculated. Per group, the 
results were averaged and compared with the average results in the other groups. Errors 
in the variations were assessed as standard error of the mean (SEM). The unpaired t-test 
or one-way ANOVA with a Bonferroni post-hoc test was performed for statistical compari-
son between groups. p<0.05 was taken as significant.
3. Results
3.1. General observations
 Fluorescent in situ hybridization (FISH) with a mixture of GlyT2/GAD67 probes 
resulted in cytoplasmic labeling of neurons that contained either GlyT2 mRNA, GAD67 
mRNA or both mRNAs, thus representing neurons that use glycine and/or GABA as 
neurotransmitter(s) (Gly/GABA neurons) (Fig. 1A, B). In the superficial dorsal horn we ob-
served labeled neurons that were relatively small in size. These neurons contain most 
likely GABA and not glycine since glycinergic neurons are scarce in laminae I and II [19,46]. 
Labeled neurons in the deep dorsal and ventral horn were mostly medium to large in size, 
representing neurons using glycine and/or GABA as neurotransmitters [47]. 
 Fluorescent immunohistochemistry (IHC) for c-fos resulted in labeling of nuclei 
with various intensities (Fig. 1C). In the spinal cords of naïve rats c-fos labeled neurons 
were rare, while many were present in the spinal cords of rats that received a nociceptive 
stimulus. Most c-fos labeled neurons were located ipsilateral to the stimulus in the su-
perficial (laminae I-II) and deep (III-VI) dorsal horn and much less in the ventral horn (VII-
X). When FISH was combined with IHC, double labeled neurons were observed in which 
the labeling for c-fos (reddish nucleus) was surrounded by the labeling for GlyT2/GAD67 
mRNA (greenish cytoplasm) (Fig. 1C, D, and E).
Fig. 1. Fluorescence micrographs of lumbar spinal sections showing the distribution of neurons labeled for 
GlyT2 and/or GAD67 mRNAs, and/or neurons labeled for c-fos protein after stimulation with formalin (45 
min). (A and B) Note that labeled neurons in the superficial layers, which are mostly small and somewhat diffi-
cult to see at this magnification, are predominantly GABAergic neurons, while small and large labeled neurons 
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in the deeper laminae are glycinergic and/or GABAergic. (C, D and E) Labeling for c-fos protein in nuclei of neu-
rons in the deep dorsal horn after stimulation with formalin (45 min) combined with labeling for GlyT2 and/
or GAD67 mRNAs. Note that double labeled neurons are yellow. Roman figures indicate laminae; DF: dorsal 
funiculus; Scale bar: 50 µm. 
3.2. Capsaicin, formalin, CFA and SNI pain models
 The effects of nociceptive stimulations were assessed by behavioral analysis us-
ing Von Frey hair monofilaments. As expected, we found that the mechanical threshold 
(grams) was significantly decreased in the capsaicin (33 g before treatment, 3 g after cap-
saicin, p<0.001), chronic inflammation (CFA; 37 g before treatment, 5 g after CFA 1.5 hrs, 
p<0.005; 7 g after CFA 20 hrs, p<0.005; 10 g after CFA 4 days, p<0.01) and neuropathic 
pain (SNI; 27 g before treatment, 2 g after SNI 1 wk, p<0.005; 1 g after SNI 2 wks, p<0.005) 
groups as compared to the mechanical threshold of the same paw before treatment. In the 
sham-SNI groups we did not find a significant decrease in the mechanical threshold (27g 
before treatment, 20 g after sham-SNI 1wk, p>0.05; 19 g after sham-SNI 2 wks, p>0.05) 
3.3. c-fos labeling pattern
 In naïve unstimulated rats we found on average a total 0.5 ± 0.2 c-fos labeled 
neurons per section. In view of this low number, we did not further investigate the colocal-
ization of c-fos in Gly/GABA neurons in naïve rats. Stimulation with capsaicin or formalin 
induced significantly higher average numbers of c-fos labeled neurons per section than 
stimulation with saline (control) (Fig. 2). In the CFA pain model, there were no significant 
differences between the numbers of c-fos labeled neurons obtained at different survival 
times (ANOVA). In the SNI pain model there were no significant differences between the 
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number of c-fos labeled neurons at 1 wk (18 ± 2.8) or 2 wks (14 ± 1.9) after nerve in-
jury, and they were significantly lower (p<0.001, ANOVA) than at 2 hrs after nerve injury 
(Fig. 2). When considering all pain models (Fig. 2), the highest numbers of c-fos labeled 
neurons were found 90 minutes after stimulation wit formalin (53 ± 4) and at 2 hrs after 
spared nerve injury (61 ± 3.6). 
 With respect to the laminar distribution (Table 1A), c-fos labeled neurons were 
approximately equally abundant in laminae I&II and in laminae III-VI in the acute pain 
models (after saline, capsaicin, formalin) and in the acute phases of inflammation and 
neuropathic pain. However, in the chronic phases of inflammation (CFA 20 hrs and 4 days) 
and neuropathic pain (1 wk and 2 wks) the bulk of c-fos labeled neurons was present in 
laminae III-VI (Table 1A). In all pain models, laminae VII-X contained the lowest numbers 
of c-fos labeled neurons.  
3.4. The number of c-fos labeled Gly/GABA neurons
 In the saline, capsaicin and formalin models, the average number of c-fos labeled 
Gly/GABA neurons per section was significantly higher after stimulation with capsaicin 
(11 ± 1.1), 45 and 90 minutes after formalin injection (15 ± 0.8 and 21 ± 1.7, respectively) 
when compared to saline (4 ± 0.3, control) (Fig. 3, Fig. 4 and Fig. 5). These findings indicate 
that a saline injection, which served as control, also induced c-fos expression in spinal Gly/
GABA neurons. 
Fig. 2. Histogram showing the average number of c-fos 
labeled neurons per section in lumbar spinal cord in vari-
ous rat pain models and their controls. Capsaicin, 45 and 
90 minutes after formalin injection induced significantly 
higher numbers of c-fos labeled neurons than the control 
stimulation with saline (ANOVA). The SNI models induced 
significantly higher numbers of c-fos labeled neurons than 
their corresponding sham models (unpaired t-test). * = 
p<0.05; ** = p<0.01; *** = p<0.005; **** = p<0.001.
 In the CFA inflammation model there were no significant differences between the 
numbers of c-fos labeled Gly/GABA neurons at 1.5 hrs (10 ± 2.7), 20 hrs (10 ± 0.4) and 4 
days (10 ± 2.3) after injection of CFA (Fig. 4 and Fig. 5). In the SNI model, the numbers of 
c-fos labeled Gly/GABA neurons were higher in nerve injured than in the corresponding 
sham-SNI operated animals (controls) at all time points (Fig. 4). Further, a significantly 
(p<0.001, ANOVA) higher number  of c-fos labeled Gly/GABA neurons was found at 2 hrs 
after nerve injury (25 ± 3.1) than at 1 wk (8 ± 1.2) or 2 wks (8 ± 1.4). Note that the higher 
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number at 2 hrs after nerve injury is partly explained by the contribution of the operation 
procedure, as shown by the relatively high number of activated Gly/GABA neurons in the 
sham operated animals (Fig. 4). 
Fig. 3. Fluorescence micrographs from lumbar spinal sections showing labeling for c-fos protein and GlyT2/
GAD67 mRNAs. Arrows indicate c-fos labeled neurons that also contained GlyT2 and/or GAD67 mRNAs. (A, B 
and C) Superficial dorsal horn at caudal L4 level of a rat stimulated with capsaicin. (D, E and F) Deep dorsal horn 
at caudal L5 level of a rat with chronic inflammation (CFA 4 days). Asterisk indicates a c-fos labeled neuron that 
was out of focus but also contained GlyT2 and/or GAD67 mRNA. Scale bar: 50 µm.
Fig. 4. Histograms showing the average number of c-fos la-
beled neurons per section that also contained GlyT2 and/
or GAD67 mRNAs (Gly/GABA neurons) in different rat pain 
models. Capsaicin, 45 and 90 minutes after formalin injec-
tion induced significantly higher numbers of c-fos labeled 
Gly/GABA neurons than the control stimulation with sa-
line (ANOVA). The SNI models induced significantly higher 
numbers of c-fos labeled neurons than their corresponding 
sham models (unpaired t-test). * = p<0.05; ** = p<0.01; *** 
= p<0.005; **** = p<0.001.
 When comparing the number of c-fos labeled Gly/GABA neurons in all the pain 
models, there were no significant differences (p>0.05, ANOVA) between the capsaicin (11 
± 1.1) , CFA 1.5 hrs (10 ± 2.7), CFA 20 hrs (10 ± 0.4), CFA 4 days (10 ± 2.3), SNI 1 wk (8 ± 1.2) 
and SNI 2 wks (8 ± 1.2) pain models (Fig. 4, Fig. 5). Further, SNI 2 hrs (25 ± 3.1) induced sig-
nificantly the highest number of c-fos labeled Gly/GABA neurons as compared to all other 
pain models (p<0.05, ANOVA), except for 90 minutes after formalin injection. When con-
sidering the distribution pattern of c-fos labeled Gly/GABA neurons, in most pain models 
the majority of the labeled neurons were located in the deep dorsal horn (III-VI), and with 
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lower percentages in the superficial dorsal horn and in the ventral horn (Table 1B). 
Table 1. Laminar distribution of c-fos 
labeled and c-fos labeled Gly/GABA 
neurons in the various pain models. 
(A, B) Percentages (± SEM) of the total 
number of c-fos labeled (A) or c-fos la-
beled Gly/GABA (B) neurons that were 
located in laminae I-II, III-VI or VII-X 
are shown for each pain model. Note 
that the majority of c-fos labeled and 
c-fos labeled Gly/GABA neurons were 
located in the deep dorsal horn (lami-
nae III-VI), especially in the chronic 
pain models.  
3.5. The percentage of c-fos labeled neurons that were Gly/GABA
 After calculating the average percentages of c-fos labeled neurons that were dou-
ble labeled with Gly/GABA in all the pain models, we found that in the chronic phase of 
the CFA, sham-SNI and SNI models, there were no significant differences (p>0.05, ANOVA) 
between the percentages obtained for the two chronic survival times in each model. Since 
we were interested in possible differences between the acute and chronic phases,   we 
 
Fig. 5. Drawings showing the spinal distribution of c-fos labeled and c-fos labeled Gly/GABA neurons in ran-
domly chosen single sections from the lumbar spinal cord, each from a different pain model. An open circle 
represents a single c-fos labeled neuron, and each filled triangle represents a single c-fos labeled neuron that 
also contained GlyT2/GAD67 mRNAs (Gly/GABA).  90 min after formalin injection and 2 hrs after nerve injury 
induced the highest numbers of c-fos labeled Gly/GABA neurons. Note that in most pain models, the bulk of c-
fos labeled Gly/GABA neurons were located in the deep dorsal horn (laminae III-VI; see also table 1B). In most 
pain models, few c-fos labeled Gly/GABA neurons were located in the ventral horn (laminae VII-X).
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combined in each group the chronic phases (i.e. 20 hrs + 4 days in the CFA model; 1wk 
+ 2wks in the sham-SNI and SNI models). We then compared the result for the chronic 
phase with that of the acute phase in the different models (Fig. 6). This showed that in the 
CFA and SNI models the percentages of c-fos labeled neurons that were Gly/GABA were 
significantly higher in the chronic phases as compared to their acute phases. Also in the 
formalin model there was no significant difference between the two survival times. We 
therefore combined the two results and found that the percentage of c-fos labeled neu-
rons that were Gly/GABA was significantly higher in the formalin model as compared to 
the saline and capsaicin models (Fig. 6).  
 We then averaged the percentages of all the chronic phases in the various mod-
els (i.e. CFA 20 hrs and 4 days; sham-SNI and SNI 1 wk and 2 wks), and compared it with 
the average percentages of all the acute phases (saline, capsaicin, formalin, CFA 1.5 hrs, 
sham-SNI and SNI 2 hrs). As a result we found that in the chronic phase the overall aver-
age percentage of the c-fos labeled neurons that were Gly/GABA was 46% (± 1.5), which 
is significantly higher (p<0.0005; unpaired t-test) than 34% (± 2), the overall percentage 
obtained for the acute phase.
Fig. 6. Histogram showing the average percentages of 
c-fos labeled neurons per section that also contained 
GlyT2/GAD67 mRNA (Gly/GABA). A significantly higher 
percentage was found in the combined formalin (45 + 
90 min) models as compared to the saline and capsa-
icin models (ANOVA). Note that the percentages of c-
fos labeled neurons that were Gly/GABA in the chronic 
phases of the CFA (20 hrs + 4 days), and SNI (1 wk + 
2 wks) models were significantly higher than the cor-
responding acute phases (unpaired t-test). * = p<0.05; 
**** = p<0.001.
Fig. 7. Histograms showing the average numbers (A) or 
percentages (B) of c-fos labeled neurons after formalin 
stimulation in rats pretreated with saline (control, 20 
min) or morphine (20 min). (A) The average number 
per section of c-fos labeled neurons or the average 
number of c-fos labeled neurons containing GlyT2/
GAD67 mRNA (Gly/GABA) after formalin stimulation. 
(B) The percentage of c-fos labeled neurons that were 
Gly/GABA. Note that despite the decrease in the to-
tal number of c-fos labeled Gly/GABA neurons (A), the 
percentage of c-fos labeled neurons that were Gly/
GABA did not change significantly when the rats were 
pretreated with morphine. *: p<0.05
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3.6. Effects of morphine application in the formalin model 
 In order to determine the effect of morphine on the number of c-fos labeled Gly/
GABA neurons we used the formalin pain model. The behavioral analysis confirmed the 
notion that morphine significantly reduced the licking time (saline: 630 sec ± 77, morphine: 
71 s ± 12, p<0.005, unpaired t-test) and the number of fluttering and flinches (saline: 676 ± 
61, morphine: 16 ± 5, p<0.005, unpaired t-test) of the injected paw. After formalin stimula-
tion, the total number of c-fos labeled neurons and the number of c-fos labeled Gly/GABA 
neurons decreased by subcutaneous morphine application when compared to control 
(Fig. 7A). When considering the percentage of c-fos labeled neurons that were Gly/GABA, 
we found no difference between the percentages of the control and the morphine treated 
groups (Fig. 7B).
4. Discussion
 In the present study we have shown that Gly/GABA neurons are activated (i.e. 
expressing c-fos protein) in all the pain models that we have investigated. Our data fur-
ther showed that the percentage of activated neurons that are Gly/GABA is higher in the 
chronic phase (46%) than in the acute phase (34%). Furthermore, the systemic application 
of morphine, preceding formalin injection, reduced the activation of Gly/GABA neurons 
and non-Gly/GABA (presumed excitatory) neurons in an equal manner. These findings 
show that active recruitment of Gly/GABA neurons is inherent to the normal and patho-
logical processing of nociceptive stimuli in the spinal cord.
 
4.1. Technical aspects 
 FISH was used to identify glycinergic neurons by their expression of glycine trans-
porter 2 (GlyT2) mRNA [23,28], and GABAergic neurons were identified by their expres-
sion of the mRNA for the GABA synthesizing enzyme (GAD) [13]. The GAD67 isoform of 
this enzyme is found in the large majority of spinal GABAergic neurons, often together 
with the GAD65 isoform [30]. A few neurons in the ventral horn, involved in presynap-
tic inhibition of 1A afferents only express the GAD65 isoform [20]. These neurons have 
not been identified in the present study, but it is highly unlikely that this has significantly 
affected our results. GABA and glycine are often colocalized in neurons [43,47] and co-
released at synapses [22]. Therefore, we did not attempt to identify glycinergic and GAB-
Aergic neurons separately but rather aimed at labeling them simultaneously. 
 For identifying spinal neurons that were activated in various pain models we have 
used c-fos, an immediate early gene (IEG) that is widely used as a marker for neuronal ac-
tivation in pain research [8]. Our results on the expression of c-fos in various pain models 
are in general agreement with other studies [6,21,29]. Application of GABA and glycine an-
tagonists in naïve animals leads to a hypersensitive spinal cord [38,39]. This indicates the 
presence of a continuous inhibitory tone, which is most likely due to activity in nearby Gly/
GABA neurons [1]. Apparently, the activity of these neurons does not induce significant 
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amounts of c-fos protein, since labeled c-fos neurons are very low in naïve animals. Thus, 
c-fos expression in spinal neurons signals phasic activity associated with active nociceptive 
processing rather than tonic activity associated with the presumed ongoing inhibition in 
the naïve spinal cord. Therefore, the results obtained in the present study are associated 
with the processing of phasic nociceptive stimuli in the different pain models.
4.2. c-fos expressing Gly/GABA neurons 
 In all our pain models, we found that a substantial proportion (ranging between 
24 and 53%) of the activated neurons expressed glycine and/or GABA. It seems likely that 
this activation was induced by nociceptive afferents, which are known to contact Gly/
GABA neurons [5,10,14,16], although indirect activation through interneurons cannot be 
excluded. Previous studies [46,54,55] using different techniques have also shown the acti-
vation of spinal inhibitory neurons by means of c-fos expression after capsaicin or formalin 
stimulation. Our data are in general agreement with the study by Todd et al. [46], however 
we found a lower percentage of activated GABAergic neurons in the superficial dorsal 
horn after capsaicin stimulation when compared to the studies by Zou et al [54,55]. 
 In our study, capsaicin induced a significant increase in the number of Gly/GABA 
activated neurons, when compared to saline. However, the percentages of activated Gly/
GABA neurons after saline (24%) and capsaicin (26%) stimulation were similar. This shows 
that in this paradigm, irrespective of the stimulus intensity (i.e. low after saline and high 
after capsaicin), the number of activated Gly/GABA neurons is proportional to the total 
number of activated neurons. In the formalin model, which typically shows a first and 
second phase in the behavioral response [44], the total number of activated neurons is 
higher at 90 min after formalin injection than at 45 min. Also in this case the percentages 
of activated Gly/GABA neurons were not significantly different at the two time points, 
although, when combined, it was higher than after saline or capsaicin injections. These 
results suggest that in a given pain model the proportion of activated neurons that are 
Gly/GABA remains stable, irrespective of the stimulus intensity. However, when we exam-
ined the CFA experiments we found the reverse situation: the total number of activated 
Gly/GABA neurons was similar at the different time points (i.e. 1.5 hrs, 20 hrs and 4 days), 
while the percentage of activated Gly/GABA neurons was higher in the chronic phase than 
at 1.5 hrs. In the SNI experiments, the total number of activated Gly/GABA neurons de-
clined significantly in the chronic phase, while there was a significant increase in the per-
centage. In the sham-SNI group, in which the operation procedure by itself resulted in a 
significant number of c-fos expressing neurons, the percentage did not increase in the 
chronic phase as compared to the acute phase. We therefore concluded that there was 
no consistent pattern of Gly/GABA neuronal activation when comparing the different pain 
models. However, within a particular pain model there were consistencies in the numbers 
or percentages of activated Gly/GABA neurons.  
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 We then examined the data from another viewpoint by subdividing all pain mod-
els in acute (≤ 2 hrs) and chronic (≥ 20 hrs) phases. Our data showed that in the chronic 
phase the percentage of activated Gly/GABA neurons (46%) was higher than in the acute 
phase (34%). This increase in the percentage in the chronic phases was due to a decrease 
in the total number of activated neurons while the number of activated Gly/GABA neu-
rons remained stable. Assuming that the majority of the non-Gly/GABA activated neurons 
were excitatory, our data show a decline in the number of activated excitatory neurons in 
the chronic phase. 
 Hypersensitivity in chronic pain conditions has been shown to result from loss of 
spinal inhibition due to blockade of glycinergic and GABAergic receptors [53]. At the same 
time, our data indicate an increased activity of inhibitory neurons in chronic pain condi-
tions. Whether the balance between these apparently opposing mechanisms determines 
the sensitivity of spinal neurons for incoming nociceptive stimuli, or whether they act on 
different aspects of pain transmission, is presently unclear. 
4.3. Laminar distribution of c-fos labeled Gly/GABA neurons
 Activated Gly/GABA neurons in the superficial dorsal horn are mainly GABAergic 
[19,46], while activated Gly/GABA neurons in the deep dorsal horn are glycinergic and/
or GABAergic [47]. Deeper located Gly/GABA neurons have been suggested as a source 
of inhibitory input to the superficial dorsal horn [51], which may be lost in chronic pain 
states, leading to touch evoked allodynia. There is also loss of GABAergic inhibition in the 
superficial dorsal horn in chronic neuropathic pain states, which may be due to loss of 
GABAergic interneurons [32,34,35]. Our data showed that the number of activated Gly/
GABA neurons in the deep dorsal horn remained stable over time in the chronic phase, 
while the numbers of presumed excitatory neurons were declining. Thus, our results on 
activated Gly/GABA neurons do not indicate loss of inhibition in chronic pain states due to 
decreased activation of spinal Gly/GABA neurons. 
 It has been suggested that GABAergic neurons in the superficial dorsal horn re-
ceive C-fiber input [16], and are important for regulating the spinal transmission of innoc-
uous and nociceptive information, especially during acute pain [10]. Our data confirm the 
presence of activated Gly/GABA neurons in the superficial dorsal horn, but their numbers 
are low when compared to the number of activated Gly/GABA neurons in the deep dorsal 
horn. 
4.4. The morphine experiment
 After a systemic morphine injection preceding a formalin injection to the hind 
paw, there was a significant reduction in the total number of c-fos labeled neurons and a 
proportional decrease in the number of c-fos labeled Gly/GABA neurons. It seems most 
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likely that most inhibition induced by morphine is due to presynaptic inhibition of primary 
afferents expressing mu-opioid receptors [3]. Postsynaptic mu-opioid receptors in the su-
perficial dorsal horn are expressed preferentially by neurons, mainly in laminae II, that 
are not GABAergic or glycinergic [25]. This would suggest that inhibitory neurons escape 
postsynaptic inhibition by morphine. However, our finding of an equal reduction of c-fos 
expression in Gly/GABA and non-Gly/GABA (presumed excitatory) neurons, indicates that 
the overall effect of the pre- and postsynaptic inhibition induced by morphine is about 
equally strong on inhibitory and excitatory neurons. Similarly, the suggestion [7] that mor-
phine would activate Gly/GABA neurons, especially GABAergic neurons in lamina II, is not 
supported by our findings. Thus, the proportional decrease in the number of c-fos labeled 
Gly/GABA neurons after morphine injection shows that morphine did not specifically re-
cruit spinal Gly/GABA neurons for the inhibition of nociceptive inputs. 
4.5. Conclusions 
 A characteristic feature of the pain models that we have examined is the develop-
ment of hypersensitivity for (in)nocuous stimuli. This phenomenon is due to glutamate 
induced sensitization in spinal neurons [27,49], along with a blockade [53] or reversal [9] 
of inhibitory impulses. We now show that similar numbers of Gly/GABA neurons are ac-
tivated by nociceptive stimuli during acute and chronic pain states, while in chronic pain 
states the activation of presumed excitatory neurons is declining. Therefore it seems most 
likely that the balance between all these mechanisms, and the disturbances therein dur-
ing pathological pain states, will determine the sensitivity of our pain system during health 
and disease.
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Abstract
 In the present study we have investigated the c-fos activation pattern of glycin-
ergic and/or GABAergic (Gly/GABA) neurons in the spinal cord after capsaicin injection 
in rats with acute, chronic inflammatory (i.e. complete freund’s adjuvant (CFA) induced 
inflammation) or neuropathic pain (i.e spared nerve injury (SNI)). For this purpose we 
employed fluorescent in situ hybridization (FISH) in order to identify glycinergic (GlyT2 
mRNA) and GABAergic (GAD67 mRNA) neurons, and fluorescent immunohistochemistry 
(IHC) for identifying c-fos, a marker for neuronal activation. In rats in which capsaicin, CFA 
(1.5 hrs or 20 hrs), or saline was injected in the hind paw, stimulation of the contralateral 
hind paw with capsaicin did not result in a significantly different number or percentage 
of c-fos labeled neurons that were Gly/GABA as compared to capsaicin injection alone. 
However, we found a higher number and percentage of c-fos labeled neurons that were 
Gly/GABA after contralateral capsaicin injection in rats with chronic inflammatory (4 days), 
sham-SNI or SNI (2 weeks) as compared to capsaicin injection alone. In these rats, the me-
chanical threshold after capsaicin injection, as determined by Von Frey hairs, did not dif-
fer from the mechanical threshold in rats that only received capsaicin injection. Our data 
show that chronic inflammatory and neuropathic pain in a hindpaw alters the activation 
pattern of Gly/GABA neurons on the contralateral side of the spinal cord, indicating that 
not only the ipsilateral, but also the contralateral side of the spinal cord is affected by a 
nociceptive stimulation on one side. 
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1. Introduction
 Nociceptors are primary afferent nerve fibers that are activated by stimuli that are 
potentially damaging to our body. These nociceptive signals are conveyed to the spinal 
cord, where nociceptors establish synapses with secondary nociceptive specific or wide-
dynamic range neurons in various laminae of the dorsal horn [21]. Many of these neu-
rons also receive inputs from local interneurons and neurons from supraspinal sites. Apart 
from excitatory inputs, a substantial number of these inputs are inhibitory in nature, since 
they use GABA and/or glycine as their neurotransmitter [23]. This network of inputs forms 
a system that plays a major role in setting the responsiveness of the spinal nociceptive 
system to incoming nociceptive signals [1, 9, 22]. 
 At the spinal level, incoming nociceptive stimuli activate neurons on the ipsilateral 
side of the spinal cord, which are nociceptive-specific  neurons located in the superficial 
(laminae I-II) and wide-dynamic range neurons in the deep dorsal horn (laminae III-VI) [3]. 
In many studies, activated spinal nociceptive neurons are identified by the expression of 
the c-fos protein [3, 6], which is an immediate early gene [12]. After peripheral nociceptive 
stimulation, spinal neurons expressing c-fos are predominantly located on the ipsilateral 
side, but c-fos is also expressed on the contralateral side [3], especially during chronic 
pain states. This suggests that nociceptive neurons on both sides of the spinal cord are ac-
tivated by a unilateral stimulus. In animal models, when noxious stimulation (formalin or 
complete Freund’s adjuvant ) of a hind paw is followed by a second noxious stimulation of 
the contralateral paw, c-fos expression induced by the second stimulus was stronger when 
compared to a single stimulus [15]. Further, it has been shown that peripheral Transcu-
taneous Electrical Nerve Stimulation (TENS) of the side contralateral to the nerve injured 
side reduces mechanical allodynia on the injured side [20]. These studies suggest that ac-
tivated spinal neurons on the contralateral side of the stimulus may play a functional role 
in nociceptive processing. 
 In the present study, we investigated the number and the percentage of c-fos ex-
pressing neurons that use glycine and/or GABA (Gly/GABA neurons) as their neurotrans-
mitter after capsaicin stimulation, when a prior noxious stimulus was applied to the contra-
lateral hind paw. This study is a continuation to a previous study in which we investigated 
the expression of c-fos in spinal Gly/GABA neurons after a single noxious stimulus [9]. The 
objective of the present study was to investigate whether the activation pattern of spinal 
Gly/GABA neurons in an acute pain model is modulated by prior noxious stimulation of 
the contralateral hind paw. We show here that the number and the percentage of c-fos ex-
pressing Gly/GABA neurons is increased when chronic inflammation or neuropathic pain 
is induced previously in the contralateral hind paw. 
2. Methods
 All animal experiments were approved by the Rotterdam Animal Ethical Commit-
tee and were in line with ethical guidelines of International Association for the study of 
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pain [26]. 
2.1. Pain models
 All noxious stimulations were applied under anesthesia with 2% isofluoran in 
30%O
2
/70%N
2
O
 to the left paw (the first noxious stimulation) or the right paw (the second noxious stimu-
lation, or capsaicin injection in the control group). The following stimulants were applied 
to either the right and/or the left hind paw (see also Table): Group A-K: Capsaicin (50μl 
of 0.3%; N-Vanillylnonanamide, Sigma-Aldrich, diluted in 80% saline, 10% Tween-80, and 
10% ethanol-100%); Group C-E: Complete Freund’s 
Adjuvant (chronic inflammatory pain; CFA, 100μl); 
Group F and G: Spared Nerve Injury (SNI) model 
(neuropathic pain) was applied following the proto-
col described in [4]. In short, the three branches of 
the sciatic nerve are exposed, and the tibial and com-
mon peroneal branches are ligated and cut 2-3 mm 
distal to the ligation. The sural branch is left intact. As control operation (sham) the three 
branches of sciatic are only exposed; Group H-K: Injection of an empty syringe or sterile 
saline (100µl; 0.9% sodium chloride, Baxter).
2.2. Mechanical threshold
 The mechanical threshold was assessed using the Von Frey hair monofilaments 
(Stoelting). Before commencement of experiments, all rats were habituated to the experi-
menter, the experiment room, and a transparent cage (15cm x 15cm; gridded floor) for 5 
days. Thereafter, prior to each experiment the rats were habituated for 30 minutes to the 
experiment room, and for 10 minutes to the transparent cage. Each Von Frey hair was ap-
plied for 2 seconds at 5 seconds interval, and the threshold was set at 3 evoked responses 
in a maximum of 5 applications.  In all the groups, the mechanical threshold after capsaicin 
stimulation was assessed 60 minutes after injection. Further, in the groups with bilateral 
stimulation, the mechanical threshold of the left hind paw (first stimulation) was assessed 
30 minutes prior to the capsaicin injection in the right hind paw (second stimulation). 
2.3. Tissue preparation
 All rats were received an overdose of sodium pentobarbital 90 minutes after cap-
saicin injection, and were transcardially perfused with 150 ml saline followed by 750 ml of 
4% PFA. Thereafter, the lumbar spinal cord was dissected and incubated overnight at 4°C 
in a RNAse free solution of 4% PFA and 30% sucrose dissolved in phosphate buffer (PB). 
Coronal sections were cut at 30 μm in a freezing microtome and stored in glycerol at -20°C. 
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2.4. Fluorescent in situ hybridization combined with fluorescent immunohistochemistry
 For fluorescent in situ hybridization (FISH) the following partial cDNA templates 
encoding the following mRNAs were used: GlyT2 (3.1kb; a generous gift from Dr. N. Nel-
son, Tel Aviv University), GAD67 (3.2kb; a generous gift from Dr. A.J. Tobin, UCLA). The 
riboprobes were obtained by linearizing the recombinant plasmids with the appropriate 
restriction enzymes and RNA polymerases. The transcription was performed in the pres-
ence of fluorescein-labeled 11-UTP (Roche). For (FISH) the following modifications were 
applied to the protocol described in [10]: sections were incubated with GAD67 mRNA 
together GlyT2 mRNA in order to identify GABAergic and/or glycinergic (inhibitory) neu-
rons. After riboprobe hybridization, the sections were incubated (48 hours at 4 ºC ) with 
mouse monoclonal anti-fluorescein antibody (Roche; 1:500) and rabbit anti-c-fos (1: 4000; 
Oncogene Research Products, La Jolla, CA) in a cocktail of phosphate buffered saline (PBS), 
2% milk powder (Profitar Plus, Nutricia) and 0.5% Triton X-100. Thereafter, sections were 
rinsed in PBS and incubated with biotinylated goat-anti-mouse (GAM, Vector) and donkey-
anti-rabbit tagged with Cy3 in a 2% milk powder cocktail for 90 minutes at RT. Subse-
quently, after rinsing in PBS sections were incubated (overnight at 4°C) with Avidin-Biotin-
Complex (ABC, Vector) tagged with horseradish peroxidase (HRP). After rinsing in PBS, a 
tyramide amplification procedure was performed by reacting HRP with H
2
O
2
 and a self 
made FITC tyramide according to protocol described in [8]. Thereafter, the sections were 
washed in PB and mounted on slides and coverslipped with Vectashield (Vector). 
2.5. Analyzing c-Fos labeled neurons
 Analysis was carried out on sections from lumbar (L4 and L5) segment of the spi-
nal cord. Sections for analysis were chosen by starting in the first row of mounted sections 
and searching for undamaged sections of appropriate segmental level, ranging from ros-
tral L4 to caudal L5. Per rat, 5 to 6 sections were analyzed, and were analyzed in a Leica 
fluorescent microscope with FITC and/or Cy3 filter. Fluorescent labeling for GAD67+GlyT2 
mRNA was accounted as neuronal labeling if the staining was present in the cell soma and 
an empty nucleus was apparent. However, in the superficial dorsal horn some neurons 
labeled for GAD67+GlyT2 mRNA are intensely stained, and an empty nucleus was not 
always visible. These neurons were accounted as labeled neurons if the shortest diameter 
was at least 10μm.
 In order to investigate the colocalization of c-fos with GAD67/GlyT2 mRNA, first 
c-fos labeling was assessed in a 40x objective. Thereafter, in the same focus field, the c-fos 
labeled neuron was analyzed for cytoplasmatic labeling of a mRNA. If the same focus field, 
c-fos labeling was surrounded by somatic mRNA staining, then the neuron was accounted 
as a double labeled neuron. Single or double labeled neurons were plotted by hand in an 
illustrated representation of the appropriate segmental level. The grey matter was divided 
in three main parts (laminae I-II, laminae III-VI, and laminae VII-X) according to the lami-
nae distribution described [16]. The unpaired t-test was performed for statistical compari-
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son between the groups, and P<0.05 was taken as significant. 
3. Results
3.1. General observation
 Applying FISH with GlyT2 mRNA together with GAD67 mRNA resulted in cytoplas-
matic labeling of spinal inhibitory, i.e. Gly/GABA neurons (Fig. 1). Labeled neurons were 
located in all the laminae of the grey matter and were of various sizes, and in most cases 
cytoplasmatic labeling was apparent. By using GlyT2 together with GAD67 mRNA, spinal 
inhibitory neurons were identified as one group without distinction between GABAergic 
and/or glycinergic neurons. Our labeling pattern was consistent with previous findings 
[9, 23, 24]. In order to identify activated spinal neurons, the neuronal activation marker 
c-fos was detected by applying fluorescent immunohistochemistry (IHC), which resulted 
in nuclear labeling of neurons (Fig. 1). Depending on the type of peripheral stimulus, c-Fos 
labeled neurons were located solely in the superficial dorsal or in the superficial and deep 
dorsal horn, and sometimes also in the ventral horn of the spinal cord. 
Fig. 1: Fluorescence micrographs showing labeling for GlyT2/GAD67 mRNAs (Gly/GABA neurons) and for c-fos 
protein. A, B, C: c-fos expression in spinal dorsal horn neurons after stimulation with capsaicin in rats with 
inflammatory pain (A, C), and neuropathic pain (B). Arrows indicate Gly/GABA neurons that also expressed 
c-fos protein. Scale bar:50µm. 
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3.2. Capsaicin injection (control)
 After a single capsaicin injection (90 minutes), which served as control, we found 
51 ± 3.7 c-fos labeled neurons on the ipsilateral side of the spinal cord. 47% ± 2 (mean ± 
SEM) of these neurons were located in laminae I-II and 45% ± 2 were located in laminae 
III-VI. Furthermore, when c-fos was colocalized with GAD67/GlyT2 mRNAs, 13 ± 1 c-fos 
labeled neurons also contained GAD67/GlyT2 mRNA, indicating that these neurons were 
inhibitory. This accounted for 26% ± 3 of the total c-fos labeled neurons, and these double 
labeled neurons were mainly located in laminae III-VI. 
3.3. Bilateral paw stimulation
 In the following groups, a first noxious stimulation was applied to the left hind 
paw followed by a second stimulation with capsaicin of the right hind paw. Results on 
c-fos expression and colocalization pattern after subsequent capsaicin stimulation were 
compared to the results in the control group in which only single capsaicin stimulation 
(see above) was applied. 
3.3.1. Capsaicin-capsaicin
Number of c-fos cells
 When capsaicin injection in the left hind paw was followed by a capsaicin injection 
in the right hind paw, the second capsaicin injection induced 48 ± 4 c-Fos labeled neurons 
(Fig. 2), which is not significantly different from a single capsaicin injection (51 ± 4, see 
above) (p>0.05, unpaired t-test). Also, the distribution of c-fos labeled neurons in laminae 
I&II and laminae III-VI was not different between the two groups (Table 1A). 
Fig. 2: Histogram showing the total number of 
c-fos labeled neurons in laminae I to X of the 
grey matter after capsaicin injection in naive 
(control) rats, and rats in pretreated with cap-
saicin, CFA (1.5hrs, 20hrs, or 4 days), sham-SNI 
(1 wk, or 2 wks), SNI (1 wk, or 2 wks) or saline 
(20hrs, or 4 days). We found no significant dif-
ferences in the number of c-fos labeled neu-
rons between the control stimulation (single 
capsaicin injection) as compared to other pain 
models. 
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Percentage and number of c-Fos and GAD67/GlyT2 mRNA double labeled cells
 When the second capsaicin injection was applied to the right hind paw after a 
prior left sided capsaicin injection, 28% ± 2 of c-fos positive neurons were inhibitory (Fig. 
3A), and this was not significantly different from single capsaicin stimulation (26% ± 3) 
(p>0.05, unpaired t-test). Also, the number of c-fos double labeled neurons that were 
inhibitory neurons was not different after second capsaicin stimulation (Fig. 3B). Further, 
the distribution of c-fos neurons containing GlyT2/GAD67 in laminae I&II and laminae III-
VI was not different between the two groups (Table 1B). 
 
Fig. 3: Histogram showing the percentage (A) and the number (B) of c-fos labeled neurons that also contained 
GlyT2/GAD67 mRNA in various pain models. * =  p<0.05, as compared to control. 
3.3.2. CFA-capsaicin
Number of c-Fos cells
 When CFA was injected in the left hind paw, followed by right hind paw stimula-
tion with capsaicin at different time points (1.5 hrs, 20 hrs, and 4 days), the number of 
c-fos labeled neurons induced by the second stimulation was not significantly different 
from a single capsaicin injection (Fig. 2) (p>0.1, ANOVA). There was also no difference in 
the laminar distribution of c-fos labeled neurons between CFA-capsaicin treated groups 
and capsaicin injection alone (Table 1A). 
Percentage and number of c-Fos and GAD67/GlyT2 mRNA double labeled cells
 The number of c-fos labeled neurons that were inhibitory after subsequent cap-
saicin stimulation (left paw) was significantly higher (35 ± 4) after 4 days of CFA induced 
inflammation in the contralateral hind paw (right paw) (Fig. 3B) (p<0.05, ANOVA), in com-
parison to 1.5hrs (12 ± 2) or 20hrs (18 ± 3) of inflammation in the right hind paw, or single 
capsaicin stimulation (control). Furthermore, the percentage of c-fos labeled neurons that 
was inhibitory after subsequent capsaicin stimulation significantly increased at 4 days of 
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inflammation in the contralateral paw when compared to single capsaicin injection (Fig. 
3A) (p<0.05, ANOVA). Thus, our data indicate that a relatively decreased threshold for 
capsaicin induced c-fos expression is achieved in spinal inhibitory neurons when inflam-
mation (4 days) is induced in the contralateral paw.
Table 1: The percentages of c-fos labeled (A), and c-fos labeled neurons that also contained GlyT2/GAD67 
mRNAs (B) that were located in laminae I-II and in laminae III-VI of the spinal cord. C: The mechanical thresh-
old (g) in the hind paw after capsaicin injection. 
3.3.3. SNI-capsaicin
Number of c-Fos cells
 When compared to a single capsaicin injection, the number of c-fos labeled neu-
rons is not different after a subsequent capsaicin stimulation if sham or SNI is applied two 
weeks before to the contralateral (left) paw (Fig. 2). 
Percentage and number of c-Fos and GAD67/GlyT2 mRNA double labeled cells
 We found that the number of c-fos positive inhibitory neurons is increased after 
subsequent capsaicin stimulation (compared to single capsaicin stimulation), when SNI or 
sham operation is previously applied to the contralateral paw (Fig. 3B) (p<0.05, ANOVA). 
Also the percentage of c-fos positive inhibitory neurons after subsequent capsaicin is in-
creased when sham or SNI is previously applied to the contralateral hind paw (Fig. 3A) 
(p<0.05, ANOVA). There was no difference in the number or percentage of c-fos double la-
beled neurons after capsaicin stimulation between sham or SNI is applied to the contralat-
eral hind paw (p>0.05, unpaired t-test). Also, the distribution of c-Fos neurons containing 
GlyT2/GAD67 in laminae I&II and laminae III-VI was not different between the two groups 
(Table 1B).
3.3.4. Saline and capsaicin
 Saline (20hrs or 4days) stimulation of the hind paw contralateral to the capsaicin 
stimulated hind paw did not affect the number of c-fos labeled neurons induced by cap-
saicin, when compared to single capsaicin stimulation (Fig. 2) (p>0.05, ANOVA). Also, nei-
ther the percentage nor number of c-fos labeled neurons that is inhibitory (GAD67/GlyT2 
mRNA) is changed (Fig. 3) (p>0.05, ANOVA). 
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3.4. Mechanical thresholds
 After capsaicin injection, the mechanical threshold of the stimulated hind paw 
decreased from 33 ± 3 grams to 3 ± 2. In all the other groups, the mechanical threshold 
was determind after subsequent capsaicin stimulation, and we found no difference in the 
threshold when compared to single capsaicin stimulation (Table 1C).  
4. Discussion
 In the present study we have investigated the expression of c-fos in spinal inhibi-
tory, Gly/GABA neurons after hind paw stimulation with capsaicin when a prior noxious 
stimulus was applied to the contralateral paw. We found that after capsaicin stimulation, 
the number of Gly/GABA neurons that expressed c-fos was significantly increased if chron-
ic inflammation (CFA 4 days), postoperative pain (sham operations) or neuropathic pain (2 
wks) was induced priory in the contralateral paw, when compared to capsaicin stimulation 
in naïve rats. Furthermore, in most cases the increase in the number of c-fos expressing in-
hibitory neurons was observed in laminae I and II. Thus, our data suggest that application 
of peripheral noxious stimuli, especially chronic pain states, increases c-fos expression in 
superficial dorsal horn inhibitory neurons on the contralateral side of the spinal cord upon 
capsaicin stimulation. 
 We used GAD67 together with GlyT2 mRNAs to identify somas of spinal GABAer-
gic and/or glycinergic neuronal somatas. In spinal cord, glycine and GABA are the main 
inhibitory neurotransmitters, which are involved in anti-nociception [18, 19, 25]. Since 
glycine and GABA are often colocalized in the spinal cord [24], we identified glycinergic 
and/or GABAergic neurons as one group, representing spinal inhibitory neurons. Previous 
studies have shown that c-fos is expressed in spinal inhibitory neurons after a variety of 
noxious stimuli and nerve injury of a hind paw [9, 22]. Here, we used capsaicin as a nox-
ious stimulus, which induces a transient burning pain and leads to hyperalgesia for heat 
and mechanical stimuli [2]. c-fos was strongly expressed in spinal inhibitory neurons on 
the ipsilateral side after capsaicin stimulation in naïve animals, which is in accordance with 
our previous findings [9]. 
 As a step further, in the present study we have shown that inducing a chronic 
pain condition in one hind paw increases c-fos expression in spinal inhibitory neurons on 
the contralateral side after stimulation with capsaicin. This finding suggests that induc-
tion of a chronic pain state, i.e. inflammation or neuropathic, reduces the threshold for 
c-fos expression in spinal inhibitory neurons on the contralateral side. Previous studies 
have shown increased number of c-fos expressing neurons on the contralateral side of 
the spinal cord after a unilateral stimulus [11, 13] and after a stimulation of one hind paw 
(mechanical or chemical) when a prior stimulus was applied to the contralateral hind paw 
[14, 15]. The general belief is that application of the first noxious stimulus sensitizes spinal 
nociceptive neurons located on the contralateral side of the spinal cord, which results in 
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a lower activation threshold and hence c-fos expression in these neurons. We found an 
increase in the total number of c-fos labeled Gly/GABA neurons after capsaicin stimula-
tion only if chronic inflammation (CFA 4 days), postoperative pain or neuropathic pain 
(SNI 2wks) was induced in the contralateral paw. Thus, only chronic pain is able to induce 
contralateral sensitization of spinal inhibitory neurons. 
 Our data showing a preference for increased c-fos expression in spinal inhibitory 
neurons, suggest an increase in the number of activated neurons that have an inhibitory 
input in spinal nociceptive processing. However, the rats developed normal pain behavior 
as indicated by no significant changes in the mechanical threshold compared to a single 
unilateral capsaicin injection. Thus, there is an increase in the number of activated, i.e. 
c-fos expressing, spinal inhibitory neurons without any changes in pain behavior. The en-
suing question would be whether activation of spinal inhibitory neurons during a painful 
event is actually involved in inhibiting spinal pain transmission. 
 It has been shown that in inflammatory and neuropathic conditions there is a loss 
of synaptic inhibition in spinal cord [15]. Many behavioral signs of inflammatory and neu-
ropathic conditions are mimicked in naïve animals with reduced GABAergic and/or glycin-
ergic neurotransmission in the dorsal horn [19]. Therefore we expected that increased GA-
BAergic and/or glycinergic neurotransmission would decrease pain behavior. Since we did 
not find any changes in the behavior response might suggest that the Von Frey hairs are 
not sensitive enough to detect possible changes in the mechanical threshold. On the other 
hand, it is also possible that the increased activation of Gly/GABA neurons does not result 
in an increase of spinal inhibition, and thus explaining the absence of any changes in the 
pain behavior. C-fos is a proto-oncogene that links neuronal activity to protein synthesis by 
regulating the downstream expression of target genes [6]. In the past two decades, many 
studies on spinal nociception have used c-fos as a marker for neurons that are activated 
in response to noxious stimulation. Further, it has been shown that spinal c-fos expression 
pattern is linked to the type of noxious stimuli, and that c-fos is expressed in spinal noci-
ceptive neurons that project to higher centers, and also in neurons that use GABA and/or 
glycine, dynorphin or enkephalin as neurotransmitter(s) [3]. However, conflicting evidence 
dispute the functional role of c-fos expressing in spinal cord, i.e. inhibiting or facilitat-
ing nociception, and also to what extent c-fos expression correlates with spinal neuronal 
activity [6]. Also, the threshold for induction of c-fos is different between the subpopula-
tion of spinal neurons [6]. Thus, it is necessary to be cautious when drawing inferences 
about spinal nociceptive activity based on the number or type of neurons expressing c-fos. 
Therefore, our finding that after subsequent capsaicin stimulation there is increased c-fos 
expression in spinal inhibitory neurons is not necessarily linked with increased activation 
of these neurons. And this suggestion is further substantiated by the lack of finding any 
changes in mechanical hyperalgesia. However, we did not measure the thermal threshold 
in order to assess the development of thermal hyperalgesia, which might have changed 
by the increased inhibition. Further, an alternative suggestion would be that c-fos expres-
sion is indeed linked with neuronal activity, and hence an increase in inhibition of spinal 
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nociception. However, this inhibitory effect might rather serve as a counterpart to the 
activation of spinal excitatory neurons, most likely the pain transmitting neurons, which 
are also activated after a noxious stimulation. This would suggest that activation of inhibi-
tory neurons does not result in active inhibition of pain transmission but rather serving as 
a balancing factor in spinal nociceptive processing. Therefore, it remains elusive whether 
increased inhibitory input by spinal inhibitory neurons is indeed altering the output of 
spinal nociceptive processing, and subsequently modulating the pain behavior. All the al-
ternative suggestions made above are based on the assumption that applying a noxious 
stimulus alters the activation threshold of neurons located on the contralateral side of the 
spinal cord. This contralateral effect might be the result of commissural pathways, which 
are especially prominent in the dorsal horn [17], or by descending pathways that modu-
late the spinal nociceptive processing [5, 7]. 
 In conclusion, our data show an increase in c-fos expression in inhibitory neurons 
after capsaicin stimulation, if a chronic pain state is induced on the contralateral paw. 
Whether this enhancement in c-fos activation pattern of inhibitory interneurons leads to 
an increase in spinal nociception is currently unclear. 
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Abstract 
 Descending projections from rostral ventromedial medulla (RVM) on spinal dorsal 
horn neurons are important modulators of spinal nociception by facilitating and inhibiting 
spinal nociception. In the present study we have investigated the distribution pattern of 
glycinergic and/or GABAergic (Gly/GABA) neurons in the RVM that project to the lumbar 
dorsal or ventral horn and the cervical spinal cord. For this purpose we used fluorescent 
retrograde tracing for identifying projection neurons and combined this with fluores-
cent in situ hybridization (FISH) for identifying glycinergic (GlyT2 mRNA) and GABAergic 
(GAD67 mRNA) neurons. Our data showed that in the RVM 40% of neurons projecting 
to the cervical spinal cord were Gly/GABA, while this was 43% for neurons projecting to 
the lumbar dorsal horn, and 35% for neurons projecting to the lumbar ventral horn. We 
found no differences in the percentages for projection neurons containing GlyT2, GAD67 
or Gly2/GAD67 mRNA(s), indicating that these descending inhibitory projections use both 
glycine and GABA as their neurotransmitters. In addition, we have found a novel ascend-
ing pathway in the spinal cord to the RVM originating predominantly from Gly/GABA neu-
rons located in the area around the central canal. In the cervical and lumbar segments 
of the spinal cord, 22% and 21% of the neurons projecting to the RVM were Gly/GABA, 
respectively.  Further, these ascending projections likely use both glycine and GABA as 
their neurotransmitters. Taken together, this is the first study that describes the distribu-
tion pattern of glycinergic and GABAergic neurons in the RVM  that project to the spinal 
cord, and has identified a novel ascending Gly/GABA projection from the spinal cord to the 
RVM, indicating that the spinal cord might be involved in modulating the RVM.  
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1. Introduction 
 Nociceptive information from the periphery has to go through several synaptic 
relay stations before it becomes a conscious pain experience. For the whole body, except 
the head, the first relay station is the spinal dorsal horn [53]. Here, the synaptic transmis-
sion of the nociceptive information is influenced by local interneurons [70], glial cells [35, 
59], and also by descending projections from the brainstem [22]. One important source 
of descending control from the brainstem is the rostral ventromedial medulla (RVM) [14, 
76], which includes the midline nucleus raphe magnus (RM) and the adjacent reticular 
formation. The RVM is mainly under control of the periaqueductal grey (PAG) [22], which 
in turn receives projections from limbic cortical and subcortical areas [4, 66, 81]. The im-
portance of the PAG and the RVM for the inhibition of pain transmission in the spinal cord 
was shown in 1976 as analgesia was produced by electrical stimulation of the PAG [48]. 
Further studies showed that analgesia was also produced by electrical stimulation of the 
RVM, and by microinjection of morphine in the PAG or the RVM [79]. Since the RVM has 
extensive projection to the spinal dorsal horn [16, 22], unlike the PAG [45], the effects of 
the PAG on spinal nociception are produced through the RVM.
 The RVM not only produces inhibition but also facilitation of spinal nociception 
[77], resulting in hyperalgesia and allodynia as observed in inflammatory and neuropathic 
pain models [76]. The existence of both inhibitory and facilitatory descending control from 
the RVM suggest that there are specific subset of RVM projection neurons that are in-
volved in inhibiting and facilitating spinal nociception. Indeed, electrophysiological studies 
have shown that there are so-called ON-cells in the RVM that have a net facilitatory effect 
on nociception [15], while a second group, designated as OFF-cells, have a net inhibitory 
effect on nociception [21]. Another group of cells, designated as neutral cells, did not 
show any characteristics of the ON- or OFF-cells activity pattern, and are most likely are 
not involved in modulating nociception [15, 47]. While the neutral cells were shown to 
contain serotonin [19, 62], it is not certain which neurotransmitters are used by the ON- 
and OFF-cells to induce facilitation and inhibition respectively. An electron microscopical 
study, combining anterograde tracing from the RVM to the spinal dorsal horn with im-
munohistochemistry for GABA and glycine has shown that there are projections from the 
brainstem that contain GABA and/or glycine (Gly/GABA) and likely originate in the RVM 
[3]. However, up to now the distribution pattern of these spinally projecting glycinergic 
and GABAergic neuronal somata in the RVM has not been identified. 
 In order for the RVM to change its activation pattern in response to nociceptive 
stimuli, it must receive information from the spinal cord [11, 2]. However, direct projec-
tions from the spinal cord to the RVM are limited [78], and it is assumed that the RVM 
receives most information from the spinal cord indirectly by projections from the PAG, 
or adjacent to the RVM located LPGi [6, 7, 74, 75]. However, a retrograde tracing study 
from the brainstem has shown that a spinal neurons in the area around the central canal 
[78] project to the RVM area, and that some of these neurons contain the neuropeptide 
enkephalin, which may have an inhibitory effect [55]. 
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 In the present study we have combined retrograde tracing with in situ hybridiza-
tion for GABA and glycine to identify the location of the Gly/GABA neurons in the RVM that 
project to the cervical and lumbar spinal cord. In addition, we have investigated whether 
the RVM received a projection from Gly/GABA neurons in the spinal cord. We found that 
Gly/GABA neurons in the area around the central canal project to the RVM, showing that 
there is a reciprocal inhibitory connection between the RVM and the spinal cord.   
2. Materials and methods
 In this study we used a total of 43 male Wistar rats. All animal experiments were 
approved by the Rotterdam Animal Ethical Committee. 
2.1. Tracer injections
 We used FluoSpheres (0.04 µm; molecular Probes, Eugene, OR), consisting of fluo-
rescent polystyrene micro spheres for retrograde tracing. For tracer injections in the spinal 
cord and the brainstem the rats were kept under general anesthesia with 2% isofluoran. 
For injections, a glass micropipette was used, and with each injections between 80 to 100 
nl of FluoSpheres tracer was injected. Further, after each injection the micropipette was 
left untouched for a period of 3 minutes in order to avoid regurgitation of the injected 
volume. All injections were made in the left side of the spinal grey matter or in the left side 
of the brainstem. After the operation the animals were returned to standard housing for a 
period of 25-28 days.
2.2. Spinal cord injections
 For identifying neurons in the RVM that project to the spinal cord, FluoSpheres 
was injected in the enlargement area of the lumbar segment or the cervical segment. 
First, laminectomy was performed at L4-L6 levels (lumbar injections) or at C4-C6 levels 
(cervical injections) of the spinal cord, producing an open area of approximately 3 mm 
with a visible dura mater. Next, the animal was fixed using stereotaxic instruments, and 
the posterior spinal vein was taken as the reference for the midline. In the lumbar spinal 
cord, injections were made between 0.7 and 0.9 mm lateral to the midline, and in the 
cervical spinal cord injections were made between 0.5 and 1.5 mm lateral to the midline. 
For injections in the lumbar dorsal horn (n = 7), the spinal cord was approached dorsally at 
an angle of 45 °, and the injections were made at of 0.5 and 0.9 mm deep into the spinal 
cord. For the ventral horn (n = 5), the spinal cord was approached in the lateral axis at an 
angle of ± 30 °, and the injections were at depths of 1.2 and 1.7 mm into the spinal cord. In 
the cervical spinal cord (n = 5), we did not differentiate between the dorsal and the ventral 
horn, and therefore the injections were made at different depths ranging between 0.5 and 
1.5 mm deep into the spinal cord at different lateral distances from the midline.  
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2.3. Brainstem injections
 The injections were made in the left rostral ventromedial medulla (RVM), encom-
passing the raphe magnus (RM), gigantocellular reticular nucleus (Gi) and lateral paragi-
gantocellular reticular nuclei (LPGi) (n = 6). The rostral part of the cervical vertebrae and 
the caudal part of the skull was revealed and laminectomy was performed. The sulcus in 
the medulla oblangata was taken as the reference for the midline. The injections were 
made at ± 1.6 mm rostral to the obex, between 0.4 and 1.0 mm lateral to the midline, and 
between 4.5 and 5.0 mm deep into the tissue. 
2.4. Tissue preparation
 After survival periods of 25-28 days, the rats received an overdose of sodium pen-
tobarbital, and were then transcardially perfused with 150 ml saline followed by 750 ml of 
4% paraformaldehyde (PFA). Thereafter, the spinal cord and the brainstem were dissected 
and incubated overnight at 4 °C in RNAse free solution consisting of phosphate buffer 
(PB), 4% PFA and 30% sucrose. Coronal sections were cut at 30 μm with a freezing mi-
crotome, collected in 9 separate jars and stored in a solution consisting of PB/formamide 
(50%/50%) at -20 °C. We did not use glycerol, since we had experienced that glycerol 
reduced the fluorescence intensity of the beads over time. This was not observed when 
sections were stored in PB/formamide solution. 
2.5. Fluorescent in situ hybridization
 Fluorescent in situ hybridization (FISH) was performed using the protocol de-
scribed in Hossaini et al. [29, 31] , using the same cDNA templates (GlyT2 cDNA: 3.1 kb; 
a generous gift from Dr. N. Nelson, Tel Aviv University; GAD67 cDNA: 3.2 kb; a generous 
gift from Dr. A.J. Tobin and N. Tillakaratne, PhD, UCLA) to produce the GlyT2 and GAD67 
mRNA probes. After riboprobe hybridization, as primary antibody we used sheep anti-
digoxigenin poly antibody (Roche) to identify digoxigenin. Subsequently, on the last day 
of the experiment the primary antibody was identified with biotinylated rabbit-anti-goat 
antibody (Vector). The subsequent steps in the procedure were performed as described in 
the previous protocol [29, 31]. 
2.6. Analyzing labeled neurons
 In rats with tracer injections in the RVM, we analyzed sections from the cervical, 
upper and lower parts of the thoracic, lumbar and sacral segments. Sections for analysis 
were chosen by starting in the first row of the randomly mounted sections and searching 
for sections from the appropriate segmental level (C4 to T5 for cervical and upper tho-
racic segments; T10 to S4 for lower thoracic, lumbar and sacral segments).  Per rat, 10-12 
sections for cervical and upper thoracic segments, and 10-12 sections for lower thoracic, 
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lumbar and sacral segments were analyzed in a Leica fluorescent microscope with a FITC 
and/or Cy3 filter. In rats with tracer injections in the cervical or lumbar spinal cord, sec-
tions from the caudal medulla at three levels that included the inferior olive nucleus (OI), 
sections from the pons at three levels ranging from caudal to rostral RVM were analyzed. 
 Labeling for GlyT2 and/or GAD67 mRNAs (FITC; greenish) was determined as neu-
ronal labeling if the staining was present in the cell soma and the shortest diameter was 
at least 10μm. In order to investigate colocalization of the FluoSpheres beads (apparent as 
red dots using a Cy3 filter) with GlyT2/GAD67 mRNAs (FITC) staining, first labeling for the 
tracer (red dots) was determined in a 40x objective. A neuron was counted as positive for 
tracer labeling if at least ten bright red dots were present in the soma. Then, in the same 
focus field, we determined whether there was labeling for GlyT2/GAD67 mRNA present in 
the cytoplasm. If in the same focus field, tracer labeling was present together with somatic 
GlyT2/GAD67 mRNA staining, the neuron was counted as a double labeled neuron. Single 
tracer positive neurons, and tracer positive neurons that also contained GlyT2/GAD67 
were plotted by hand in an illustrated representation of the appropriate segmental level. 
In the illustration used for spinal cord sections, the grey matter was divided in 10 laminae 
according to the laminar distribution in the rat [51]. For brainstem sections, we used sec-
tions from the rat brain illustrated in [61]. Per rat, the average numbers of tracer positive 
and tracer/Gly/GABA double labeled neurons was determined. Thereafter, we calculated 
the percentage of tracer positive neurons that also contained GlyT2 and/or GAD67 mRNA. 
Per group, the results on the numbers and the percentages were averaged and compared 
with the average results in the other groups. Errors in the variations were assessed as 
standard error of the mean (SEM). The unpaired t-test or one-way ANOVA with a Bonfer-
roni post-hoc test was performed for statistical comparison between groups. p<0.05 was 
taken as significant.
3. Results
3.1 General observations
 Inhibitory neurons, i.e. neurons that use either glycine or GABA or both transmit-
ters, were labeled by applying fluorescent in situ hybridization (FISH) with a mixture of 
GlyT2 mRNA and GAD67 mRNA (GlyT2/GAD67) probes, resulting in labeling of glycinergic 
and/or GABAergic (Gly/GABA) neurons  (Fig. 1 and Fig. 6). We also applied FISH with only 
GlyT2 (for identifying glycinergic neurons) and with only GAD67 (for identifying GABAer-
gic neurons) probes, in order to reveal any differences between these two population of 
inhibitory neurons. FISH was applied on sections from the spinal cord and the brainstem, 
and as a result we found greenish labeled neuronal somata of various sizes. The distribu-
tion pattern of the labeled neurons, i.e. glycinergic and/or GABAergic, in the spinal cord 
and the brainstem was in accordance with previous findings [30, 44, 69, 82]. 
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 After injection of fluorescent microspheres in different parts of the spinal cord, 
we found retrogradely labeled neurons of various sizes in the brainstem (Fig. 1). Bright red 
dots, representing the retrogradely transported microspheres, were present in the soma-
ta and primary dendrites of the labeled neurons. The number of red dots varied between 
the labeled neurons. Similar labeling characteristics were found for retrogradely labeled 
neurons in the spinal cord after injection of fluorescent microspheres in the brainstem 
(Fig. 6).   
Fig. 1: Fluorescence micrographs showing retrogradely (red) labeled neurons, and neurons that contain GlyT2/
GAD67 mRNA. A: Gly/GABA (GlyT2+GAD67 mRNA) neurons in the rostral RVM projecting to the lumbar dorsal 
horn. B: Gly/GABA neurons in the caudal RVM projecting to the ventral lumbar horn. C: Gly/GABA neurons at 
the caudal Olive Inferior level projecting to the lumbar ventral horn. D: Gly/GABA neurons at the rostral Olive 
Inferior level projecting to the cervical spinal cord (dorsal+ventral). E: Glycinergic (GlyT2 mRNA) neurons in the 
caudal RVM projecting to the cervical spinal cord (dorsal+ventral). Arrows indicate projections neurons that 
also contained GlyT2 and/or GAD67 mRNA. Scale bar = 50µm
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3.2. Projections to the cervical spinal cord
3.2.1. Description of injection sites
 For this experiment we injected fluorescent microspheres in the cervical spinal 
enlargement, i.e. C5 and C6. Several injection were made unilaterally in the dorsal as well 
as the ventral horn, encompassing both the medial and lateral parts of the horn (Fig. 2A). 
In addition, we found also fluorescent microspheres present in the laterodorsal and ven-
tral white matter.
3.2.2. Projections from the caudal medulla to the cervical spinal cord
 In the caudal medulla we analyzed retrogradely labeled neurons that were lo-
cated in the following nuclei: raphe pallidus (RP), raphe obscures (ROB), medial reticular 
formation (MRF), gigantocellular reticular nucleus (Gi), the ventral part of Gi (GiV), and 
the lateral paragigantocellular nucleus (LPGi), ranging from the caudal to the rostral part 
of the olive nucleus inferior (OI). We found that 76% of the total number of retrogradely 
labeled neurons were located on the side ipsilateral to the injection sites in the spinal 
cord. Further, our data showed that 19% ± 3 of the retrogradely labeled neurons on the 
ipsilateral side also contained GAD67 mRNA, 15% ± 5 contained GlyT2 mRNA, and 18% ± 
4 contained GlyT2/GAD67 mRNA. Similar results were found for neurons located on the 
contralateral side. There were no significant differences in the percentages obtained for 
the different mRNA probes (p > 0.1, ANOVA).
3.2.3. Projections from the RVM to the cervical spinal cord
 We analyzed sections from the pons ranging from caudal to rostral parts of the 
RVM area, which included the midline nucleus raphe magnus (RM), RP, part alpha of the Gi 
nucleus (GiA), part alpha of the LPGi nucleus (LPGiA), and the external part of LPGi (LPGiE). 
Our data showed that 87% ± 3 of the total retrogradely labeled neurons in the RVM were 
located on side ipsilateral to the injections. Further, about 60% of the retrogradely labeled 
neurons were located in the RM + GiA, while the remaining 40% was found in the LPGiA 
and LPGiE. We found on the ipsilateral side that 40% ± 6 of the neurons projecting to the 
spinal cord contained also GlyT2/GAD67 mRNA. However, the percentage of retrogradely 
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labeled neurons on the ipsilateral side that also contained GAD67, GlyT2, or GlyT2/GAD67 
mRNA was significantly higher in the RM and GiA as compared to the LPGiA and LPGiE (p < 
0.05, unpaired t-test) (Fig. 2B). This difference between these subgroups of nuclei was not 
found for retrogradely labeled neurons that were Gly/GABA located on the contralateral 
side (Table 1A).
     Fig. 2A    Fig. 2B
Fig. 2: A: Illustrations showing the injection sites of fluorescent microspheres in the cervical sections of two 
different rats. B: Histogram showing the percentage of RVM neurons projecting to the cervical spinal cord 
that also contained GlyT2 and/or GAD67 mRNA. RM: nucleus Raphe Magnus; LPGi: lateral paragigantocellular 
reticular nuclei; GiA: gigantocellular reticular nucleus pars Alpha. *=P<0.05.
3.3. Projections to the lumbar spinal cord
 In the analysis of the results, we found that the majority of the retrogradely la-
beled neurons (>77%) were located in the RM and the GiA (RM + GiA) when compared to 
LPGiA + LPGiE. This was true for the ipsilateral and contralateral side of the RVM. We then 
analyzed the percentages of retrogradely labeled neurons that also contained GlyT2 and/
or GAD67 mRNA, and found no differences in the percentages between RM + GiA nuclei 
and the LPGiA + LPGiE nuclei in contrast to the cervical spinal cord. Therefore, in the de-
scription of the results below we combined the results on these nuclei (RM + GiA + LPGiA 
+ LPGiE) on each side, and refer them as the RVM.
3.3.1. Description of injection sites
 For this experiment we injected fluorescent microspheres either in the dorsal or 
ventral horn of the lumbar spinal cord, ranging from L4 to L6 segments (Fig. 3). With re-
spect to the dorsal horn, injection sites included laminae I to VI, and in some cases the 
dorsal and/or lateral white matter. In the ventral horn, the injections were found in lami-
nae VII to IX, and in the ventrolateral and lateral parts of the white matter.
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3.3.2. Projections from the caudal medulla to the lumbar dorsal horn and the ventral 
horn
 For projections to the dorsal horn we found the highest number of tracer labeled 
and tracer/Gly/GAD labeled neurons in the rostral IO sections (Table 1B), while for pro-
jections to the ventral horn the highest numbers were found in the mid and rostral IO 
sections (Table 1C). We found that 8% ± 1 of the retrogradely labeled neurons projecting 
to the dorsal horn also contained GAD67, 7% ± 2 contained GlyT2, and 5% ± 1 contained 
GlyT2/GAD67  (Table 1B). With respect to the neurons projecting to the ventral horn of 
the spinal cord, we found that 8% ± 1 of the retrogradely labeled neurons also contained 
GAD67, while significantly higher percentages were found for colocalization with GlyT2 
(19% ± 3) and  GlyT2/GAD67 (19% ± 3) (p<0.05, ANOVA) (Table 1C). These percentages 
were significantly higher than the percentages for projections to the dorsal horn (p<0.05, 
ANOVA)
Table 1: A: numbers represent the percentage of neurons on the contralateral side of the RVM that projected 
to spinal cord that also contained GlyT2 and/or GAD67 mRNA. B: The number and the percentage of neurons 
on the ipsi- and contralateral side of the caudal medulla that projected to the dorsal lumbar spinal cord and 
also contained Gly2 and/or GAD67 mRNA. C: The number and the percentage of neurons on the ipsi- and 
contralateral side of the caudal medulla that projected to the ventral lumbar spinal cord and also contained 
Gly2 and/or GAD67 mRNA. 
 Table 1A
 
Table 1B
Table 1C
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Fig. 3: Illustrations showing the injection sites of fluorescent microspheres in the lumbar dorsal horn, and 
in the lumbar ventral horn of two different rats for each horn. 
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3.3.3. Projections from the RVM to the lumbar dorsal horn
 In total, we counted 1082 retrogradely labeled neurons for colocalization with 
GlyT2 (n=340), GAD67 (n=338), and GlyT2/GAD67 (n=404) mRNA. Further, 77% ± 2 of the 
RVM neurons that were retrogradely labeled from the lumbar dorsal horn were located 
on side ipsilateral to the injection. Applying FISH with GlyT2/GAD67 mRNA probes showed 
that 49% ± 3 of the retrogradely labeled neurons in the ipsilateral RVM also contained 
GAD67 mRNA, 39% ± 6 contained GlyT2 mRNA, and 43% ± 4 contained GlyT2/GAD67 
mRNA (Fig. 4A). These percentages were not significantly different from each other, in-
dicating that the neurons projecting from the RVM to the lumbar dorsal horn use both 
glycine and GABA as their neurotransmitters.
       Fig. 4A               Fig. 4B
 
Fig. 4: Histograms showing the percentage of RVM neurons that project to the lumbar dorsal (A) or the ventral 
(B) horn and also contained Gly2 and/or GAD67 mRNA. Note that there were no significant differences in the 
percentages of projections neurons that contained GlyT2, GAD67, or GlyT2/GAD67 mRNA for projections to 
the dorsal and the ventral horn. 
 Therefore, when combining the three percentages, our data showed that 44% ± 3 
of the neurons projecting to the dorsal horn are inhibitory. Similar percentages for double 
labeling were found for projection neurons located on the contralateral side of the RVM 
(Table 1A).
3.3.4. Projections from the RVM to the lumbar ventral horn
 A total 1443 retrogradely labeled neurons were counted for colocalization with 
GlyT2 (n=308), GAD67 (n=631) and GlyT2/GAD67 (n=504). Similar to the projections to the 
dorsal horn, we found that 76% ± 2 of the RVM neurons that were retrogradely labeled 
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with tracer were located on side ipsilateral to the injections in the spinal cord. Our data 
showed that on the ipsilateral side 40% ± 3 of the retrogradely labeled neurons contained 
GAD67 mRNA, 34% ± 3 contained only GlyT2 mRNA, and 35% ± 3 contained only GlyT2/
GAD67 mRNA (Fig. 4B). Similar to the projections to the lumbar dorsal horn, we found no 
significant differences between the percentages indicating that the neurons projecting to 
the lumbar dorsal horn use both glycine and GABA as their neurotransmitters. Therefore, 
when combining the three percentages, our data showed that 36% ± 0.8 of the neurons 
projecting to the ventral horn are inhibitory. Similar results were found for projection neu-
rons on the contralateral side of the RVM (Table 1A).
 When comparing the percentages of RVM neurons that also contained GAD67, 
GlyT2, GlyT2/GAD67 between the  projections to the dorsal horn and the ventral horn, we 
found no differences in the percentages (p > 0.1, unpaired t-test for each mRNA) between 
them.
3.4. Inhibitory spinal neurons projecting to the RVM
3.4.1. Description of injection sites
 For this experiment, fluorescent microspheres were injected in the midline 
in the RVM area. We found that many of the injections included the pyramid tract, 
the RM nucleus, the RP nucleus, and the medial part of the LPGi nucleus (Fig. 5).
Fig. 5: illustrations showing the injection sites of fluorescent microspheres in the rostral ventromedial medulla 
(RVM) area for three different rats (yellow, blue, red). The injection areas include the raphe magnus nucleus, 
the lateral paragigantocellular reticular nucleus, and the raphe pallidus and raphe obscurus nuclei. 
3.4.2. Lumbo-sacral spinal cord
 Our data showed that a significantly higher percentage of retrogradely labeled 
neurons was located on the side contralateral (59% ± 2) to the injections in the RVM in 
comparison with the ipsilateral side (41% ± 2) (p < 0.005, unpaired t-test). Further, the 
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majority of the retrogradely labeled neurons were located in the area around the central 
canal (91% ± 2 on the ipsilateral side; 90% ± 1 on the contralateral side), which included 
lamina X and the medial parts of laminae VI, V, VI,  and VII. With respect to this population 
of retrogradely labeled neurons, when FISH was applied (Fig. 6) we found that on the con-
tralateral side 22% ± 3 of these neurons also contained GlyT2/GAD67 (Fig. 7A). This per-
centage was not different from the percentages of retrogradely labeled neurons that also 
contained only GlyT2, or GAD67, or from the percentages obtained for neurons located on 
the ipsilateral side (Fig. 7A). Further, very few double labeled retrogradely labeled neurons 
were found in the lateral spinal nucleus (LSN), and in the white matter lateral to laminae 
III, IV and V. Our findings indicate that the inhibitory spinal neurons that project to the 
RVM are predominantly located in the area around the central canal, and use both glycine 
and GABA as their neurotransmitters.
3.4.3. Cervico-thoracic spinal cord
 We found that the neurons projecting to the RVM were equally distributed on 
the ipsilateral (45% ± 3) and contralateral (55% ± 3) side to the tracer injections in the 
RVM. Similar to the projection neurons in the lumbar spinal cord, the majority of neurons 
projecting to the RVM were located in the area around the central canal (95% ± 1 for ipsi-
lateral; 93% ± 2 for contralateral). With respect to this population of retrogradely labeled 
neurons, our data showed on the ipsilateral side 21% ± 4 of these neurons also contained 
GlyT2/GAD67 (Fig. 7B). Similar percentages were found for colocalization with only GlyT2, 
or GAD67, and they were all not different from the percentages obtained for neurons 
located on the contralateral side (Fig. 7B). Further, very few double labeled retrogradely 
labeled neurons were found in the lateral spinal nucleus (LSN), and in the white matter 
lateral to laminae III, IV and V.
3.4.4. Cervico-thoracic vs. Lumbo-sacral spinal cord
 Finally, when we compared the results on the lower spinal cord with the results on 
the upper spinal cord, we found no significant differences between these segments with 
respect to the percentages of retrogradely labeled neurons that also contained GlyT2 and/
or GAD67. Thus, the RVM receives projections from inhibitory neurons that are located 
in the cervical, thoracic, and lumbar spinal cord, and use both glycine and GABA as their 
neurotransmitters.
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Fig. 6: Fluorescence micrographs showing retrogradely labeled neurons that project to the RVM area, and 
neurons that are labeled for GlyT2 and/or GAD67 mRNA (green). Arrows indicate neurons that project to the 
RVM area and also contain GlyT2 and/or GAD67 mRNA. A: FISH with GlyT2 mRNA at cervical C5 level. B + C: 
FISH with GlyT2+GAD67 mRNA at lumbar L6 level. D: FISH with GlyT2+GAD67 mRNA at lumbar L4 level. E: FISH 
with GlyT2+GAD67 mRNA at lumbar L5 level. Scale bar = 50µm.
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      Fig. 7A        Fig. 7B
Fig. 7: Histograms showing the percentage of retrogradely labeled spinal neurons in the area around the cen-
tral canal that project to the RVM and also contain GlyT2 and/or GAD67 mRNA (Gly/GABA). A: Percentage of 
projection neurons that are Gly/GABA in the lower thoracic, lumbar and sacral spinal cord. B: Percentage of 
projection neurons that are Gly/GABA in the cervical and upper thoracic spinal cord. Note that there were no 
significant differences were found in the percentages of GlyT2, GAD67, and GlyT2/GAD67 mRNA containing 
projections neurons in the sacral, lumbar, thoracic and cervical spinal segments.
4. Discussion
 In the present study we have used a combination of retrograde tracing with fluo-
rescent microspheres and ISH for GlyT2 and GAD65 to identify glycinergic and  GABAer-
gic neurons, respectively. Using this technique we investigated the distribution pattern of 
neuronal somata that project to the spinal cord  and contain glycine and/or GABA (Gly/
GABA) in the ventral part of the caudal medulla at the levels of inferior olive (OI), and 
in the rostrally adjoining RVM area. Our results showed that the percentage of neurons 
that were Gly/GABA was higher for spinal projections from the RVM as compared to the 
projections from the OI level. RVM neurons that projected to the cervical spinal cord were 
on average Gly/GABA in 40% of the cases, while this percentage was 43% for projections 
to the lumbar dorsal and 35% for the projections to the lumbar ventral horn. The per-
centages obtained for GABA and glycine separately were very similar to those obtained 
for Gly/GABA, indicating that virtually all inhibitory RVM neurons projecting to the spinal 
cord use both glycine and GABA as their neurotransmitters. In addition, we have shown 
the existence of spinal Gly/GABA neurons in the area around the central canal that have 
ascending projections to the RVM. 
 For the identification of neurons in de caudal medulla and RVM projecting to the 
spinal cord and vice versa, we used fluorescent microspheres as a retrograde tracer. This 
technique has been shown to be highly efficient for retrograde tracing and is taken up by 
terminals rather than by intact passing fibers [40]. In the spinal cord our injection sites 
also encompassed parts of the white matter. However it is unlikely that passing fibers have 
taken up tracer, since damage in the white matter was minimal. The same holds true for 
injections in the RVM. In this case damaged passing fibers in the injection site may have 
been present, although the major tracks run outside the injection site, except for the pyra-
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midal tract, but this tract will not label neurons in the spinal cord. The injection sites in the 
spinal cord varied in size, but always included the major part of the dorsal and ventral spi-
nal gray matter for the cervical injections. The lumbar injections in the dorsal horn never 
included the ventral horn, and the lumbar injections in the ventral horn, which were made 
under an angle, never included the dorsal horn. Therefore the dorsal and ventral horn in-
jections were completely separated. There were differences in the number of retrogradely 
labeled cells that were obtained for the different injections, which may be explained by 
differences in the rostro-caudal extent of the injections. The distribution pattern was in 
line with previous studies [5, 23, 24, 26, 36, 80] and the number of neurons that we found 
were comparable to a similar retrograde tracing study, using different tracers [43]. The 
injections in the RVM area always included the RVM bilaterally, but varied with respect 
to the medio-lateral, dorso-ventral and rostro-caudal extent. However the pattern of the 
retrogradely labeled cells in the spinal cord was always similar and in line with previous 
studies using retrograde tracing from the RVM [10].
 
 
 For identifying Gly/GABA neurons we applied FISH with GlyT2 and GAD67 mRNA 
probes, a previously described approach [29, 30] that results in reliable labeling of glycin-
ergic (i.e. containing GlyT2 mRNA) [44, 63] and GABAergic (i.e. containing GAD67 mRNA) 
neuronal somatas [12, 41]. Previous studies showed that labeling glycinergic neuronal so-
mata by means of IHC is difficult as it results in weak soma labeling and intense terminal 
labeling [9, 64, 71]. We have overcome these problems by using ISH for GlyT2 for the label-
ing of glycinergic neuronal somata [30].
 Previous studies [3, 38, 65] have shown that the descending projections from the 
RVM to the spinal cord contain GABA. In the present study we have confirmed this find-
ing and further showed that the percentages of RVM neurons projecting to the spinal 
cord that were only glycinergic, only GABAergic or contained GABA and/or glycine were 
not statistically different, indicating that in the RVM projections to the spinal cord that 
contain GABA, also contain glycine. The Gly/GABA projections to the dorsal horn and to a 
lesser extent those to the ventral horn showed some differences in the percentages of the 
RVM neurons that were Gly/GABA when comparing projections to the lumbar dorsal horn 
(43%), lumbar ventral horn (35%) , and the cervical spinal cord (40%). However these dif-
ferences were not statistically significant. This finding is in line with the non-topographic 
organization of the RVM projections to the spinal cord, since it has been shown that there 
is a high level of intersegmental and dorsoventral collateralization of bulbospinal projec-
tion neurons [43]. In addition we did not find any differences in the percentages of Gly/
GABA neurons when comparing the ipsilateral and contralateral side, although the num-
ber of retrogradely labeled neurons was higher on the ipsilateral than on the contralateral 
side. This finding is also in line with the diffuse character of the organization of the de-
scending projections from the RVM to the spinal cord [43].
 With respect to the functional meaning of the RVM projection to the dorsal horn, 
most studies have focused on the effects on the dorsal horn. The RVM descending control 
on the spinal cord is a parallel system that facilitates and inhibits spinal nociception de-
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pending on the type of nociceptive stimulus [22, 76, 77]. The facilitatory effect is exerted 
by the physiologically characterized ON cells [17, 22, 58], and the same effect is achieved 
by the neuropeptide transmitters cholecystokinin [42, 73], neurotensin [58, 67, 73, 72], 
which may therefore be contained within the ON cells. The inhibitory effect of the RVM 
is mainly produced by the physiologically characterized OFF cells [14, 17, 22]. For a long 
time it was believed that serotonin was the transmitter in the RVM descending pathways 
that inhibited spinal nociception [20, 34, 37, 46]. However, serotonin also facilitates noci-
ception [60], and that all serotonergic cells recorded in vivo in the RVM are characterized 
as neutral cells [19, 62]. Further, it has been shown that the activity of the RVM neurons, 
especially the serotonergic neurons, are determined by the animal’s state, i.e. level of 
arousal or stage of sleep [18], and that the activity of serotonergic neurons might modu-
late the effect of the OFF and ON cells on spinal nociception [18, 46]. However, it is still 
unclear which neurotransmitters the ON and OFF cells use to exert their effect. In the pres-
ent study, we have shown that 43% of the neurons projecting to the spinal dorsal horn are 
inhibitory, suggesting that glycine and GABA are at least partly responsible for descending 
inhibition on spinal nociception. Indeed, several studies have shown the relation of RVM 
stimulation with antinociception exerted by GABAergic and glycinergic neurotransmission 
in the dorsal horn [49, 50, 68]. Further, there is evidence that serotonin and GABA are co-
localized in RVM projection neurons [8, 25], and recently a subpopulations of GABAergic 
OFF and ON cells have been identified [52]. Also in vivo patch-clamping of the substantia 
gelatinosa of the spinal cord showed the existence of monosynaptic inhibitory potentials 
by GABA and glycine after electrical stimulation of the RVM [39]. Taken together, there is 
strong evidence for the presence of Gly/GABA in the descending RVM pathways as repre-
sented by the physiologically characterized OFF cells.  
 In the present study we have shown that 90% of the neurons projecting to the 
RVM are located in the area around the central canal (CC), and that about 20% of these 
projections neurons contain glycine as well as  GABA. This pathway is the only projection 
from the spinal cord to a supraspinal structure (i.e. the RVM area) that contains the fast in-
hibitory transmitters GABA and glycine. Using anterograde tracing, neurons located in the 
CC area, have been shown to have direct projections, albeit limited, to the RVM and the 
area adjacent to the RVM, via the ventrolateral funiculus in the spinal cord [78]. Since the 
injections that we made in the RVM also encompassed the area immediately adjacent to 
the RVM, the retrogradely labeled neurons in the CC area may also terminate in this area. 
Within the same spinal area around the CC there are also neurons that use enkephalin 
and dynorphin [55] that project to supraspinal sites including the RVM. It is therefore not 
excluded that enkephalin is also present in the Gly/GABA neurons that project to the RVM 
[33]. Many neurons in the CC area have been identified to respond to innocuous and nox-
ious stimuli from the periphery and viscera [27, 28, 54, 56, 57]. This strongly suggests that 
the neurons in the CC area are involved in the processing and transmission of sensory and 
especially visceral nociceptive information [1, 13, 32]. It is not clear whether the inhibitory 
neurons in the CC area respond to peripheral and visceral noxious stimuli and whether the 
ascending inhibitory projections are also involved in inhibiting the OFF, ON or neutral cells 
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in the RVM. 
 In conclusion, we have shown a many neurons in the RVM and the caudal medulla 
that contain both GABA and glycine and project to the dorsal and ventral horn of the spi-
nal cord. It seems likely that these inhibitory projections to the dorsal horn are involved in 
the inhibition of pain transmission in the spinal cord and thus represent the physiological-
ly characterized OFF cells. We also have shown the existence of a more limited projection 
that contains GABA and glycine, originating from the CC area and terminating in the RVM 
area. Whether these neurons are involved in regulating the activity of the (inhibitory) 
descending RVM neurons, thereby indirectly modulating spinal nociception remains to be 
determined.
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Nociceptive stimulation induces expression of
Arc/Arg3.1 in the spinal cord with a preference
for neurons containing enkephalin
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Abstract
Background: In pain processing, long term synaptic changes play an important role, especially during chronic
pain. The immediate early gene Arc/Arg3.1 has been widely implicated in mediating long-term plasticity in
telencephalic regions, such as the hippocampus and cortex. Accordingly, Arc/Arg3.1 knockout (KO) mice show a
deficit in long-term memory consolidation. Here, we identify expression of Arc/Arg3.1 in the rat spinal cord using
immunohistochemistry and in situ hybridization following pain stimuli.
Results: We found that Arc/Arg3.1 is not present in naïve or vehicle treated animals, and is de novo expressed in
dorsal h rn neurons after nociceptive stimulation. Expression of Arc/Arg3.1 was induced in an intensity dependent
manner in neurons that were located in laminae I (14%) and II (85%) of the spinal dorsal horn. Intrathecal injection
of brain derived neurotrophic factor (BDNF) also induced expression of Arc/Arg3.1. Furthermore, 90% of Arc/Arg3.1
expressing neurons also contained the activity marker c-Fos, which was expressed more abundantly.
Preproenkephalin mRNA was found in the majority (68%) of the Arc/Arg3.1 expressing neurons, while NK-1 was
found in only 19% and GAD67 mRNA in 3.6%. Finally, pain behavior in Arc/Arg3.1 KO mice was not significantly
different from their wild type littermates after application of formalin or after induction of chronic inflammatory
pain.
Conclusions: We conclude that Arc/Arg3.1 is preferentially expressed in spinal enkephalinergic neurons after
nociceptive stimulation. Therefore, our data suggest that Arc/Arg3.1 dependent long term synaptic changes in
spinal pain transmission are a feature of anti-nociceptive, i.e. enkephalinergic, rather than pro-nociceptive neurons.
Background
The experience of pain is usually initiated by the acti-
vation of nociceptors, which are the peripheral termi-
nations of nociceptive ganglion neurons. The central
projections of these neurons enter the dorsal horn of
the spinal cord to terminate on second order neurons
[1]. After strong nociceptive stimulation these neurons
may show an enhanced responsiveness to afferent
inputs, which may last for several hours [2-4]. The
mechanism underlying this enhanced responsiveness is
similar to that of long-term potentiation (LTP) [5],
which is a form of activity dependent plasticity that
has been investigated extensively in other parts of the
CNS, especially in the hippocampus [6]. Another form
of activity dependent plasticity is long-term depression
(LTD), a state of decreased sensitivity of neurons.
Whether LTP or LTD is produced in the spinal noci-
ceptive system depends on many variables, including
the type of activity in nociceptive afferents [2]. For
long term changes to become persistent it is essential
that activity regulated genes, including immediate early
genes (IEG), orchestrate a cascade of transcriptions
and subsequent protein synthesis [7]. The first IEG
that was found to be strongly increased in spinal neu-
rons after a nociceptive stimulus is c-Fos [8]. This IEG
is now widely used for the identification of activated
nociceptive neurons [9]. Other IEGs that have been
implicated in plastic changes are c-Jun, Jun-d, Krox 24
and Homer 1a [10,11]. Recently it has become clear
that in cortex, hippocampus and other higher brain
centers, the IEG named Arc/Arg3.1 (activity regulated
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centers, the IEG named Arc/Arg3.1 (activity regulated
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cytoskeleton-associated protein/activity regulated gene
3.1) plays a crucial role in activity dependent synaptic
plasticity [12]. Moreover, Arc/Arg3.1 is critically
involved in processes essential for synaptic structural
rearrangement such as LTP, LTD and homeostatic
scaling of AMPA receptors [13,14]. These mechanisms
are also essential in spinal processing [15], and dys-
functional forms of activity dependent plasticity such
as LTP and LTD that lead to persistent changes in
neuronal sensitivity, may underlie chronic pain disor-
ders [16]. Therefore, in this study we set out to investi-
gate the role of Arc/Arg3.1 in nociceptive processing
in the spinal cord.
Our findings show that Arc/Arg3.1 is not expressed at
detectable levels in naïve spinal cord. However, after
peripheral nociceptive stimulation we found de novo
expression of Arc/Arg3.1 in a limited number of neu-
rons in the superficial dorsal horn, depending on the
type of stimulus. Further, Arc/Arg3.1 is predominantly
expressed in spinal interneurons located in lamina II
and many of these neurons also contain the opioid neu-
rotransmitter enkephalin. Finally, we found that the pain
behavior in Arc/Arg3.1 knockout (KO) mice after noci-
ceptive stimuli was not significantly different from their
wild type (WT) littermates.
Results
General observations
In the spinal cord of naïve rats and mice there was no
detectable expression of Arc/Arg3.1 mRNA or protein
when using in situ hybridization (ISH) and immuno-
histochemistry (IHC), respectively. However, after
application of a peripheral nociceptive stimulus to the
hind paw, Arc/Arg3.1 was expressed in a limited num-
ber of cells in the superficial layers of the lumbar dor-
sal horn. ISH using the alkaline phosphatase (AP)
reaction produced a bluish/brownish reaction product
in the cytoplasm and in some occasions in the nucleus
and primary dendrites of Arc/Arg3.1 mRNA expressing
neurons (Fig. 1A,B). Arc/Arg3.1 protein, visualized by
bright field IHC, was present primarily in the cyto-
plasm, occasionally combined with nuclear labeling or
labeling in proximal dendrites (Fig. 1C). Applying
fluorescent IHC for Arc/Arg3.1 protein produced very
similar labeling characteristics. In order to ascertain
that Arc/Arg3.1 is expressed in neurons rather than in
glial cells, we combined FISH for Arc/Arg3.1 mRNA
with fluorescent IHC for NeuN, which is a specific
marker for neuronal cells (Fig. 1D). It was found
that 95% ± 1.3 (SEM) of the cells expressing Arc/
Arg3.1 mRNA also expressed NeuN (99% ± 0.4 for
Figure 1 Arc/Arg3.1 is only expressed in the superficial dorsal horn. Light micrographs showing the distribution of neurons expressing Arc/
Arg3.1 mRNA (A, B) or protein (C) in the rat spinal dorsal horn after peripheral stimulation with 25% mustard oil gauze wrapped around one
hind paw for 2 hours. Note that many of the Arc/Arg3.1 labeled neurons are located in laminae I&II, and very few labeled neurons are present
below lamina II. D, Fluorescent micrograph showing the expression of Arc/Arg3.1 mRNA and its colocalization with the neuronal marker NeuN.
Arrowheads indicate Arc/Arg3.1 mRNA and NeuN double labeled neurons. Scale bar: 50 μm (A and D); 25 μm (B); 100 μm (C).
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25% MO/1 h, n = 4; 95% ± 3.3 for 25% MO/2 hrs, n =
5; 94% ± 2.8 for CFA for 1.5 hrs, n = 4).
For both ISH and IHC, we observed that the intensity
of the labeled neurons varied in a single section. We did
not observe any labeling indicative of localization of
Arc/Arg3.1 in intermediate or distal dendrites. Although
labeling patterns obtained with ISH and IHC were iden-
tical, labeling efficiency was higher for ISH than for
IHC. Therefore, ISH was used for the quantification of
neurons expressing Arc/Arg3.1. The specificity of our
detection techniques was assessed by omitting the
probes/primary antibodies in the ISH and IHC proce-
dures, respectively, and by applying ISH and IHC on
spinal tissue of Arc/Arg3.1 KO mice. These experiments
did not show any labeling in the spinal cord. ISH per-
formed on cortex of naïve rats showed Arc/Arg3.1
mRNA labeling in the cortex and the hippocampus as
previously reported [17].
Distribution and quantification of Arc/Arg3.1 mRNA
expressing neurons in the spinal cord following
nociceptive stimulation
Several types of nociceptive stimuli applied to the hind
paw induced Arc/Arg3.1 mRNA expressing neurons on
the ipsilateral side (Fig. 2) but not on the contralateral
side of the lumbar superficial dorsal horn. A single sub-
cutaneous injection of capsaicin resulted in the lowest
average number of labeled neurons per section (2.6 ± 0.6
SEM, n = 6), while wrapping the paw in a gauze soaked
with 25% mustard oil (MO) for 2 hrs induced the highest
number of neurons (50 ± 3.5 SEM, n = 5). On average,
lamina II accounted for 85% ± 3.5 of the labeled neurons,
while lamina I (14% ± 3.2) and III (0.6% ± 0.4) contained
the remaining labeled neurons. The other laminae very
rarely contained labeled neurons.
Expression of Arc/Arg3.1 mRNA following nociceptive
stimulation occurs in a subset of c-Fos labeled neurons
and is intensity dependent
The number of neurons expressing the neuronal acti-
vation marker c-Fos or Arc/Arg3.1 mRNA was
counted in separate sections treated with IHC or ISH,
respectively. c-Fos labeled neurons outnumbered Arc/
Arg3.1 mRNA labeled neurons (Fig. 3A), except after 2
hrs mustard oil stimulation when about equal number
of neurons were labeled. FISH and fluorescent IHC
were applied to simultaneously visualize Arc/Arg3.1
mRNA and c-Fos protein, respectively (Fig. 3B). When
data from the 25% mustard oil and the CFA groups
were taken together (Fig. 3C), 90% ± 6.8 of the Arc/
Arg3.1 mRNA expressing neurons also contained c-Fos
protein. In order to determine whether the number of
Arc/Arg3.1 expressing neurons was stimulus intensity
dependent, rats received a single application (by brush)
of either 10% (n = 5) or 50% (n = 5) mustard oil on
one hind paw. It was found that 50% MO induced sig-
nificantly higher numbers of Arc/Arg3.1 mRNA posi-
tive neurons that 10% mustard oil (Fig. 4A). The
number of c-Fos labeled neurons showed a similar sig-
nificant increase.
Temporal expression of Arc/Arg3.1 mRNA in an acute and
a chronic pain model
As a model for acute pain, 25% MO soaked gauze was
wrapped around one hind paw, with survival times
ranging from 25 min to 8 hrs. The number of Arc/
Arg3.1 mRNA expressing neurons increased over time,
reached a peak at 4 hours and then declined (Fig. 4B).
The distribution of labeled neurons remained
unchanged over time. As a model for chronic pain
CFA was injected in the hind paw, with survival times
ranging from 1.5 hrs to 60 hrs. Temporal expression of
Arc/Arg3.1 mRNA was highest at 1.5 hrs post injection
and then gradually declined (Fig. 4C). No expression of
Arc/Arg3.1 mRNA was found at survival times of 10
hrs and longer. The number of c-Fos expressing neu-
rons was increased at all survival times. In the spared
nerve injury (SNI) model for neuropathic pain, expres-
sion of Arc/Arg3.1 mRNA was only observed at two
hours after the operation. Arc/Arg3.1 mRNA was not
expressed 1 week or 2 weeks after the operation (not
shown) when the neuropathic pain symptoms, i.e.
mechanical and thermal hyperalgesia and allodynia,
had developed. There was no significant difference in
the number of Arc/Arg3.1 mRNA labeled neurons
between the SNI and sham operated group (p>0.05,
unpaired t-test) (Fig. 4D).
Figure 2 Several types of nociceptive stimuli induce Arc/Arg3.1
mRNA in the ipsilateral superficial dorsal horn. Histogram
showing the number of Arc/Arg3.1 mRNA labeled neurons after
each specific nociceptive stimulus. Error bars represent ± SEM.
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Arc/Arg3.1 mRNA is expressed in specific subpopulations
of dorsal horn neurons
In this experiment, the colocalization of Arc/Arg3.1
with various neuronal markers was investigated (Fig.
5A-E). We found that about a fifth of Arc/Arg3.1
mRNA positive neurons also express the NK-1 recep-
tor (CFA 1.5 hrs: 21.7% ± 7.6, n = 4; MO25%/2 hrs:
17% ± 3.4, n = 5) (Fig. 6). Less than 10% of Arc/
Arg3.1 mRNA expressing neurons also expressed PKC-
g protein (CFA 1.5 hrs: 7.7% ± 3.7, n = 4; MO25%/1h:
9.3% ± 3.8, n = 4). Further, Arc/Arg3.1 mRNA expres-
sing neurons showed a low level of co-existence with
calbindin (CFA 1.5 hrs: 9.7% ± 1.4, n = 4; MO25%/1h:
10.5% ± 2.6, n = 4).
In order to identify Arc/Arg3.1 in inhibitory neurons,
FISH for GAD67 mRNA, the specific marker for
GABAergic neurons, and fluorescent IHC for Arc/
Arg3.1 protein were combined. Very few of the Arc/
Arg3.1 labeled neurons were GABAergic (CFA 3 hrs:
1.7% ± 0.8, n = 4; MO25%/2 hrs: 4.5% ± 0.8, n = 5;
MO25%/4 hrs: 4.5% ± 1.5, n = 4) (Fig. 6). Preproenke-
phalin mRNA is a marker for the subpopulation of
enkephalinergic neurons in the spinal cord. Interestingly,
a large majority of the Arc/Arg3.1 positive neurons also
expressed preproenkephalin mRNA (CFA 3 hrs: 74.2% ±
9.2, n = 4; MO25%/2 hrs: 61.5% ± 2.6, n = 4; MO25%/4
hrs: 68.1% ± 3, n = 4) (Fig. 6).
Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA
expression
Intrathecal injection of brain-derived neurotrophic fac-
tor (BDNF) induced Arc/Arg3.1 mRNA expression in
the superficial dorsal horn neurons (10 ± 1.7/section, n
= 6). We found that 45% ± 8 of Arc/Arg3.1 mRNA
labeled neurons were located in lamina I and 55% ± 8
in lamina II. 93.6% ± 2.5 of Arc/Arg3.1 mRNA labeled
neurons expressed NeuN, 55.6% ± 9.1 expressed c-Fos,
and 16.8% ± 6.4% expressed NK-1. Since it has been
shown [18] that administration of BDNF together with
NBQX, which is an AMPA receptor blocker, increases
Arc/Arg3.1 mRNA expression in cortical neurons, we
injected BDNF intrathecally together with NBQX. This
combination resulted in 13.8 ± 2.9 Arc/Arg3.1 mRNA
labeled neurons/section (n = 6) (Fig. 7A), which was not
significantly different from intrathecal BDNF injection
alone (unpaired t-test). c-Fos expression after BDNF +
NBQX injection was also not significantly different from
BDNF injection alone (p= 0.08 for lamina II) (Fig. 7B).
Intrathecal injection of vehicle (n = 2) or NBQX (n = 2)
alone did not induce Arc/Arg3.1 mRNA expression in
Figure 3 The number of neurons expressing c-Fos outnumber Arc/Arg3.1 mRNA labeled neurons. A, Histogram showing the number of
neurons labeled for c-Fos or Arc/Arg3.1 mRNA following various nociceptive stimuli. capsaicin, n = 6; CFA1.5 hrs, n = 4; MO25%-2 hrs, n = 4;
MO25%-4 hrs, n = 4. B, Fluorescent micrograph showing Arc/Arg3.1 mRNA and/or c-Fos protein labeled neurons in spinal dorsal horn after
stimulation with 25% mustard oil for 2 hours. Arrows indicate Arc/Arg3.1 mRNA labeled neurons that were not in focus and therefore not
included in the analysis. Arrow heads indicate Arc/Arg3.1 mRNA and c-Fos protein labeled neurons. C, Histogram showing the percentage of
Arc/Arg3.1 mRNA labeled neurons that also express the neuronal activation marker c-Fos. Scale bar: 50 μm. Error bars represent ± SEM.
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the spinal cord. Furthermore, we found that intrathecal
injection with NMDA (n = 2), which served as a positive
control, also induced Arc/Arg3.1 expression in the dor-
sal horn (not shown).
Pain behavior in the Arc/Arg3.1 KO mice
Mechanical and thermal thresholds
Freely moving Arc/Arg3.1 knockout (KO) mice did not
display any overt behavioral abnormalities in compari-
son with their wild type (WT) littermates, as reported
previously [13]. With respect to pain behavior, the
mechanical thresholds and hot plate withdrawal laten-
cies were tested. We found that the mechanical thresh-
olds in Arc/Arg3.1 KO mice were not significantly
different from their WT littermates (Fig. 8A). However,
in the hotplate test Arc/Arg3.1 KO mice showed
significantly longer withdrawal latencies than WT mice
(Fig. 8B).
Acute pain: formalin test
Subcutaneous injection of formalin in the hind paw
induced a two-phased pain behavior in both WT and Arc/
Arg3.1 KO mice, consisting of licking and fluttering of the
injected paw. In both groups, the first phase was apparent
in the first 10 minutes after injection, and the second
phase began 25 minutes after injection with licking as the
prominent behavior. No significant difference (repeated-
measures ANOVA, p>0.05) was found between the WT
and Arc/Arg3.1 KO mice in licking or fluttering behavior
(Fig. 9A,B). Also the total licking time (WT: 200 sec. ± 34
(SEM); KO: 275 sec. ± 49 (SEM); p>0.05, unpaired t-test)
nor the total numbers of flutters (WT 100 ± 21 (SEM);
KO 128 ± 32 (SEM); p>0.05, unpaired t-test) were
Figure 4 Arc/Arg3.1 expression is stimulus intensity dependent and is present only in the acute phase of chronic inflammatory and
neuropathic pain. A, Histogram showing the numbers of Arc/Arg3.1 mRNA or c-Fos protein labeled neurons at 2 hours after a brush applied
stimulation with either 10% (n = 5) or 50% (n = 5) mustard oil. * = p < 0.05; ** = p < 0.005 (unpaired t-test). B, Time course of Arc/Arg3.1 mRNA
and c-Fos protein expression after stimulation with 25% mustard oil gauze wrapped around one hind paw for different survival times. 25 min, n
= 4; 45 min, n = 4; 1 h, n = 4; 2 hrs, n = 5; 4 hrs, n = 4; 8 hrs, n = 4. C, Time course of Arc/Arg3.1 mRNA and c-Fos protein expression after CFA
injection in the hind paw. 1.5 hrs, n = 4; 3 hrs, n = 4; 4 hrs, n = 4; 10 hrs, n = 4; 20 hrs, n = 4; 60 hrs, n = 4. D, The number of Arc/Arg3.1 mRNA
labeled neurons 2 hours after sham operation (n = 3) or after cutting the common peroneal and tibial nerves in the SNI model (n = 3). Error
bars represent ± SEM.
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Figure 5 Arc/Arg3.1 is expressed in a subpopulation of superficial dorsal horn neurons with a preference for neurons containing
enkephalin. A-E, Fluorescent micrographs showing neurons in the superficial dorsal horn that express Arc/Arg3.1 mRNA (A-C) or protein (D and
E) and markers that identify neurons expressing the neurokinin-1 receptor (NK1), protein kinase C gamma (PKC-g), Calbindin, GAD67 mRNA
(GABAergic neurons), or preproenkephalin mRNA (enkephalinergic neurons) respectively. The following nociceptive stimuli were used. A, CFA,
survival time 1.5 hrs, B and C: Mustard oil 25% gauze wrapped, survival time 1 h, D and E, Mustard oil 25% gauze wrapped, survival time 2 h.
Arrow heads indicate Arc/Arg3.1 labeled neurons that also express one of the markers mentioned above. Scale bar: 50 μm.
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significantly different. In addition, c-Fos expression due to
the formalin injection did not appear different from the c-
Fos expression in the WT mice.
Chronic pain: inflammation
Induction of chronic inflammation by CFA injection in
the hind paw resulted in decreased mechanical thresh-
olds of the injected paw (Fig. 10A). A repeated measures
ANOVA did not reveal any significant differences
between WT and Arc/Arg3.1 KO mice regarding the
mechanical or thermal thresholds at any time point (Fig.
10A,B).
Discussion
In this study we have used in situ hybridization (ISH) and
immunohistochemistry (IHC) to show that nociceptive sti-
mulation induced Arc/Arg3.1 mRNA and protein in the
superficial dorsal horn of the spinal cord. Both techniques
specifically identified Arc/Arg3.1 since standard controls,
most notably nociceptively stimulated spinal cord of Arc/
Arg3.1 knockout (KO) mice, did not show any specific
labeling. In naïve or vehicle treated animals expression of
Arc/Arg3.1 mRNA and protein was absent in the spinal
cord, in agreement with a study using RT-PCR [19]. This
strongly indicates that in the spinal cord a nociceptive sti-
mulus induces de novo expression of Arc/Arg3.1, in con-
trast with other areas of the nervous system, like
hippocampus [17] and cortex [20].
Arc/Arg3.1 mRNA and protein were induced in the
superficial dorsal horn in the acute phases of all pain
models that we tested, i.e. after nociceptive stimulation
with capsaicin, CFA, formalin and mustard oil. Injection
of CFA induces an inflammatory process [21] that leads
to the release of cytokines and other local messengers,
all of which may activate different types of receptors on
nociceptive fibers. Capsaicin, however, specifically acti-
vates nociceptive fibers expressing the transient receptor
potential vanilloid-1 (TRPV1) [22]. Further, mustard oil
and formalin both specifically activate the TRPA1 recep-
tor, although formalin may exert TRPA1-independent
effects at higher concentrations [23,24]. The number of
neurons producing Arc/Arg3.1 mRNA varied in the dif-
ferent pain models, and increasing the intensity of the
pain stimulus resulted in an increased number of neu-
rons expressing Arc/Arg3.1 as shown in the mustard oil
experiments. Therefore, our data indicate that the num-
ber of neurons expressing Arc/Arg3.1 depends on the
intensity of the stimulus, but is not limited to the activa-
tion of one specific receptor on peripheral nerves.
Neurons expressing Arc/Arg3.1 in the spinal cord are
most likely driven by direct input from afferent
Figure 6 Histogram showing the averaged percentages of
neurons expressing Arc/Arg3.1(induced after various
nociceptive stimuli, as in fig. 5), that co-express either NK1,
PKC-g, Calbindin, GAD67 mRNA or preproenkephalin mRNA.
Error bars represent ± SEM. For details, see text.
Figure 7 Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA expression in spinal dorsal horn. A and B, The averaged number of
neurons that express Arc/Arg3.1 mRNA (A) or c-Fos protein (B) after intrathecal injection with BDNF or BDNF together with NBQX. Error bars
represent ± SEM.
Hossaini et al. Molecular Pain 2010, 6:43
http://www.molecularpain.com/content/6/1/43
Page 7 of 13
         99
Nociceptive stimulation induces expression of Arc/Arg3.1 in the spinal cord with a preference for neurons containing enkephalin
nociceptive fibers that use glutamate as their main neu-
rotransmitter [25]. Apart from glutamate and various
neuropeptides, these fibers may also contain growth fac-
tors like BDNF [26] or GDNF [27]. We found that
intrathecal injection of NMDA or BDNF induced Arc/
Arg3.1 mRNA in spinal dorsal horn neurons. This is in
line with Arc/Arg3.1 expression in cultured neurons fol-
lowing BDNF application [18]. The same study showed
a significantly enhanced expression of Arc/Arg3.1
mRNA when NBQX, a potent AMPA receptor blocker,
was applied together with BDNF. However, in the pre-
sent study a significant increase in the number of Arc/
Arg3.1 mRNA expressing neurons could not be con-
firmed after intrathecal injection of BDNF and NBQX
together. Taken together, our findings are in line with
the idea that release of glutamate and/or BDNF from
activated nociceptive fibers are at least partly responsible
for Arc/Arg3.1 induction in the spinal dorsal horn.
Following nociceptive stimulation, Arc/Arg3.1 was
often expressed in activated neurons as identified by c-
Fos. Especially after nociceptive stimulation with capsai-
cin, and after chronic inflammatory pain, the number of
neurons expressing Arc/Arg3.1 is low as compared to
those showing c-Fos expression. This finding may be
interpreted to indicate that Arc/Arg3.1 is only expressed
in activated neurons that received the strongest input
from nociceptive fibers. This assumption is in line with
our finding that Arc/Arg3.1 expression is intensity
dependent. On the other hand, there may be specific
subpopulations of spinal nociceptive neurons that are
capable of producing Arc/Arg3.1, while others are not.
In search of such a neuronal subpopulation that specifi-
cally expressed Arc/Arg3.1, we focused on neurons that
were characterized by the expression of the neurokinin-
1 (NK-1) receptor, Protein Kinase C gamma (PKC-g),
calbindin, GAD67 or preproenkephalin. We found a
high percentage of Arc/Arg3.1 expressing neurons (68%)
to contain preproenkephalin, while percentages of colo-
calization with other markers were less prominent (19%
for NK-1; 8.5% for PKC-g; 3.6% for GAD67; 10% for cal-
bindin). NK-1 expressing neurons project to supraspinal
sites [28] and are essential for the initiation and mainte-
nance of chronic neuropathic and inflammatory pain
[29], and neurons expressing PKC-g are considered criti-
cally important for the development of neuropathic pain
after peripheral nerve injury [30]. The finding that only
a small number of Arc/Arg3.1 positive neurons also
expressed NK-1 or PKC-g indicates that Arc/Arg3.1 is
Figure 8 Naïve Arc/Arg3.1 knockout (KO) mice showed
significantly longer response times on the hotplate than their
naïve wild type (WT) littermates. A and B, Histogram showing
the mechanical threshold (A) and thermal withdrawal latency (B) of
Arc/Arg3.1 KO and WT mice, assessed with the Von Frey and the
hotplate test, respectively. Error bars represent ± SEM. *: p < 0.05,
unpaired t-test; n = 4 for A and for B.
Figure 9 Arc/Arg3.1 KO mice do not differ from WT mice concerning licking or fluttering of the paw injected with formalin. A and B,
Graphs showing the time spent licking (A) and the number of flutters (B) after formalin injection in the hind paw during an observation period
of 55 minutes. Error bars represent ± SEM. Differences were not significant (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
Hossaini et al. Molecular Pain 2010, 6:43
http://www.molecularpain.com/content/6/1/43
Page 8 of 13
100
Chapter VI
not strongly involved in pain processing by the NK-1 or
PKC-g subpopulations of dorsal horn neurons. This is
remarkable since especially the NK-1 expressing neu-
rons projecting to the parabrachial area or periaqueduc-
tal grey show LTP formation after high or low
frequency stimulation, respectively [31]. Our finding
indicates that Arc/Arg3.1 dependent long term changes
may occur preferentially in local interneurons rather
than in projection neurons. Further, we found low colo-
calization with GAD67, the marker for GABAergic neu-
rons, indicating that the expression of Arc/Arg3.1 is low
in the total subpopulation of dorsal horn inhibitory neu-
rons since glycinergic neurons are virtually absent in the
superficial dorsal horn [32-34], and, if present, also con-
tain GABA [35]. In the hippocampal and neocortical
neurons expression of Arc/Arg3.1 in GABAergic posi-
tive neurons is also low but this is not the case in the
dorsal striatum [20]. Together, NK-1, PKC-g and/or pre-
proenkephalin constitute more than 90% of the Arc/
Arg3.1 expressing neurons. Since to date there is no evi-
dence for the colocalization of these substances with
each other, we conclude that Arc/Arg3.1 is preferentially
expressed in the subpopulation of enkephalinergic neu-
rons. Preproenkephalin mRNA is the precursor of both
Met- and Leu-enkephalin, which are both expressed by
neurons in the spinal cord and mainly exert their effect
on the δ-opioid receptor (DOR) [36]. Also, preproenke-
phalin mRNA in the spinal cord is increased after per-
ipheral inflammation and is also present in neurons that
express c-Fos after nociceptive stimuli [37]. Further,
using VgluT2 immunohistochemistry for identifying glu-
tamatergic terminals, it was shown [38] that 85% of the
enkephalin containing terminals in the dorsal horn use
glutamate as transmitter. However, a study [39] using
cultured dorsal horn neurons showed 42% colocalization
of immunohistochemically identified GAD and enkepha-
lin. A more recent study [40] using preproenkephalin
green fluorescent protein transgenic mice, showed that
43% of the fluorescent enkephalin neurons also
expressed immunohistochemically identified GABA.
Colocalization of enkephalin with VgluT2 was not
explored in these studies. Since we found a low level of
colocalization of Arc/Arg3.1 with GABAergic neurons,
it is not unlikely that several of the enkephalinergic neu-
rons in the spinal cord that express Arc/Arg3.1 also use
glutamate as a transmitter. The functional role of gluta-
mate in these fibers is unclear, since it is not known
whether they activate inhibitory or excitatory (i.e. anti-
or pro-nociceptive) circuits in the spinal cord, nor is it
known under which circumstances enkephalin and/or
glutamate is released from these fibers. Since the activa-
tion of the delta opioid receptor (DOR), through which
enkephalin exerts its effect, decreases pain behavior dur-
ing chronic peripheral inflammation [41], we tend to
conclude that the overall effect of Arc/Arg3.1 expressing
enkephalinergic neurons is anti-nociceptive.
In order to understand the functional role of Arc/
Arg3.1 in enkephalinergic neurons at the behavioral
level, we employed Arc/Arg3.1 KO mice and their WT
littermates. The only significant difference between
these mice was that in the hotplate test the thermal
threshold of naïve Arc/Arg3.1 KO mice was significantly
higher as compared to naïve WT mice. This finding is
difficult to interpret since naïve WT mice, like their KO
littermates, do not show Arc/Arg3.1 expression in the
spinal cord. One explanation may be that there is a very
low basal expression of Arc/Arg3.1 that we and others
[19] were not able to detect, and that the permanent
lack of Arc/Arg3.1 in the KO mice may have altered
spinal processing of nociceptive thermal stimuli over
time. Alternatively there may be supraspinal changes in
nociceptive processing. After nociceptive stimuli, we did
not find any difference in the pain behavior between the
KO and WT mice in the formalin test and chronic
inflammatory pain model. We therefore conclude that
Arc/Arg3.1 KO mice do not show a clear phenotypic
change that can be attributed to pain transmission in
the spinal cord.
Figure 10 No differences in mechanical and thermal thresholds between the Arc/Arg3.1 KO and WT mice during the time course of
inflammatory pain. A and B, Graphs showing mechanical (A) and thermal (B) thresholds after CFA injection in one hind paw of Arc/Arg3.1 KO
and WT mice. Differences were not significant at any time point (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
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Several studies have shown that in hippocampus
knockdown of Arc/Arg3.1 leads to enhanced LTP in the
early phase but impaired consolidation of LTP and long
term depression (LTD) in the late phase [13]. In the
spinal cord, LTP is one of the major components of
central sensitization [16], especially in lamina I project-
ing neurons [31]. LTP leads to enhanced responsiveness
of spinal nociceptive neurons, which is important for
maintenance of hyperalgesia and allodynia during acute
and chronic pain. Our finding that Arc/Arg3.1 KO mice
develop hypersensitivity in acute and chronic pain mod-
els in the same way as their WT littermates, suggests
that the LTP formation that contributes to central sensi-
tization and subsequent developing hyperalgesia is unaf-
fected by the lack of Arc/Arg3.1. It seems therefore that
Arc/Arg3.1 is not critically involved in LTP as occurring
in the dorsal horn projection neurons, which in line
with our result that few NK-1 positive neurons express
Arc/Arg3.1.
The low number of spinal projection neurons that
express Arc/Arg3.1 may be explained by the fact that, in
contrast to other areas of the brain, structural long-term
changes in the excitability of these spinal neurons are
counterproductive if they persist after the healing pro-
cess has been completed. Our finding that Arc/Arg3.1 is
expressed predominantly in enkephalinergic neurons
may suggest that in these neurons long term changes
are actually consolidated. However, Arc/Arg3.1 KO mice
that lack consolidation of long term changes show nor-
mal pain behavior. This would not exclude that enke-
phalinergic neurons, which have an inhibitory effect on
pain transmission, may serve as an anti-nociceptive
mechanism against strong nociceptive inputs that may
occur in the future.
Conclusions
Our data show that Arc/Arg3.1, which is critically
involved in consolidating long term structural changes
in the forebrain, is preferentially induced in spinal enke-
phalinergic neurons after nociceptive stimulation. This
finding suggests that Arc/Arg3.1 dependent memory
formation in spinal pain transmission is a predominant
feature of neurons, which are anti-nociceptive rather
than pro-nociceptive.
Methods
Animal experiments
In this study we used 99 male Wistar rats and 16 Arc/
Arg3.1 KO mice and their wild type littermates.
Rats
50 μl of 0.3% capsaicin (Sigma-Aldrich) solution consist-
ing of 80% saline, 10% Tween-80, and 10% ethanol 100%
(n: 6; survival: 1.5 hrs) or 100 μl of Complete Freund’s
Adjuvant (CFA, Sigma-Aldrich; n: 24; survival: 1.5 hrs, 3
hrs, 4 hrs, 10 hrs, 20 hrs, 60 hrs) was injected in a hind
paw under anesthesia with 2% isofluorane in 30%O2/70%
N2O. In experiments applying mustard oil (MO) (Allyli-
sothiocyanat, Merck) the animals were kept under
anesthesia during entire survival time and subsequent
perfusion. For 25% MO application (n: 25; survival: 25
min, 45 min, 1 h, 2 hrs, 4 hrs, 8 hrs) the left paw was
shaved and wrapped in a gauze soaked with MO and
then covered with foil. For application of 10% (n: 5; survi-
val: 2 hrs) and 50% (n: 5, survival: 2 hrs) MO, the left paw
was shaved and MO was applied once at the beginning of
the experiment using a brush. For the experiments using
intrathecal injections, the same protocol was used as
described in [42]. Brain-derived neurotrophic factor
(BDNF, 10 μg, Tocris) was injected intrathecally in a total
injection volume of 40 μl (n: 6; survival: 75 min). In
another experiment, 5 μg of 1,2,3,4-tetrahydro-6-nitro-
2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX,
Tocris) was injected concomitantly with BDNF (n: 6; sur-
vival: 75 min). For control intrathecal experiments, 25
nmol N-Methyl-d-asparate (NMDA; Sigma, St. Louis,
MO; n: 2; survival: 75 min), or only vehicle (1% bovine
serum albumin in 0.025 M phosphate buffer; n: 2; survi-
val: 75 min) or only NBQX (n: 2; survival: 75 min) was
injected intrathecally. After the injections, the rats were
placed back in their cages. For induction of neuropathic
pain, the spared nerve injury (SNI) model and a control
operation were used [43]. In short, the sciatic nerve was
exposed and the three branches were isolated. The tibial
and the common peroneal branches were ligated and
then cut while the sural nerve was left intact (n: 9; survi-
val: 2 hrs, 7 days, 14 days). As a control, the sciatic nerve
was only exposed and isolated (n:7; survival: 2 hrs, 7 days,
14 days).
Arc/Arg3.1 KO and WT mice
All mice were habituated for 5 days to the experimenter,
the experiment room, and the transparent cage that was
used for the Von Frey measurements. Thereafter, prior
to each experiment the mice were habituated for 30
minutes to the room in which the behavioral experi-
ments took place.
Von Frey experiment before each Von Frey measure-
ment, the mice were allowed to habituate to a transpar-
ent cage (15 cm × 15 cm with a gridded floor) for 10
minutes. We used calibrated von Frey filaments, which
were applied for 2 seconds at 5 seconds interval, and
the threshold was set at 3 evoked responses in a maxi-
mum of 5 applications.
Hotplate test the thermal thresholds were assessed by
measuring the time a mouse spent on the hotplate (51°
C) before showing a response like fluttering or licking of
the hind paw, or jumping. Immediately after a response
or after maximally 45 seconds, the mouse was taken off
the hotplate.
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The formalin pain model the mice were restrained by
the experimenter and 15 μl of formalin, i.e. a freshly
made solution of 4% paraformaldehyde (PFA) in phos-
phate buffer (PB), was injected subcutaneously in the
left hind paw. The number of flutters and the time
spent licking of the injected paw were measured during
55 minutes post-injection. After 90 minutes the mice
were perfused and the tissue was processed as described
below. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
The CFA pain model 25 μl of CFA was injected in a
hind paw of restrained mice and thereafter the mechani-
cal and thermal thresholds were assessed at 1.5 h, 4 hrs,
1 d, 3 d, 4 d, 8 d, 14 d, 21 d, 28 d, 34 d, and 42 d post-
injection. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
Statistical analysis An unpaired t-test or a repeated
measures ANOVA was performed, p < 0.05 was taken
as significant.
Examination of the Arc/Arg3.1 KO mice spinal tissue
After experiments the mice were sacrificed and further
processed for immunohistochemistry (IHC) or in situ
hybridization (ISH). Histological examination of Arc/
Arg3.1 KO mice spinal cord did not reveal any morpho-
logical abnormalities in comparison with their WT
littermates.
Tissue preparation
At the end of the survival times the animals received an
overdose of sodium pentobarbital and were transcar-
dially perfused with 100 ml saline (rats) or 10 ml (mice)
followed by 750 ml of 4% PFA (rats) or 50 ml (mice)
dissolved in 0.12 M phosphate buffer (PB), pH 7.4. The
spinal cord was dissected and left overnight in a solution
of 4% PFA and 30% sucrose at 4°C. Subsequently, sec-
tions were cut (30 μm) on a freezing microtome and
collected in RNAse-free PB. Serial sections were cut and
collected in 9 separate jars, and therefore sections in
one jar were at least 270 μm apart. The sections were
kept in a solution of 40% glycerol, 40% ethyleenglycol
and 20% RNAse-free PB for long-term storage at -20°C.
In situ hybridization and immunohistochemistry
The partial cDNA templates encoding the following
mRNAs were used: Arc/Arg3.1 (3.5 kb, full length probe
encoding the mus musculus Arc/Arg3.1 gene, GeneID:
11838; Image Clone number: 3498057), GAD67 (3.2 kb;
a generous gift from Dr. A.J. Tobin, UCLA), preproen-
kephalin (0.95 kb, a generous gift from Dr. S.L. Sabol,
NIH). The riboprobes were obtained by linearizing the
recombinant plasmids with the appropriate restriction
enzymes and RNA polymerases. The transcription was
performed in the presence of digoxigenin (DIG)- or
fluorescein-labeled 11-UTP (Roche). ISH based on
alkalic phosphatase (AP) reaction was performed follow-
ing the protocol described previously [32]. For fluores-
cent in situ hybridization (FISH) the following
modifications were applied to the protocol. After ribop-
robe hybridization, the detection of DIG or fluorescein
was achieved with sheep polyclonal anti-Dig antibody
(Roche) or mouse monoclonal anti-fluorescein antibody
(Roche), respectively (1:500; 48 hours at 4°C in phos-
phate buffer saline (PBS), 2% milk powder and 0.5% Tri-
ton X-100). Thereafter, the anti-DIG or anti-fluorescein
primary antibodies were detected using biotinylated rab-
bit-anti-goat (Vector) or goat-anti-mouse (Vector),
respectively. Subsequently, the sections were incubated
with Avidin-Biotin-Complex (ABC, Vector) tagged with
horseradish peroxidase (HRP). A tyramide amplification
procedure was performed by reacting HRP with H2O2
and a self made FITC tyramide according to protocol
described in [44]. Thereafter, the sections were washed
in PBS and processed for fluorescent IHC using the fol-
lowing antibodies diluted in 2% milk power solution:
rabbit anti-Arc (1/3000; a generous gift from Dr. D.
Kuhl), rabbit anti-c-Fos (1: 40.000; Oncogene Research
Products, La Jolla, CA), rabbit anti-neurokinin-1 (NK1;
1:5000; Advanced Targeting System, CA, USA), rabbit
anti-calbindin (1:7000; Swant, Switzerland), rabbit anti-
PKC-g (1/750; Santa Cruz), and mouse anti-neuronal
nuclei (NeuN) monoclonal antibody (1:5000, Chemicon).
These primary antibodies were detected with Cy3 tagged
fluorescent secondary antibodies donkey-anti-rabbit or
donkey-anti-mouse (1:200). Thereafter, the section were
washed in PB and mounted on slides and coverslipped
with Vectashield (Vector).
Data analysis
Analysis was carried out on L4 and L5 segments of the
spinal cord, except for the BDNF experiments, in which
also S1 and S2 segments were included in the analysis.
Slides were systematically examined starting from the
first section in the first row for the appropriate segmen-
tal level. The first 5 to 6 sections that were encountered
and were not damaged during the procedure were
included in the analysis [42]. For illustrations, light
micrographs were made with a digital camera and con-
focal images with a Zeis LSM 510 confocal laser scan-
ning microscope and a 20× objective. The images were
processed using Adobe Photoshop and were not
manipulated, except for brightness and contrast. Quanti-
tative analysis of Arc/Arg3.1 mRNA positive neurons
based on AP-ISH was achieved using a camera lucida
microscope (Neurolucida, Microbrightfield Inc., Willis-
ton, VT). The grey and white matter and the boundaries
between the laminae were drawn according to [45] and
labeled neurons were identified only if the largest dia-
meter was at least 10 μm, and the cell soma contained a
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bluish/brownish product. Labeled neurons were
expressed as the average number of labeled neurons per
section.
For double labeling based on FISH combined with
fluorescent IHC, confocal images were analyzed using
the Zeis LSM image browser. For each section, the dor-
sal horn showing Arc/Arg3.1 labeled neurons was ana-
lyzed in a vertical plane consisting of 9 slices with an
optical thickness of 2.46-2.76 μm. Every fifth section
was analyzed for double labeled neurons. For markers
that label the cytoplasm, the criterion was that the dia-
meter of a profile was at least 10 μm to be counted as a
neuron. For statistical analysis, an unpaired t-test was
performed, and p < 0.05 considered significant.
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Chapter VII
 In this thesis we have identified the location of glycinergic neurons in the spi-
nal cord and investigated the activation pattern of spinal glycinergic and GABAergic (Gly/
GABA) neurons in various acute and chronic pain states. Further, we have identified spi-
nal Gly/GABA neurons in the area around the central canal that project to the RVM, and 
we have investigated the expression pattern of Arc/Arg3.1 in naive spinal cord and after 
stimulation with nociceptive stimuli. Finally, with respect to descending pathways we have 
investigated the distribution pattern of Gly/GABA neurons in the RVM that project to the 
spinal cord. The following general discussion will first focus on the role of spinal Gly/GABA 
neurons in the naive spinal cord, and during spinal nociception. Thereafter, we will focus 
on the expression of Arc/Arg3.1 in the spinal cord and long-term memory consolidation in 
nociceptive pathways. Finally, we will discuss the role of the descending projection of Gly/
GABA neurons in the RVM and their role in the inhibitory control of spinal nociception.
1. The role of spinal glycinergic and GABAergic neurons in pain inhibition
 In the 1960’s it was shown for the first time that glycine and GABA act as inhibitory 
neurotransmitters in the central nervous system [3, 44]. Glycine is an amino acid produced 
from serine by the enzyme serine hydroxymethyltransferase, which is not specific for gly-
cinergic neurons. Further, glycine is an important transmitter in the spinal cord and the 
brainstem, but is not found in higher levels of the nervous system, where GABA is the main 
inhibitory transmitter [6, 39, 69]. The inhibitory effect of glycine is produced by the glycine 
receptor, a ligand gated chloride channel, opening of which leads to membrane hyperpo-
larization [41]. GABA is an amino acid that is produced from glutamic acid by the enzyme 
glutamic acid decarboxylase (GAD) [81]. GAD is only present in neurons that use GABA as 
their transmitter and can therefore be used for the identification of GABAergic neurons 
[14, 40]. GABA acts on GABA receptors of which there are two main types: GABA-A and 
GABA-B receptors. GABA-A receptors are ligand gated chloride channels, the opening of 
which leads to membrane hyperpolarization. GABA-B receptors, on the other hand, are 
G-protein coupled receptors, which are indirectly linked to a potassium channel, that also 
has a hyperpolarizing effect on the membrane [53]. Glycine and GABA are often colocal-
ized in spinal neurons [48], both in the dorsal [86, 87] and ventral horn [82]. In accordance, 
physiological studies have shown that glycine and GABA and are co-released at synapses 
[36]. Only few populations of spinal neurons use only glycine or only GABA as their inhibi-
tory neurotransmitter [24, 87]. They include neurons in the superficial dorsal horn, which 
are predominantly GABAergic since there are few glycinergic neurons in these laminae, as 
we have shown in chapter 2. Furthermore, in the ventral horn there are specific GABAergic 
neurons that express GAD65, which is one of the isoforms of GAD and often colocalized 
with the other isoform GAD67, that are involved in the presynaptic inhibition of muscle 
spindle afferents on motoneurons [31]. Next to the inhibitory input provided by these Gly/
GABA interneurons, there is also inhibitory input from descending glycinergic and GAB-
Aergic terminals originating from Gly/GABA neurons in the RVM [2, 5, 49, 56]. The termi-
nals of these Gly/GABA projections contact projection neurons in the superficial layers [2], 
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interneurons in the deeper layers (laminae III-VI), and also neurons located in the ventral 
horn [28, 29]. Taken together, glycinergic and GABAergic neurotransmission in the spinal 
cord is either produced by spinal Gly/GABA interneurons or by Gly/GABA neurons in the 
RVM with projections to the spinal cord.
1.1. The naive spinal cord
 Abolishing glycinergic or GABAergic neurotransmission in the naive spinal cord 
results in many behavioral signs of hypersensitivity as observed in neuropathic and inflam-
matory pain conditions [75, 78, 97]. This finding indicates that nociceptive spinal neurons, 
including projections neurons, are active in the absence of a nociceptive stimulus, and 
there is the necessity for a continuous glycine and GABA induced inhibition of nociceptive 
neurons in order to block their activity in the naive animal. It is unclear which Gly/GABA 
neurons, i.e. spinal interneurons and/or RVM projection neurons, are the source of this 
inhibitory control. Although there is evidence of descending Gly/GABA terminals contact-
ing spinal dorsal horn neurons [2], and for inhibitory effects after RVM stimulation [50], 
it remains unclear whether Gly/GABA projection neurons in the RVM are involved in the 
tonic inhibition of the naive spinal cord. Similarly, the role of spinal inhibitory neurons 
in this tonic inhibition of nociceptive neurons in the naive spinal cord is not clear. C-fos 
protein, which is an immediate early gene that is widely used as a marker for neuronal 
activation [32], is expressed by spinal neurons that are activated by a nociceptive stimulus 
[22]. In the naive spinal cord, c-fos is only expressed by very few neurons [9], suggesting 
the absence of active inhibitory neurons in the naive spinal cord. Thus, based on c-fos 
activation, it seems that spinal Gly/GABA neurons do not play a role in inhibiting nocicep-
tive spinal neurons in the naive animal. This apparent contradiction may be resolved when 
it is assumed that c-fos expression in spinal neurons is induced by phasic activity rather 
than tonic activity. Therefore, the lack of c-fos expression in the naive spinal cord would 
not necessarily imply the absence of active Gly/GABA neurons. Apparently, these neurons 
only start to express c-fos when they become activated after a nociceptive stimulus, which 
leads to a sudden strong increase in their activity. In conclusion, spinal inhibitory neurons, 
whether or not in combination with descending inhibitory neurons, probably play a role 
in inhibiting nociceptive neurons in the naive spinal cord but the mechanisms underlying 
this inhibition are still unclear. 
1.2. Nociceptive activated spinal cord
1.2.1. Ipsilateral pain stimulation
 In the past decade, is has become increasingly clear that glycine and GABA play 
an important role in controlling spinal nociceptive processing. For example, during chronic 
inflammatory pain glycinergic inhibition is blocked in the spinal cord by a pathway that 
involves prostaglandin E2 (PGE2) [58, 72], a process which underlies the development 
of thermal and mechanical hyperalgesia [98]. Further, activation of selective subunits of 
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the GABA receptor, i.e. the α2 and/or α3, result in pronounced pain inhibition in chronic 
pain states [42]. During neuropathic pain states, there is evidence for reduced GABAergic 
inhibition in the superficial dorsal, which may [57] or may not [65, 66] be due to loss of 
GABAergic interneurons. At the same time there is loss of synaptic inhibition due to a shift 
in the chloride gradient, which reverses the inhibitory effect of GABA into a depolarizing 
one [11]. 
 Despite the knowledge on the involvement of inhibitory neurotransmission in spi-
nal nociceptive processing, there are few data about the role of  Gly/GABA interneurons 
in the loss of spinal inhibition and their activation pattern in acute and chronic pain states 
[85, 101, 102]. In chapter 3 of this thesis, we have investigated the activation pattern of 
spinal Gly/GABA neurons in various acute and chronic pain states affecting one hindpaw 
by determining the number and the percentage of c-fos activated neurons that were Gly/
GABA on the ipsilateral side. We found that the percentage of c-fos activated neurons that 
was inhibitory was higher (46%) in chronic (≥ 20hrs) pain states as compared to  acute (≤ 
2hrs) pain states (34%). This increase in percentage was caused by a reduction in the num-
ber of c-fos expressing non-Gly/GABA neurons in chronic pain states while the number of 
c-fos expressing Gly/GABA neurons remained stable. This finding indicates that in chronic 
pain states there is a relatively increased activation of Gly/GABA neurons. However, as 
mentioned earlier, several studies have shown a loss of inhibitory transmissions in the 
spinal cord during chronic inflammatory and neuropathic pain [99]. A possible explanation 
may be that the activated Gly/GABA neurons that we found are not functional, because 
the effects of the glycine and GABA they release is blocked at the synaptic level or that 
there effect is reversed (see above). Another explanation may be that the activated Gly/
GABA neurons serve as a compensation, albeit insufficient, of the apparent loss of inhibi-
tory neurotransmissions in other pathways during chronic pain states. Yet another view 
would be that the expression of c-fos occurs in Gly/GABA neurons involved in phasic activ-
ity, while the loss of inhibition occurs in tonically active Gly/GABA neurons, which are not 
identified by the expression of c-fos. Finally it may be argued, that the activated Gly/GABA 
neurons are involved in another role, unrelated to the inhibition of pain transmission in 
the dorsal horn, e.g. related to inhibition of motoneurons. Next to the activity of spinal 
interneurons, there are also glycinergic and GABAergic inputs by descending pathways 
from the RVM to the spinal cord [2, 50]. Therefore, it is possible that the activity in these 
inhibitory descending pathways is decreased, counteracting the effect of the activated 
Gly/GABA neurons that we have indentified during chronic pain states.
 In conclusion, in chronic pain states there is loss of synaptic inhibition in the spinal 
cord while at the same time there are c-fos activated spinal Gly/GABA neurons, and pos-
sibly inhibitory input by descending pathways from the RVM. Whether all these inhibitory 
inputs are blocked, resulting in the observed loss of spinal inhibition in chronic pain states, 
or whether their activation is induced by the loss of spinal inhibition but fail to compen-
sate for that loss is currently unclear. 
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1.2.2. Contralateral pain stimulation
 In chapter IV of this thesis we have shown that the number of activated Gly/GABA 
neurons is increased after a capsaicin injection in the hindpaw of rats which have chronic 
inflammatory or neuropathic pain in the other hindpaw. This indicates that a unilateral 
chronic pain state increases the excitability of Gly/GABA neurons on the contralateral side 
of the spinal cord. As a result a subsequent pain stimulus on that side will activate a larger 
number of Gly/GABA neurons, relative to non-Gly/GABA neurons. Previous studies have 
shown that primary afferent fibers not only result in ipsilateral activation of the spinal 
cord, but also in contralateral activation by polysynaptic mechanisms [27]. Further, it has 
been shown that an one sided noxious stimulation induces c-fos activation of spinal neu-
rons on the contralateral side [9], and that the number of c-fos expressing neurons is 
increased after a second stimulus on that contralateral side [45, 46]. In accordance, it was 
shown recently by means of autofluorescent flavoprotein imaging that there is activity 
on the contralateral side of the spinal cord immediately after an ipsilateral nociceptive 
stimulation [37]. The following question now arises: what is the functional meaning of the 
activation and the increased excitability that develops on the contralateral side? One pos-
sible explanation may be that it is important for survival: when a body part is injured on 
one side, the same body part on the contralateral side must remain functional despite the 
injuries and possible new injuries to that body part. In this situation, an enhancement of 
the local inhibition of nociception would be beneficial for a proper function of that body 
part [63, 70]. However, in these situations it is likely that the PAG-RVM system, that con-
trols spinal pain transmission through its descending projections to the dorsal horn [26], 
will also become involved. Therefore it is likely that changes that we have observed on the 
contralateral side of an injury, are the result of changes in the activity and excitability of 
local spinal neurons as well as neurons in the RVM. Taken together our findings show that 
the excitability and subsequent activation pattern of Gly/GABA neurons on one side of the 
spinal cord are affected by painful events on the contralateral side, while the underlying 
mechanisms need further investigation.
2. Long-term memory consolidation in spinal nociceptive pathways
 Central sensitization plays a important role in the development and the mainte-
nance of hyperalgesia and allodynia after nociceptive stimuli. There are three mechanisms 
that underlie the central sensitization [94, 95]. In the first place there is wind-up, a form 
of activity dependant plasticity, resulting in the increase of action potential output of dor-
sal horn neurons. Wind-up is induced by and only manifest during a train of repeated 
low-frequency C-fiber or nociceptor stimuli [12, 52, 55, 83] and occurs only at the active 
synapse (homosynaptic). For example, when a noxious thermal or mechanical stimulus 
with a constant intensity is repeatedly applied to the skin, wind up of spinal neurons in-
duces an increase in pain with each successive stimulus, while the intensity of the noxious 
stimuli is constant [68]. 2) A second mechanism is heterosynaptic central sensitization. In 
this case the increased excitability of spinal nociceptive dorsal horn neurons, elicited by 
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a brief and intense nociceptive stimulus, results in the activation of dorsal horn neurons 
by primary afferent inputs that are normally subthreshold [10, 51, 96]. This form of cen-
tral sensitization is heterosynaptic, meaning that that the potentiation of synaptic output 
not only applies to the synapses that were activated by the initiating stimulus, but also 
to other synapses not activated by the initiating stimulus [76]. At the behavioral level, 
this heterosynaptic potentiation is the underlying cause of secondary hyperalgesia and 
allodynia in the area around the primary injury site [77]. A third mechanism is known as 
long-term potentiation (LTP), a process at the homosynaptic level which results in an in-
creased efficacy of excitatory primary afferent input [34, 92]. It has been shown that this 
LTP induced enhancement of monosynaptic excitatory synaptic responses lasts for days to 
weeks, is NMDA receptor dependent, and leads to the phosphorylation of AMPA recep-
tors and the recruitment of new AMPA receptors into the cell membrane [71, 90]. It is gen-
erally assumed that most processes inherent to LTP formation in cortical and hippocampal 
neurons are probably similar to the LTP-related processes occurring in spinal nociceptive 
neurons [35]. Taken together, there is evidence for nociception induced homosynaptic and 
heterosynaptic enhancement of spinal nociceptive neuronal excitability, and LTP based 
long-term consolidation of synaptic changes in spinal nociceptive pathways, and all these 
mechanisms contribute to central sensitization.  
 In this thesis we have investigated the expression pattern of Arc/Arc3.1 mRNA 
and protein in the rat spinal cord after nociceptive stimuli, and determined the pain be-
havior in Arc/Arg3.1 knockout (KO) mice. Arc/Arg3.1, an immediate early gene (IEG), was 
first identified and extensively investigated in cortex and hippocampus [8, 21, 64, 73, 74], 
where it plays an essential role in long-term memory consolidation by regulating AMPA re-
ceptor trafficking [7]. Consequently, knockdown of Arc/Arg3.1 results in the loss of LTP and 
long term depression (LTD), and the loss of long-term memory while short term memory 
is unchanged [64]. In chapter 6 we showed that Arc/Arg3.1 is de novo expressed after a 
nociceptive stimulus and that the expression of Arc/Arg3.1 is intensity dependent, i.e. a 
stronger nociceptive stimulus induces a higher number of Arc/Arg3.1 expressing neurons. 
We further found that Arc/Arg3.1 is predominantly expressed in enkephalinergic inter-
neurons, and not in NK1 receptor expressing projection neurons, that relay nociceptive 
signals to supraspinal levels, nor in Gly/GABA interneurons that are likely involved in the 
local inhibition of spinal pain transmission. In line with this lack of expression in the most 
important neurons of the spinal nociceptive system, we found that the Arc/Arg3.1 KO 
mice showed no changes in their pain behavior to acute (formalin) and chronic (inflam-
mation) pain stimuli as compared to their wild type littermates. This strongly suggests 
that the important “memory molecule” Arc/Arg3.1 is not crucially involved in the long-
term consolidation of “pain memory”, i.e. the changes that occur during inflammatory and 
neuropathic pain states. This finding may reflect a special property of pain memory in the 
spinal cord, which is that it should be reversible and not lead to permanent changes. In 
functional terms: if an injured part of our body remained sensitized to non-noxious (allo-
dynia) and noxious (hyperalgesia) stimuli, we would be forced to maintain the protection 
of an injured area long after the healing process of that area had been completed. Instead, 
         111
General discussion
central sensitization in the spinal cord that develops post injury slowly subsides with tis-
sue healing, resulting in the disappearance of hyperalgesia and allodynia in and around 
the area of tissue injury. As a consequence the functional organization of the spinal cord, 
and the sensitivity of the healed area of injury, will return to the normal pre-injury situa-
tion. Since Arc/Arg3.1 is involved in establishing permanent changes in synaptic strength, 
its absence from spinal nociceptive projection neurons, as well as Gly/GABA expressing 
spinal neurons, is in line with the idea that permanent changes in the spinal pain system 
are unfavorable for its proper function. However, there is one group of neurons that did 
express Arc/Arg3.1 after nociceptive activation: the enkephalin expressing neurons. This 
indicates that these neurons will develop permanent changes after nociceptive activation 
and become more sensitive for incoming nociceptive stimuli for a long period of time. As a 
consequence, these enkephalinergic neurons, which are a minority of the c-fos activated 
neurons, may become more easily activated when the injured area would be injured a 
second time. Since enkephalin exerts an inhibitory effect on pain transmission in the dor-
sal horn [17, 61], this would mean that a subsequent injury would be less painful then the 
previous one. If this effect is strong enough, it would be possible to test this hypothesis in 
Arc/Arg3.1 KO mice. However, due to a limited availability of these mice, were not able to 
put this to the test. 
 In conclusion, our results indicate that Arc/Arg3.1 in the spinal cord is not involved 
in the development of pain behavior in the formalin and chronic inflammation models. 
This indicates that mechanisms that produce central sensitization in the spinal cord do not 
lead to long-term changes that outlast the healing period. In that sense, LTP in the spinal 
cord is different from other areas of the central nervous system (CNS), where long term 
consolidation of synaptic changes is a prerequisite for memory formation. 
3. Inhibitory projections from the RVM to the spinal cord
 Next to the spinal interneurons, descending projections from the RVM are also 
important in modulating spinal nociception [16], as activation of these projections leads 
to facilitation or inhibition of spinal nociceptive transmission [15]. The facilitating effect 
of the RVM on spinal nociception is induced by the ON cells [4, 15, 25], while inhibition 
of spinal nociception by descending RVM projections is mainly achieved by OFF cell acti-
vation [15, 26], with simultaneous inhibition of the ON cells. Many studies have focused 
on the transmitters involved in producing the effects of the descending RVM projections 
and most of the neuropeptides that were identified showed a facilitating effect, including 
cholecystokinin [43, 89] and neurotensin [60, 79, 88, 89]. With respect to the inhibitory 
projections from the RVM, it was believed for a long time that the transmitter involved 
was serotonin [23, 33, 38, 47]. However, more recently it became clear that serotonin may 
also induce facilitation of spinal pain transmission [62, 84, 100] and that serotonin was not 
localized in ON or OFF cells, but in Neutral cells, which show an activity pattern unrelated 
to nociceptive stimulation [18, 67]. Thus, if serotonin is not present in the OFF cells, which 
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is then the main transmitter, producing direct inhibition on spinal nociception? There is 
evidence that glycine and GABA are released in the dorsal horn upon RVM stimulation [49, 
50, 80], but is has not been established from which terminals, i.e. descending projections 
or local spinal interneurons. In fact there are several mechanisms that may result in the 
inhibition of spinal nociception, including direct inhibition of projection neurons in the 
dorsal horn [91, 93], opioid dependent inhibition of transmitter release by primary noci-
ceptive afferents [19], direct inhibition of nociceptive neurons in the dorsal horn [13, 20] 
and the activation of inhibitory interneurons in the dorsal horn [1, 54, 80]. In an electron 
microscopical study [2], which combined anterograde tracing from the RVM with glycine 
and GABA immunohistochemistry, it was shown that in the dorsal horn glycine and GABA 
were present in terminals that were labeled from the RVM. In chapter 6 we have shown, 
using retrograde tracing from the spinal cord with fluorescent in situ hybridization for 
GABA and glycine, that 44% of the neurons projecting to the spinal dorsal horn are indeed 
Gly/GABA. Thus, based on this anatomical evidence, it seems very likely that Gly/GABA 
neurons represent the OFF cells. Whether this means that glutamate is the likely fast ex-
citatory transmitter in the ON cells (next to various neuropeptides) remains unclear. 
 In chapter 6 we have also shown that there are Gly/GABA neurons in the spinal 
cord, located in the area around the central canal (CC), that project to the RVM. This path-
way is the only projection from the spinal cord to a supraspinal structure (i.e. the RVM) 
that contains the fast inhibitory transmitters GABA and glycine. This finding shows that the 
spinal cord is not merely “passing on” information to higher structures, but is also involved 
in the inhibition of specific supraspinal nuclei, like the RVM. Within the same spinal area 
around the CC there are also neurons that use opioids such as enkephalin and dynorphin 
[59] that project to supraspinal sites including the RVM. Enkephalin is frequently colocal-
ized with GABA in the spinal cord [30], therefore it is not excluded that the opioids in 
these neurons act as modulators that are colocalized with fast transmitters like GABA and 
glycine, and thus represent the same neurons that we have identified as Gly/GABA. It is 
presently unclear which type(s) of neurons in the RVM are inhibited by these connections 
and whether or not they act as feedback loops involved in the control of the nociceptive 
transmission in the spinal cord. Taken together, our finding of glycinergic and GABAergic 
ascending pathways from the spinal cord to the RVM, shows that the idea of the spinal 
cord as a relay station for sensory information, should be adapted to include the existence 
of inhibitory connections, controlling the activity of supraspinal structures, like RVM. 
4. Final conclusions
 In this thesis we have shown that spinal Gly/GABA neurons have specific activation 
pattern in acute and chronic pain states. Whether these activated Gly/GABA neurons can 
compensate for the loss of inhibitory neurotransmission during chronic pain, or whether 
they are involved in another process inherent to chronic pain states is unclear. Our inves-
tigation on the spinal expression of Arc/Arg3.1 indicates that Arc/Arg3.1 based long-term 
memory consolidation is not predominant in the spinal cord. This finding is in line with 
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our suggestion that long-term consolidation of synaptic activity in the spinal cord is unfa-
vorable as it would lead to a hypersensitive spinal cord with permanent hyperalgesia and 
allodynia even after tissue healing. Further, our findings provide strong evidence for the 
involvement of RVM Gly/GABA projection neurons in spinal processing. However, whether 
Gly/GABA projection neurons are the OFF cells that have been characterized to inhibit 
spinal nociception, or that they are a specific subset of neurons, next to OFF cell popula-
tion remains to be determined. Finally, the existence of reciprocal inhibitory connections 
between the RVM and the spinal cord suggest that the spinal cord may, via a feed-back 
loop, be able to modulate RVM neurons in order to alter its own neurons that are under 
control of descending RVM pathways.  Taken together our findings further underline the 
importance of Gly/GABA neurons in the spinal cord and the brainstem for controlling the 
feeling we all know: pain
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 In this thesis we have employed fluorescent in situ hybridization (FISH) in order 
to identify neurons in the spinal cord and the brainstem that use glycine or gamma-ami-
no butyric acid (GABA) or both transmitters (Gly/GABA neurons). With this technique we 
have made a detailed analysis of the localization of glycinergic cell somata in the spinal 
cord (Chapter 2). In the subsequent experiments we have combined FISH with the retro-
grade tracing technique, using fluorescent microspheres, or with the fluorescent immu-
nohistochemistry technique for identifying various proteins, including c-fos, a marker for 
neuronal activation.
 In Chapter 3 it is demonstrated that spinal Gly/GABA neurons have specific acti-
vation patterns in acute, chronic inflammatory and neuropathic pain. Furthermore, the 
averaged percentage of activated neurons that were Gly/GABA in the chronic phase (≥20h 
survival, 46%) was significantly higher than in the acute phase (≤2h survival, 34%). Mor-
phine application equally decreased the total number of activated neurons and activated 
Gly/GABA neurons. This showed that morphine did not specifically activate Gly/GABA 
neurons to achieve nociceptive inhibition. Since there is evidence for an overall loss of 
spinal inhibitory neurotransmissions in chronic pain states, we conclude that the effect of 
the activated Gly/GABA neurons is insufficient to produce an overall increase in inhibition 
during these chronic pain states. 
 In Chapter 4 we have shown that a chronic pain state in the hind paw on one side 
leads to increased excitability of Gly/GABA neurons located on the contralateral side of 
the spinal cord, since a pain stimulus on that contralateral side resulted in an increased 
number of activated Gly/GABA neurons. 
 In Chapter 5 we have used FISH combined with fluorescent retrograde tracing. 
The results showed that about 40% of the neurons in the rostral ventromedial medulla 
(RVM) that project to the cervical spinal cord were Gly/GABA, i.e. containing either gly-
cine or GABA or both transmitters. From the projections of the RVM to the lumbar dorsal 
horn 43% were Gly/GABA and this percentage was 35% for the projections to the lumbar 
ventral horn. In the caudal medulla, relatively few neurons projecting to the lumbar dorsal 
horn were Gly/GABA (5%), while this percentage was much higher (19%) for projections 
to the ventral horn. The percentages obtained for GABA and glycine separately were very 
similar to those obtained for Gly/GABA. These findings show that virtually all of the Gly/
GABA projections to the spinal cord contain both transmitters and that the projections to 
the dorsal horn originate preferentially in the RVM. In this chapter we have also shown 
the presence of spinal Gly/GABA neurons located in the area around the central canal that 
project to the RVM. This inhibitory ascending pathway, which is the only inhibitory (Gly/
GABA) pathway from the spinal cord to the brainstem identified up to now, might allow 
the spinal cord to modulate the RVM, thereby controlling the descending control of the 
RVM on spinal pain processing. 
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 In Chapter 6 we have investigated in the spinal cord the role of Arc/Arg3.1, an im-
mediate early gene that is essential for long-term memory consolidation in cortical and 
hippocampal neurons. Arc/Arg3.1 is not present in the naive spinal cord, but is de novo 
expressed by nociceptive stimuli. The majority (68%) of the Arc/Arg3.1 expressing neu-
rons contained enkephalin, while only 19% were neurokinin-1 expressing projection neu-
rons and 3.6% were inhibitory (GABA) neurons. These findings showed that Arc/Arg3.1 
is expressed in only a few projection and inhibitory neurons, which belong to the most 
important neurons of the spinal pain system. Accordingly Arc/Arg3.1 knockout mice did 
not show any changes in their pain behavior after formalin injection and after induction of 
chronic inflammation. These findings suggest that long term memory consolidation is not 
required and may even hamper normal functioning of the nociceptive system. 
 Taken together, this thesis gives a detailed analysis of the distribution pattern of 
activated Gly/GABA neurons in the spinal cord during different pain states as well as the 
distribution of Gly/GABA neurons in the RVM that project to the spinal cord. The expres-
sion pattern of Arc/Arg3.1 during different pain states substantiates the idea that long 
term synaptic changes in the spinal pain system, including the Gly/GABA neurons, are un-
favorable for the normal functioning of spinal pain transmission. Thus our findings further 
underline the importance of Gly/GABA neurons in the spinal cord and the brainstem for 
controlling the feeling we all know: pain. 
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 In dit proefschrift hebben we gebruik gemaakt van de fluorescerende in situ hy-
bridizatie (FISH) techniek om de neuronen in het ruggenmerg en de hersenstam te iden-
tificeren die glycine of gamma-amino boterzuur (GABA) of beide transmitters bevatten 
(Gly/GABA neuronen). Met deze techniek hebben we een gedetailleerde analyse gemaakt 
van de localisatie van de glycinerge neuronen in het ruggenmerg (Hoofdstuk 2). In de 
volgende experimenten hebben we de FISH techniek gecombineerd met de retrograde 
neuronale opsporingstechniek met behulp van fluorescerende micro-bolletjes of met de 
fluorescende immunohistochemie techniek om verschillende eiwitten te identificeren, 
waaronder c-fos, het eiwit dat geactiveerde neuronen labelt.
 In Hoofdstuk 3 wordt aangetoond dat Gly/GABA neuronen in het ruggenmerg vol-
gens een specifiek patroon geactiveerd worden gedurende acute pijn, chronische ontstek-
ingspijn en neuropathische pijn. Het gemiddelde percentage geactiveerde Gly/GABA neu-
ronen was significant hoger in de chronische fase (≥20h overleving, 46%) vergeleken met 
de acute phase (≤2h overleving, 34%). De toediening van morfine verminderde het totale 
aantal geactiveerde neuronen en het totaal aantal geactiveerde Gly/GABA neuronen in 
dezelfde mate. Dit laat zien dat de pijnonderdrukking door morfine niet tot stand kwam 
door het activeren van Gly/GABA neuronen. Op grond van aanwijzingen dat de totale 
mate van pijnonderdrukking in het ruggenmerg minder wordt gedurende chronische pijn, 
kan worden geconcludeerd dat het effect van de geactiveerde Gly/GABA neuronen onvol-
doende is om gedurende chronische pijn een toename van pijnonderdrukking te bewerk-
stelligen. 
 In Hoofdstuk 4 laten we zien dat chronische pijn aan de achterpoot aan één kant, 
leidt tot een verhoogde prikkelbaarheid van Gly/GABA neuronen aan de andere kant van 
het ruggenmerg, aangezien een pijnprikkel aan die andere kant resulteerde in een ver-
hoogd aantal geactiveerde Gly/GABA neuronen. 
 In Hoofdstuk 5 hebben we de FISH techniek gecombineerd met de retrograde neu-
ronale opsporingstechniek. De resultaten lieten zien dat ongeveer 40% van de neuronen 
in de rostral ventromediale medulla (RVM) die naar het cervicale ruggenmerg project-
eerden Gly/GABA bevatten, ofwel dat deze neuronen of glycine of GABA of beide trans-
mitters bevatten. Van de projecties van de RVM naar de lumbale dorsale hoorn waren 43% 
Gly/GABA en wat betreft de projecties naar de lumbale ventrale hoorn was dit percentage 
35%. De ventrale medulla, caudaal van de RVM, bevatte relatief weinig neuronen met 
Gly/GABA (5%), die naar de lumbale dorsale hoorn projecteerden, terwijl dit percentage 
veel hoger lag (19%) voor de neuronen met projecties naar de lumbale ventrale hoorn. 
De percentages die werden verkregen voor GABA en glycine apart waren vrijwel gelijk 
aan de bovengenoemde percentages voor Gly/GABA. Samengevat kan gesteld worden dat 
nagenoeg alle projecties van de RVM en caudale medulla naar het ruggenmerg zowel gly-
cine als GABA bevatten en dat de projecties naar de dorsale hoorn voornamelijk afkomstig 
zijn van de RVM. In dit hoofdstuk hebben we ook laten zien dat er Gly/GABA neuronen 
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aanwezig zijn rond het centrale kanaal van het ruggenmerg die naar de RVM projecteren. 
Deze baan van het ruggenmerg naar de hersenstam is de enige opstijgende baan, met een 
remmend (Gly/GABA) effect, die tot nu toe bekend is. Waarschijnlijk kan deze baan de 
RVM beïnvloeden en daarmee de afdalende banen van de RVM controleren, die op hun 
beurt de pijnverwerking in het ruggenmerg controleren.  
 Hoofdstuk 6 laat in het ruggenmerg het onderzoek zien aangaande Arc/Arg3.1, 
een snel afgeschreven genproduct dat in de cortex en de hippocampus neuronen essen-
tieel is voor het vastleggen van het lange termijn herinneringen. Arc/Arg3.1 is normaliter 
niet aanwezig in het ruggenmerg, maar wordt pas tot expressie gebracht als er een pi-
jnprikkel wordt toegediend. De meeste neuronen die Arc/Arg3.1 tot expressie brengen 
bevatten enkephaline (68%), terwijl slechts 19% de neurokinine-1 receptor (kenmerkend 
voor projectie neuronen) tot expressie brengen en 3.6% waren GABA neuronen, die een 
remmende werking hebben. Deze bevindingen tonen aan dat Arc/Arg3.1 slechts in enkele 
projectie-neuronen en remmende neuronen tot expressie komt, terwijl die neuronen be-
horen tot de belangijkste in het pijnsysteem van het ruggenmerg. In overeenstemming 
hiermee lieten Arc/Arg3.1 knockout muizen dan ook geen veranderingen zien in hun pi-
jngedrag na injectie van formaline en gedurende chronische infectie. Deze bevindingen 
geven aan dat het vastleggen van “pijnherinneringen” voor de lange termijn niet noodza-
kelijk of zelfs hinderlijk zijn voor het normaal functionerende pijn systeem.
 Samengevat kan gesteld worden dat dit proefschrift een gedetailleerde analyse 
geeft van zowel de organisatie patronen van geactiveerde Gly/GABA neuronen in het rug-
genmerg bij verschillende oorzaken van pijn, als ook de verdeling van de organisatie van 
de Gly/GABA neuronen in de RVM en caudale medulla, die naar het ruggenmerg pro-
jecteren. Het expressie patroon van Arc/Arg3.1 gedurende de verschillende oorzaken van 
pijn verschaft een basis aan het idee dat het vastleggen van synaptische veranderingen 
voor de lange termijn in het pijnsysteem, daarbij inbegrepen de Gly/GABA neuronen, on-
gunstig zijn voor het normaal functionerende pijnsysteem in het ruggenmerg. Deze bevin-
dingen benadrukken nogmaals het belang van Gly/GABA neuronen in het ruggenmerg en 
de hersenstam voor het controleren van het gevoel dat we allemaal kennen: pijn.
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 Het is 22.56 uur op een donderdagavond in een stilstaande trein op het centraal 
station in Breda. Het is zoals gewoonlijk een regelrechte chaos op de Nederlandse spoor-
wegen en de ergernis van de reizigers trekt als een dampige mist over de spoorwegen. 
Moedig had ik besloten om vanavond na mijn avonddienst op de spoedeisende hulp in 
het Amphiaziekenhuis toch naar huis terug te reizen, maar mijn moed is nergens meer 
te bekennen en de stilstaande trein maakt me onrustig. Dan maar aan mijn dankwoord 
beginnen:
 Allereerst wil ik mijn promotor Prof. Chris de Zeeuw bedanken. Alhoewel wij maar 
een paar minuten met elkaar hebben gesproken in de afgelopen zeven jaar en de meeste 
zaken tussen ons via Joan zijn verlopen wil ik je hierbij bedanken voor de steun op de ach-
tergrond en meedelen dat je ambities mij aan het denken hebben gezet. Hierbij wil ik ook 
graag de rest van de leden van de promotiecommissie bedanken voor de tijd die ze hebben 
genomen om mijn proefschrift te lezen en vragen te formuleren.
 Mijn copromotor en begeleider Dr. J.C. Holstege. Beste Joan, we hebben wonder-
lijk genoeg meer dan zeven jaar met elkaar samengewerkt en evenredig aan het aantal 
jaren, evenzoveel artikelen geschreven. Ik ben in de afgelopen jaren veel veranderd en 
jij bent een van de weinigen geweest die daar invloed op heeft gehad. Je ongezouten 
mening, dat vaak de waarheid weerspiegelde, heb ik altijd op prijs gesteld. Vaak had je 
aan begeleiding je handen vol aan mij, en in de wetenschap was mijn enthousiasme vaak 
ongericht, maar gelukkig was jij er om me de goede richting in te sturen. Je kennis over 
het pijnsysteem heeft me vaak verrast, en je manier van aanpak om een vraagstuk te be-
antwoorden heeft mij veel bijgeleerd. Verder, het feit dat een artikel minstens 25x her-
geschreven moest worden laat zien hoe perfectionistisch jij bent of hoe slecht ik ben. De 
wetenschappelijke en niet-wetenschappelijke gebeurtenissen die wij in de afgelopen jaren 
hebben meegemaakt is een unieke en leerzame ervaring geweest. Het is niet makkelijk 
om volledig te zijn in mijn bewoordingen maar het komt er op neer dat ik een geweldige 
tijd heb gehad en ik wil je hierbij bedanken voor je hulp en geduld. Aangezien we vaak fi-
losofische gesprekken hebben gevoerd, zal ik mijn dank maar eindigen met het volgende: 
‘Perceptie maakt wetenschap mogelijk, en wetenschap is een feitelijke handgreep om te 
sublimeren. Maar gelukkig is sublimatie een droom binnen dromen.’ Ps. Ik moet wel toe-
geven dat het nog steeds jeukt dat we geen paper over ‘Jeuk’ hebben gepubliceerd.
 Beste Elize! In de afgelopen jaren heb ik ontelbare keren ‘Elize’ geroepen en altijd 
werd dat met een vriendelijke lach beantwoord. Jij bent zeker de onmisbare schakel in het 
histologielab, en zonder jouw kennis had ik het op bepaalde momenten niet kunnen red-
den. Hierbij wens ik je in de komende jaren veel plezier op het histolab, en geniet van je 
jaarlijkse reizen naar de meest exotische plekken op de aarde. 
 Erika, bedankt voor de vele leuke gesprekken. Jouw gevoel voor humor komt re-
delijk dicht in de buurt van die van Joan en ergens denk ik dat jouw vele jaren op het lab, 
en je samenwerking met Joan aan het begin van je carrière, wel degelijk van invloed zijn 
geweest. Als je de Masterstudenten ooit zat wordt, geef me dan een seintje, want dan 
kunnen we ons toneelstuk uitproberen. Mandy, Loes, en Edith, jullie ook bedankt voor jul-
lie hulp in de afgelopen jaren, en nog veel plezier op de afdeling in de aankomende jaren.
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 Liron, als jij niet op de afdeling was verschenen zouden de afgelopen twee jaar 
voor mij heel moeilijk zijn geweest. Jij bent een chirurg die wetenschappenlijk is inge-
steld, een Kosovaar van top tot teen en gekleed volgens de regels van de Italiaanse mode. 
Jouw Balkanese mentaliteit gecombineerd met mijn Perzische mentaliteit heeft veel leuke 
momenten opgeleverd in de late avonduren op het lab; onze manier om de wetenschap-
pelijke tegenslagen van de dag te verteren. Dit was vooral het geval in het eerste jaar toen 
we alle immunotechnieken aan de gang moesten krijgen en hierdoor hebben wij ook een 
sterke vriendschap opgebouwd. Je experimenten lopen nu goed en voor je het weet begin 
jij ook aan het dankwoord van jouw proefschrift! En bedankt dat je mijn paranimf wilt zijn!
 Somesh, jij arriveerde op het juiste moment! In het laatste jaar hadden Liron en ik 
het allebei zwaar, maar met jouw hulp konden we weer alles aan. De drie dagen in Milaan 
waren goed genoeg om weer maanden vooruit te kunnen. Bedankt voor je hulp met mijn 
onderzoek en de vriendschap die we hieraan hebben overgehouden. Veel succes met je 
nieuwe huis en tot volgende week waarschijnlijk! 
 Beste Sebastian, wij rolden het Master of Neuroscience programma binnen in het 
tweede jaar nadat het gestart was. We hebben drie soorten knockout muizen ‘gepijnigd’ 
maar uiteindelijk hebben zij óns gepijnigd. Wat waren we toch gemotiveerd aan het begin 
en wat waren wij toch gedemotiveerd aan het eind! Wat wij waren toch naïeve Masterstu-
denten aan het begin en verbitterde Masterstudenten aan het eind. Maar het blijven leuke 
tijden! Vooral de memorabele ‘formaline test’ in het kleine donkere kamertje waarbij de 
slapeloosheid van ons evenredig was aan die van de muizen. Veel succes met je opleiding 
tot Psychiater en hopelijk zal ik in de toekomst niet tegenover jou komen te zitten, want 
dan is er iets goed misgegaan!
 Querido John! Yo tu prometido que yo dar gracias en Español, et yo cumplir de 
promesa usanta Van Dale diccionario. Muchas gracias por leccionas de Español, entre-
tenids y algunas veces locos tiempos en laboratorio. Nosotros tenemos abiertas mentas, 
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geduurd om het af te schrijven. 


